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Abstract
There have been significant changes in the management of patients with diabetes in the 
United Kingdom (UK) over the last 20 years, with the introduction of analogue insulins 
and the drive toward tighter glycaemic control, with its concomitant risk of increased 
hypoglycaemia.
This thesis describes changes in insulin prescribing in the UK between 1999 and 2009, 
examines the associations between a patient’s characteristics and the type of insulin they 
are prescribed, and between a patient’s insulin exposure and their risk of serious 
hypoglycaemic events.
Data for the study was obtained from the General Practice Research Database (GPRD), a 
UK primary-care database providing anonymised patient data for approximately 6% of 
the UK population. A cohort of insulin-using patients was identified, from which 
subgroups of patients newly-starting insulin therapy and patients switching insulins were 
extracted for analysis.
There was a rapid uptake of analogue insulins and by 2009 they accounted for more than 
80% of insulin prescriptions. While some of a patient’s characteristics, including age 
and ethnicity, influenced the choice between analogue and human insulin in new insulin 
users, the largest effect size was the calendar year in which therapy started: clinician (or 
patient) choice seemed to be the driving factor.
The risk of serious hypoglycaemic events under exposure to human or analogue insulin 
was examined in new users and insulin switchers. After adjusting for patient 
characteristics, some of which, including ethnicity, were associated with a change in the 
risk of an event, the study confirmed that new users of long-acting analogue insulins had 
a lower risk of serious hypoglycaemic events compared with users of human insulin. 
However, following a switch from human insulin no difference in the risk of serious 
hypoglycaemic events was found in patients switching to either analogue insulin or to a 
different combination of human insulins.
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Introduction
1 I
1.1 Diabetes mellitus and Its treatment
T h e  r e g u l a t io n  o f  b l o o d  g l u c o s e  
Glucose metabolism
The body’s demand for glucose is continuous: in a resting adult the obligatory 
requirement is approximately 6.5-7.5 g/hr: a 70kg adult uses ~200g of glucose each 
day, of which about half is used by the brain. ^
Excess glucose is stored as the polysaccharide glycogen (glyco gene sis), predominantly in 
the liver although there are also stores in the kidneys and skeletal muscle,^ or 
metabolised (in the hepatocytes) into precursors for fatty acid synthesis. In turn, excess 
fatty acids can be stored as triglycerides (esters of fatty acids and glycerol, also known as 
triacylglycerols).^ In the fasting or post-absorptive state plasma glucose levels are 
maintained by the release of glucose from the liver and kidneys.
Two metabolic processes produce glucose: the breakdown of stored glycogen 
(glycogenolysis), and synthesis (gluconeogenesis) from 3-carbon precursors including 
lactate (from muscle), glycerol (from adipose tissue) or most of the amino acids (from 
the diet or protein degradation)."^ In an early post-absorptive state most glucose is 
supplied by glycogenolysis, with the liver providing 70% to 90% of the requirements, 
and the kidneys the remainder. As fasting continues gluconeogenesis becomes more 
important.
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Normoglycaemia and the hormonal control of hlood glucose
In normal physiology the plasma glucose level is usually between 3.5-5.5 mmol/1 
(63-100 mg/100ml) and rarely rises above 8 mmol/1 despite the body’s varying demand 
for energy and the fluctuating level of supply as the products of digestion are absorbed.
Hormonally-controlled feedback mechanisms, together with sympathetic and 
parasympathetic nervous system activity,^ act to balance glucose storage and production 
processes to produce a stable plasma glucose level.
The most important hormones in the control of plasma glucose are insulin, which acts to 
reduce plasma glucose and glucagon and adrenaline (epinephrine), which act to increase 
it.^ Both insulin and glucagon are produced by the islets of Langerhans in the pancreas; 
insulin by the beta-cells and glucagon by the alpha-cells.^
The primary trigger for the secretion of insulin is the presence of glucose, ^  although 
other stimulants include amino acids, fatty acids, and sulphonylurea drugs. Secretion of 
the incretin gut hormones -  principally glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIF) -  increases following nutrient 
intake, and stimulates glucose-dependent insulin secretion.^ Insulin secretion is reduced 
by the presence of insulin itself, by alpha2-adrenoceptor stimulation of the beta-cells, by 
the presence of somatostatin, and by amylin (a peptide secreted by the pancreatic 
beta-cells at the same time as insulin).
Insulin affects a number of metabolic pathways involved in the control of fuel substrates.
Overall it acts to increase the uptake of plasma glucose and inhibit processes that 
produce free plasma glucose or its potential substrates. Insulin suppresses 
gluconeogenesis and the breakdown of glycogen (glycogenolysis), and stimulates 
glycogen synthesis. Higher levels of insulin increase the uptake of glucose by skeletal 
muscle, stimulate triglyceride synthesis through the uptake of fatty acids and glucose by 
adipocytes, and inhibit lipolysis and the oxidation of fatty acids.
The actions of insulin are opposed by the counter-regulatory hormones: glucagon, 
adrenaline, growth hormone and cortisol. These act on the liver (glucagon, adrenaline), 
adipose tissue (adrenaline, growth hormone) and skeletal muscle (adrenaline and
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cortisol) to increase gluconeogenesis and the production of its substrates, and stimulate 
glycogenolysis.
A persistent elevated blood glucose level (hyperglycaemia) -  the characteristic symptom 
of diabetes -  can be produced by an absolute or relative deficiency of insulin, or by 
insulin resistance (a state in which insulin is unable to produce its usual biological effects 
at circulating concentrations that are effective in normal physiology). Diabetes 
mellitus is the name given to a group of metabolic disorders "characterised by 
hyperglycaemia resulting from defects in insulin secretion, insulin action, or both".
D i a b e t e s  m e l l it u s
In its various forms, diabetes mellitus (DM) is one of the most common 
noncommunicable diseases. Globally, the International Diabetes Federation (IDF) 
estimated that in 2011 366 million people had diabetes, and that by 2030 552 million 
people may be affected. In the UK in 2011 2.9 million people had been diagnosed with 
diabetes; 4.45% of adults, accounting for ~10%  of the NHS budget for England and 
Wales. People with diabetes generally have a reduced life expectancy,  ^ and are at risk 
of serious complications. Given the association of Type 2 diabetes with increasing 
age^^ and with obesity, itself increasing in many populations including the UK,^^ it is 
clear that diabetes will continue to have a substantial impact on society, both in terms of 
the quality of life of the individual and in costs to health care systems.
Classification and diagnosis of diabetes
Different pathogenic processes give rise to diabetes mellitus, and the American Diabetes 
Association (ADA) describes four categories based on aetiology: Type 1 or 
immune-mediated diabetes. Type 2 diabetes, gestational diabetes and "other types", 
listed below, all of which are rare.
• Genetic defects o f beta-cell function: monogenetic defects characterised by impaired 
insulin secretion with little or no defects in insulin action. Also known as maturity 
onset diabetes of the young (MODY).
• Genetic defects o f insulin action: impaired insulin receptor due to mutation of the 
insulin receptor gene.
• Diseases o f  the exocrine pancreas: pancreatic or adrenal cancers and any condition 
capable of extensive pancreatic damage (including pancreatitis, traumatic injury, or
1. Introduction Diabetes mellitus and its treatment
cystic fibrosis) can trigger diabetes.
• Endocrinopathies: diabetes may result from conditions resulting in excess 
production of the counter-regulatory hormones (glucagon, adrenaline, corticol and 
growth hormone), generally in patients with pre-existing defects in insulin secretion.
• Drug or chemical induced: a number of drugs (including thiazides, glucocorticoids, 
and alpha-interferon) can impair insulin secretion, and may precipitate diabetes in 
patients with insulin resistance.
• Infections: some viruses, including congenital rubella, Coxsackie virus B, 
adenovirus and mumps, have been linked to beta-cell destruction.
• Uncommon forms o f  immune-related mediated diabetes: currently two conditions 
are classified separately from Type 1 diabetes (others may be found); the 
autoimmune condition "stiff-man syndrome" and a condition where insulin 
resistance results from high levels of insulin receptor antibody production.
• Other genetic syndromes: there is an increased risk of diabetes with a number of 
genetic syndromes, including Down’s, Klinefelter’s, Turner’s and Prader-Willi.
Gestational diabetes is defined as any degree of glucose intolerance during pregnancy, 
usually during the second or third term; it generally clears after delivery.
Development in the first trimester or persistence after delivery may indicate pre-existing, 
undiagnosed. Type 2 diabetes.
The World Heath Organisation (WHO)^° and ADA^^ guidelines note a spectrum of 
intermediate forms of hyperglycaemia characterised by the patient’s results from 2-hour 
post-challenge plasma glucose and fasting plasma glucose tests. Table 1.1 summarizes 
the WHO diagnostic criteria.
Table 1.1: G l u c o s e  t o l e r a n c e  s t a t e s :
W o r l d  H e a lth  O r g a n is a t io n  c r i t e r i a ®^
F a stin g  p la sm a  g lu c o s e 2-hour p la sm a  g lu c o s e
C ondition (mm oi/I) (m m ol/l)
Impaired Fasting G lucose (IFG) 6.1 to 6 .9 < 7 .8  (if m easured)
Impaired G lucose Tolerance (IGT) < 7 .0 > 7 .8  and < 1 1 .0
D iabetes > 7 .0 > 1 1 .1
Patients may pass through the states of impaired fasting glucose (IFG) and impaired 
glucose tolerance (IGT) before developing clinical diabetes, although progression is 
not automatic. In 6 prospective studies reviewed by Rao et al. between 3.6% and 8.7% of 
patients with IGT progressed to Type 2 diabetes per year.^^
The majority of patients present with primary Type 1 or Type 2 diabetes.
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Type 1 diabetes
Type 1 diabetes (previously known as insulin dependent diabetes mellitus [IDDM]) is an 
autoimmune disease producing an absolute deficiency of insulin. It typically accounts 
for 5% to 10% of all cases. In the most common form (Type lA) the pancreatic 
beta-cells are selectively destroyed by a T-cell-mediated process. When the beta-cell 
mass has been eroded to a critical level (probably 5-10% of normal), there is insufficient 
insulin to prevent hyperglycaemia and clinical diabetes develops. ^
Clinically, the majority of cases present in childhood, with patients showing a 
progressive reduction in insulin production from, normally, around 7 years of age (hence 
its older name of juvenile-onset diabetes), and reaching full clinical diabetes by their 
teens or early adulthood. The classic symptoms —  polyuria, thirst and weight loss —  
often appear over a 2 to 6 week period, and may be accompanied by ketonuria. Although 
predominantly a disease of the young. Type 1 diabetes can develop at any age: about 
40% of cases are over 18 at presentation.^^ In some patients the progression to insulin 
deficiency is slower, occurring in adulthood: this "latent autoimmune diabetes" (LADA) 
may be difficult to distinguish from Type 2 diabetes. ^
Causation of Type 1A diabetes is complex and not yet fully understood. There is a 
genetic component, predominantly associated with the HLA system (a group of genes on 
chromosome 6 involved in the body’s immune response system^), although a number of 
other gene loci have also been implicated. However, in genetically susceptible 
individuals the disease only develops following exposure to some environmental 
trigger(s).^^ While a number of such factors have been postulated, including congenital 
rubella, Coxsackie B4 and various other viruses, early exposure to cows’ milk protein, 
and environmental toxins including nitrosamines, no clear causal relationship has yet 
been found. ^
Type IB diabetes (also known as idiopathic or fulminant diabetes) is a rare variant form, 
found mainly in patients of African or Asian descent, although Imagawa et a l  have 
suggested that it may account for ~20%  of Type 1 cases in Japan. Onset is usually 
abrupt and associated with ketoacidosis. Patients have almost no C-peptide secretion and 
a high plasma glucose but almost normal glycosylated haemoglobin.^"^ They do not show
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beta-cell autoimmunity and, while there is a strong inherited component, the association 
with the HLA genotype differs from that in Type lA  diabetes. Its cause is unknown.
Type 2 diabetes
Type 2 diabetes is characterised by insulin resistance associated with defective insulin 
secretion. The condition can range from predominantly insulin resistance with 
relative insulin deficiency to predominantly defective insulin-secretion, with or without 
insulin resistance. The primary difference between this and Type 1 diabetes is that 
there is no autoimmune destruction of the beta-cells.
This is the most common form of diabetes, accounting for 90^95%  of all cases.
Prevalence rises with age: in England in 2011 ~2%  of those aged 16 to 35 were affected, 
rising to about 13% of those aged 75 or older. There are marked variations among ethnic 
groups, with higher rates seen in those of South Asian, African or Afro-Caribbean 
descent than in the general population.
Type 2 diabetes shows a range of clinical presentations.  ^ Its onset may be subacute, 
particularly in older patients, and symptoms may have been present for months or years 
before presentation. While most patients present with only moderate symptoms, about 
20% of patients have evidence of long term complications at diagnosis.
As with Type 1, the specific causes of Type 2 diabetes remain unclear. Its aetiology is 
complex, with genetic and environmental components,  ^ while Fernandez-Real and 
Fisher have suggested that infection or injury can lead to chronic activation of the 
"innate immune" response, in turn triggering Type 2 diabetes.
Obesity, high rate of weight gain in adulthood and (independently) increased deposition 
of abdominal fat are risk factors for Type 2 diabetes, and it is likely that obesity 
predisposes to both insulin resistance (hyperinsulinaemia) and beta-cell failure.
Obesity is also a risk factor for cardiovascular disease (CVD), and patients with diabetes 
or IGT often have other risk factors for CVD, including dyslipidemia and 
hypertension.^^ This cluster of symptoms has been called the "metabolic syndrome", 
and is known to indicate an increased risk of CVD beyond that of the individual
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symptoms. The WHO considers people with metabolic syndrome, even with normal 
glucose tolerance, to be at high risk of progression to diabetes.
T r e a t m e n t  o f  d ia b e t e s
In normal physiology there is a continuous low ("basal") level of insulin production, 
which rises rapidly after an increase in blood glucose ("first-phase" insulin production). 
This rapidly declines into a longer second phase if plasma glucose levels remain high 
(Figure 1.1).
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Figure 1.1; S C H E M A T I C  R E P R E S E N T A T I O N  O F  ( A V E R A G E )  N O R M A L  
P H Y S I O L O G I C A L  P L A S M A  I N S U L I N  L E V E L S  ( F R O M
M c C o r m a c k ,®^ w i t h  p e r m i s s i o n )
The ideal therapy would be one that restored normal physiology, something potentially 
offered by transplantation of the pancreas or of islet cells. However, like all whole organ 
transplants, pancreatic transplantation requires life-long immunosuppression and has 
been associated with peri-operative mortality and significant morbidity. Islet cell 
transplantation is potentially less invasive but has met with limited success: of 325 
recipients reported to the International Islet Transplant Registry up to 2008 only 23% 
were insulin-independent after 3 years.^ Transplantation is a promising technology for 
the future but is not yet a significant contributor to therapy and for the foreseeable future 
the majority of patients will rely on controlling blood glucose through diet (and other 
lifestyle changes) and anti-diabetic drugs, including exogenous insulin.
Patients with Type 1 diabetes typically begin insulin therapy immediately following 
diagnosis, although full insulin replacement may be delayed in a small proportion of
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patients with some residual beta-cell function. ^
For patients with Type 2 diabetes the National College of Chronic Disease update to the 
NICE guidelines suggests a progressive strategy. Where feasible, hyperglycaemic 
control should first be attempted through diet and lifestyle measures. Where this is not 
effective, oral hypoglycaemic drugs should be introduced: the guidelines recommend 
starting the patient on metformin (or sulphonylureas in patients of normal weight). 
Exenatide should be considered as a possible 3rd line therapy, with migration to insulin 
(possibly in combination with oral hypoglycaemic drugs) as the disease progresses and if 
it is required. The non-insulin anti-diabetic drugs are summarised in Table 1.2.^^’^ ^
Table 1.2: A n t i- d ia b e t ic  d r u g s  o t h e r  t h a n  in s u l in
Class Products Route Action
Sulphonylureas chloropromide,®
glibenclamide,
gliclazide,
tolbutamide
Oral Insulin secretagogues {i.e. they augment 
insulin secretion), and hence require 
some residual beta-cell function.
Biguanides metformin Oral Decreases gluconeogenesis and 
increases peripheral utilisation of 
glucose. Acts only in the presence of 
endogenous insulin.
Meglitinides repaglinide,
nateglinide
Oral Short-acting insulin secretagogue.
Thiazolidinediones pioglitazone,
rosiglitazone^
Oral Reduce peripheral insulin resistance.
DPP-4 inhibitors sitagliptin,
vildagliptin,
saxagliptin
Oral Blocks the action of dipeptidyl pedtidase 
IV, so reduces the degradation of 
glucagon-like peptide 1 (GLP-1), hence 
increasing insulin secretion and 
suppressing glucagon production
In cretin mimics exenatide, liraglutide SCfi Mimics the action of incretin (GLP-1) and 
hence increases glucose-dependent 
insulin secretion, suppresses glucagon 
production, delays gastric emptying and 
promotes satiety.
Alpha-
glucosidase
inhibitors
acarbose, miglitol Oral Inhibits alpha-glucosidase, delays and 
attenuates postprandial blood glucose 
peaks.
Amylin analogs pramlintide acetate Oral Delays gastric emptying, reduces 
postprandial glucagon release and 
modulates appetite. (Not currently 
licenced in the UK)
a) Chloroproamide h as been  discontinued in the UK
b) Rosiglitazone\NBS, withdrawn in the UK in 2010 , b e c a u se  of an increased  risk of cardiovascular disorders
c) SCI = su b-cutaneous injection
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Indications for the initiation of insulin include weight loss in (non-dieting) patients of 
normal or low weight, symptoms of hyperglycaemia, non-tolerance or contra-indication 
of oral hypoglycaemic drugs, or unsatisfactory glycaemic control even when at the 
maximum oral hypoglycaemic dosage. Not all Type 2 patients necessarily benefit from 
moving to insulin, and the potential benefits of improved control and reduced long-term 
complications must be weighed against the disruption of the change to an injected 
regimen. Examples of patient groups where the change may not be justified include 
elderly patients with a short duration of diabetes and without significant comorbidities, 
the obese (who may gain weight but see little improvement in glycaemic control), and 
patients who still have scope to adjust their oral treatment. Nevertheless, in the hope of 
reducing longer-term complications, some clinicians now prefer to initiate insulin earlier.
Insulin regimens
Insulin can be delivered by manual sub-cutaneous injections or by insulin pumps*.
Insulin pumps provide a continuous infusion of short or rapid acting insulin with 
manually-controlled bolus additions. This continuous subcutaneous insulin infusion 
(CSII) therapy potentially gives an insulin profile close to that seen in non-diabetics, and 
hence helps the patient achieve tight glycaemic control. However, current NICE 
guidance recommends insulin pumps only in patients with Type 1 diabetes who have 
failed to achieve satisfactory glycaemic control, or who experience "disabling 
hypoglycaemia" with multiple daily insulin injections (MDI).^^ Accordingly relatively 
few patients use insulin pumps and most rely on periodic sub-cutaneous injections.
The most appropriate injection regimen depends on the type of diabetes, with patients 
with Type 1 diabetes (who require insulin to survive) generally needing more intensive 
regimens than insulin-dependent patients with Type 2 diabetes.
Physiologic replacement insulin therapy aims to mimic the normal pattern of plasma 
insulin, and requires multiple daily injections (or the use of an insulin pump).
Manually-injected basal/bolus therapy uses an intermediate or long-acting insulin as the
In 2006 an inhaled insulin formulation (Exubera) was licensed for restricted use in the UK, however 
uptake was poor and in October 2007 the product was withdrawn by the manufacturer.^®
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"basal" component, supplemented by short or fast acting "bolus", or prandial, insulin 
before each meal. About 50% of the total daily insulin requirement is taken as basal 
insulin, and 107o-20% taken as each bolus. Such regimes have the advantages of 
providing some flexibility with mealtimes and helping to achieve better glycaemic 
control, but at a higher risk of hypoglycaemia. Other insulin regimens require only 1 or 2 
injections per day, but do not mimic the physiological insulin pattern. These 
non-physiologic regimens are better suited to patients with Type 2 diabetes, where basal 
insulin replacement is less critical.
The patient’s clinician needs to identify the most appropriate insulin regimen, however 
the British National Formulary recommends a number of typical protocols:
• A multiple injection regimen of short or rapid-acting insulin before meals with 
intermediate or long-acting insulin at bedtime.
• Intermediate-acting or long-acting insulin mixed with short-acting or rapid-acting 
insulin, once or twice daily (before meals)
• Intermediate or long-acting insulin, once or twice daily, with or without short or 
rapid-acting insulin before meals.
• Subcutaneous insulin infusion, where the patient meets the NICE criteria.
Regardless of the regimen, successful management requires the active involvement of the 
patient, who is encouraged to pay attention to lifestyle factors such as diet, alcohol intake 
and the level of physical exercise, and to regularly monitor their blood glucose level.
However, these direct blood glucose measurements, although used in the daily 
adjustment of therapy, give little indication of a patient’s longer-term glycaemic control: 
this is more accurately estimated from the measurement of glycosylated haemoglobin.
Glycosylated haemoglobin
Circulating haemoglobin is heterogeneous, containing unmodified haemoglobin (HbAo) 
and various minor forms produced by the irreversible non-enzymatic linkage of glucose 
(or some other carbohydrate) over the lifetime of a red blood cell (~120 days). There are 
a number of these glycosylated (or glycated) forms. The HbA i haemoglobins have 
various carbohydrates attached to the N-terminal valine of the beta-chain: the three most 
common variants are designated HbAia, HbAib, and HbAic (based on the order of their 
elution in ion-exchange chromatography), but other forms are known.
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The proportion of glycosylated forms is raised in diabetes. The extent of glycosylation is 
a measure of the level of glycaemic control over the preceding weeks, and has been 
widely used as such in clinical trials. It provides a weighted measure: the blood glucose 
level in the month before testing contributes more to the measured glycosylated 
haemoglobin than does the level 3 months before.
HbAic is the largest single component (typically forming 60^80%  of glycosylated 
forms), and is often measured on its own. However, there are more than 30 different 
commercial assays, and, historically, measurements have not necessarily been 
comparable across l a b o r a t o r i e s . F o l l o w i n g  the Diabetes Control and 
Complications Trial (DCCT) the analytical method it used -  ion-exchange 
high-performance liquid chromatography (HPLC) -  was widely adopted as a reference.
Where the relationship between the DCCT’s method and other assays was known results 
were often presented as "DCCT-aligned" or "HbAic-equivalent" regardless of the actual 
assay used,"^ however the recognition of its importance led to international efforts to 
standardise HbAic measurement. The International Federation of Clinical Chemistry 
and Laboratory Medicine (IFCC) Working Group on HbAic Standardisation"^^ has 
developed two reference methods (mass spectroscopy and capillary electrophoresis) and 
also recommended a change to the method of reporting: as mmol/mol rather than as a 
percentage of the total haemoglobin, a change which has been adopted by the UK.^
However, this thesis uses percentages for HbAic results, as that was the method used in 
most of the study data.
To monitor a patient’s glycaemic control NICE recommends that HbAic measurements 
are taken every 2-6 months and that targets should be 6.5% for Type 2 and 7.5% (with 
encouragement to achieve 6.5%) in Type 1 patients. Such control is achieved by 
careful titration of the insulin dosage, but this carries an increased risk of iatrogenic 
hypoglycaemia.
 ^ The IFCC have also produced a validated conversion between mmol/mol and %Hb measurements:
P  —  (0.09148 * M ) -f 2.152 where P =  percentage of total haemoglobin and M =  H bA ic in mmol/mol
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1.2 Diabetic complications
The hyperglycaemia that characterises diabetes is implicated in the development of 
chronic microvascular and macrovascular complications, however, in the shorter-term, 
lack of insulin can induce potentially fatal ketoacidosis, while an excess of insulin can 
produce hypoglycaemia.
K e t o a c id o s is
While mainly seen in untreated Type 1 diabetes, ketoacidosis can result from the 
interruption of insulin therapy, and may occur in Type 2 patients with severe infections 
and other illnesses. ^
In normal metabolism the acetyl-CoA produced by fatty acid oxidation can be used for 
energy production: it combines with oxaloacetate (a product of glucose metabolism) and 
enters the citric acid cycle. ^  However, in patients with Type 1 diabetes, the combination 
of insulin deficiency and excess glucagon results in both a reduced availability of 
oxaloacetate (due to reduced glucose processing and its preferential use in 
gluconeogenesis) and increased release of fatty acids from adipose tissue. In the absence 
of oxaloacetate the acetyl-CoA from fatty acid oxidation is converted, primarily in the 
liver, into acetoacetate and then to D-3 -hydroxybutyrate and acetone. These ketone 
bodies are a fuel, but excess accumulation in the plasma lowers the pH (they are 
moderately strong acids) and can result in ketoacidosis, leading, if uncorrected, to 
potentially fatal cerebral oedema.
V a s c u l a r  c o m p l ic a t io n s
The major causes of mortality and morbidity in diabetes are long-term microvascular 
and macrovascular complications."^^ Macrovascular complications can include 
atherosclerosis, and patients with diabetes are twice as likely to have a s t r o k e a n d  3 to 
5 times more likely to have a myocardial infarction ^  than the non-diabetic population. 
Microvascular (unlike macrovascular) complications are specific to diabetes, and tend to 
manifest in three areas: the eye, the kidney, and nerve tissues. Complications can include 
retinopathy with potential blindness; nephropathy potentially leading to renal failure; 
peripheral neuropathy, manifesting as foot ulcers and Charcot joints and potentially
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leading to amputations (foot amputations are 50 times more likely in diabetics than in 
non-diabetics);^ and autonomic neuropathy with a risk of cardiovascular damage.
Vascular complications can seriously impact the quality of life of patients with diabetes, 
and carry an increased risk of mortality.
There is substantial evidence that the degree of hyperglycaemia is linked to the 
development of microvascular damage. For example the Diabetes Control and 
Complications Trial (DCCT) showed that in Type 1 diabetes intensive insulin therapy 
substantially delays the progression of diabetic retinopathy, nephropathy and 
neuropathy, a finding confirmed in Type 2 patients by the United Kingdom Prospective 
Diabetes Study (UKPDS)^"^. The effect on macrovascular morbidity was less clear in 
these trials. Both the DCCT and the UKPDS studies showed a reduced risk of 
cardiovascular events under intensive treatment, but the effects were not statistically 
significant. However, the 10-year follow-up study of the UKPDS patients found 
significant reductions in the risk of both microvascular and cardiovascular 
complications, as well as in all-cause mortality, in patients with early glucose control.
The evidence from the DCCT and UKPDS has led to increased emphasis on the 
achievement of tight glycaemic control. Unfortunately, in insulin-treated patients, this 
can increase the risk of hypoglycaemia.
H y p o g l y c a e m ia
Hypoglycaemia is a state of low plasma glucose, typically regarded as below ~3.0 
mmol/1. In people without diabetes hypoglycaemia is rare^, however, most patients 
treated with insulin (and some of those using an insulin secretagogue) will experience 
hypoglycaemia at some point, particularly when attempting to achieve strict control.
* Hypoglycaemia in non-diabetics can result from insulinomas or other tumours, alcohol intake, following 
stomach surgery, in liver or renal failure, and in some endocrine system conditions. In rare cases treat­
ment with quinine, salicylates, propranolol or pentamidine may also induce hypoglycaemia. ^
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Frequency of hypoglycaemia
The reported rates of hypoglycaemia vary widely, probably reflecting differences in the 
definition used, the populations, and the data collection methods of the various studies.
In non-intensively-treated patients with Type 1 diabetes the DCCT found a rate of severe 
events^ equivalent to ~0 .2  event per person-year, (albeit in a selected population that 
excluded those with extensive prior hypoglycaemia),^^ while a 1997 meta-analysis of 
randomised control trials by Egger et a l  found a median rate of ~0.05 severe events per 
person-year.^^ However, there does seem to be agreement that intensive insulin therapy 
increases the risk of severe hypoglycaemia: the DCCT found a 3-fold increase in 
intensively-treated patients compared to those on conventional therapy, a finding 
confirmed in the Egger meta-analysis. A review by Cryer et a l  estimated that 
patients with Type 1 diabetes averaged 2 episodes of symptomatic hypoglycaemia a 
week, and a severe episode around once a year.
The heterogeneity of Type 2 diabetes means rates are harder to establish. A review by 
Zammitt and Frier found between 30% and 83% of patients had experienced 
hypoglycaemia while on insulin, with between 2% and 15% reporting severe episodes.
A systematic review by Akram et a i  found a wide range of rates of severe 
hypoglycaemia, ranging between zero and 73 events per 100 patient-years. The Akram 
review also noted the skewed distribution of severe hypoglycaemia, with a relatively 
small proportion of patients accounting for the majority of events. As in Type 1, patients 
attempting strict control experience more events: the UKPDS found an approximate
doubling of the risk compared with patients on conventional therapy.
The Cryer review estimated that rates of severe hypoglycaemia in insulin-treated Type 
2 diabetics were ~10%  of those in Type 1,^^ however a study by Leese et a l  looking 
at over 8 thousand Scottish patients with diabetes who needed emergency assistance, 
found little difference between Type 1 and Type 2 patients. They estimated the frequency 
of severe hypoglycaemia at 11.5 and 11.8 events per 100 patient-years in Type 1 and 
Type 2 diabetes respectively.
"Severe" hypoglycaemia is commonly defined as an episode requiring 3rd party assistance.
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Treatment with insulin secretagogues can also induce hypoglycaemia, although rates are 
lower than in insulin treatment. Among the sulphonylureas the risk is greatest with the 
longer-acting forms (such as chlorpropamide, glyburide and glipizide), and lower in 
glimepiride which, although long-acting, has a reduced affinity for the beta-cell 
receptor. The meglitinides (repaglinide and nateglinide) are short-acting secretagogues 
that have been found to provoke less hypoglycaemia than the sulphonylureas.^®
The trigger for hypoglycaemia can vary. A prospective study in Type 2 diabetes by 
Murata et al. found that in over half of the episodes the patient could not identify a 
specific cause, but where they could the most common trigger was missing a meal 
without adjusting their insulin (53% of events), while 24% were triggered by exercise.®^ 
Increased insulin dose was rarely the cause, accounting for less than 2% of the events.
Symptoms and mechanism
Glucose-sensitive neurons in the hypothalamus (and possibly in other brain regions and 
some visceral sites, including the portal vein), respond to the blood glucose level; when 
this falls the hypothalamus coordinates a sequence of responses. In normal physiology, 
as the level falls to ~4.5 mmol/1 insulin secretion decreases, and as it approaches the 
lower end of the physiological range (3.6-3.9 mmol/1) glucagon and adrenaline secretion 
increase. Should the plasma glucose level fall to around 2.8-3.0 mmol/1 "autonomic" 
warning symptoms -  typically tremor, anxiety, palpitations, hunger and sweating -  
appear, alerting the person to the need to raise their blood glucose.
On most occasions hypoglycaemia is just an inconvenience, easily resolved by eating 
something sweet, but if hypoglycaemia continues neuroglycopenic symptoms (blurred 
vision, tingling, dizziness, difficulty in thinking and faintness) develop. In severe 
episodes, where levels fall to <1.5 mmol/1, the patient may experience convulsions and 
coma, and need urgent assistance.^® Even in coma, brain damage and death do not 
normally occur because the normal processes of insulin degradation and increases in 
counter-regulatory hormones tend to increase the glucose level. However, a (small) 
number of deaths at night of patients with Type 1 diabetes have been attributed to 
hypoglycaemia (the "dead-in-bed" syndrome
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In patients using exogenous insulin, the level of circulating insulin is not governed by the 
physiological control mechanism but depends on the (passive) absorption of injected 
• insulin. Hence the initial response -  to inhibit insulin production -  is ineffective. Also, 
in established Type 1 diabetes, glucagon secretion does not increase, leaving the patients 
more dependent on the adrenaline response, although this is often shifted to a lower 
plasma glucose concentration.^^ In early Type 2 diabetes the counter-regulatory 
mechanisms are generally intact, but, as patients become increasingly insulin deficient, 
similar defects develop.
Over time, many patients experience a reduction in their ability to recognise the early 
symptoms of hypoglycaemia. It is believed the glycaemic threshold at which the 
hypothalamus triggers autonomic systems shifts to a lower plasma glucose level, and 
as a result the patient progresses to reduced cognitive functioning while being unaware 
of their condition.^® The primary cause of this glycaemic unawareness is believed to be 
recurrent hypoglycaemic episodes^®, but it is also associated with increased duration of 
diabetes, and with ageing.
Psychological effects
While hypoglycaemia is rarely life-threatening, its onset can be sudden and its symptoms 
unpleasant. Patients feel it means a loss of control over personal behaviour, and it is a 
source of great anxiety for them and their relatives. Fear of hypoglycaemia is 
recognised as a barrier to the achievement of tight glycaemic control, as patients 
may adopt strategies to avoid it, including eating regular snacks, that prevent them 
from achieving their glycaemic target.
The management of patients with diabetes needs to balance glycaemic control against 
the frequency of hypoglycaemia. There are many aspects to this, including patient 
education and professional support, however the choice of insulin regimen is also 
important. Almost from the start of insulin treatment in the 1920s, efforts have been 
made to produce insulins that can give an insulin profile closer to that seen in normal 
physiology.
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1.3 Insulin structure and pharmacokinetics
I n s u l i n  s t r u c t u r e  a n d  b i o s y n t h e s i s
Insulin is a peptide hormone, made up of an "A" chain of 21 amino acid residues and a 
"B" chain of 30 residues, linked by disulphide bonds (Figure 1.2). It is found in all 
vertebrates and its structure is well conserved although there are species differences.
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F ig u r e  1 .2 :  T h e  STRUCTURE OF in s u l in
The synthesis of insulin by the beta-cells starts with the production of preproinsulin, a 
single peptide chain in which the A- and B-sequences are separated by an intermediate 
segment of 26 to 31 peptides (depending on the species), and with an additional 
24-peptide "signal peptide" attached to the amino-end. The signal peptide is then 
removed, giving proinsulin, and the intermediate peptide chain is then cleaved producing 
insulin and a free peptide chain known as C-peptide. Both are released into the blood 
stream, so that the presence of C-peptide is a marker for insulin production.
I n s u l i n s  i n  t h e r a p y
Insulins are broadly classified by their origin: animal insulins; bio-synthetically 
produced human insulin; and structurally modified analogue insulins.
Although they are no longer in widespread use, before the commercial production of 
human-sequence insulin in the 1980s^ the insulins used in therapy were derived from 
pigs or cattle. Porcine insulin differs from human at a single residue (having Ala at B30) 
and bovine differs in three (Ala at A8, Val at AlO, Ala at B30).^^’^  ^These differences,
 ^ Biosynthetic human-sequence insulin was approved for pharmaceutical use in 1982.
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together (historically) with contamination of the preparations by peptide fragments, 
affected the immunogenic characteristics of the insulins, with some patients showing 
significant allergic reactions and antibody production. The high purity of modern 
preparations and the move away from animal insulin has reduced the immunological 
side-effects, and much recent development effort has focused on the pharmacokinetic 
properties of insulin, in particular the control of absorption.
Insulin preparations differ in their time to onset, time to peak, and duration of action. 
While the various commercial preparations differ in their exact properties, they are 
broadly classified as shown in Table 1.3. Commercial products may be single-action 
preparations, or pre-mixed formulations containing a short or rapid-acting component 
together with an intermediate form, in various proportions.
Table 1.3: I n s u l in  p h a r m a c o k i n e t i c  p r o p e r t i e s
Action Onset Peak Duration Type Products
Short 30-60 mins 2-4 hr 5-8 hr Animal, human ‘Regular’
Rapid (Fast) 10-15 mins 60-90 mins 4-5 hr Analogue Lispro, Aspart, 
Glulisine
Intermediate 1-3 hr 5-8 hr Up to 18 hr Animal, human NPH, Lente, 
isophane
Long 3-4 hr ~15 hr 22-26 hr Animal, human "Ultralente"
Extended long 90 mins Relatively
peak-less
~24 hr Analogue Glargine,
Detemir
Ultra-extended 90 mins Relatively
peak-less
~40 hr Analogue Degludec
The original injectable preparations were (essentially) solutions of animal insulin in 
water, and modern versions of this short-acting soluble insulin are still in use, typically 
as the "bolus" component of a basal/bolus regimen, or as the sole insulin in pump 
therapy. Soluble insulin (human or animal) forms dimers and hexamers around a zinc 
cation that dissociate slowly after injection, slowing absorption and producing a 
relatively long time to peak. This is inconvenient for patients, who have to inject well in 
advance of meals, and the relatively long duration increases the risk of hypoglycaemia. 
These drawbacks led to the development of soluble fast-acting insulins (lispro, aspart 
and glulisine) whose profile more closely resembles natural "bolus" insulin production. 
These analogue insulins (available in the UK from the mid-1990s), have a more rapid 
onset and peak (giving more flexibility in mealtimes), and a shorter duration (and hence
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a reduced risk of hypoglycaemia).
Almost immediately after clinical usage began, attempts were made to extend the 
duration of action, and in the 1930s it was discovered that the addition of protamine (a 
highly basic protein) to regular insulin induces the formation of poorly soluble crystals 
and so delays the rate of absorption from the injection site. These neutral protamine 
Hagedorn (NPH) or isophane insulins are still in use, and have the advantage that they 
can be pre-mixed with soluble insulins.
Complexing the insulin with zinc chloride as well as protamine to produce a defined 
ratio of free to bound insulin causes crystals to form, producing intermediate and longer 
acting insulins. Such mixtures have been in use since the mid 1940s. Unlike NPH 
insulin, zinc insulins cannot be premixed. l.72;74 j^ore recently extended-action analogue 
insulins have been developed. These have a relatively peak-less profile, to mimic natural 
basal insulin more closely.
Analogue insulins are structurally modified to achieve their different absorption profiles, 
differing in structure from both human and animal insulin; those in use in the UK are 
shown in Table 1.4.
Table 1.4: S t r u c t u r e  a n d  p r o p e r t i e s  o f  a n a l o g u e  i n s u l i n s
Insulin Structure Mechanism
Lispro B28 = Lys, B29 = Pro Less likely to self-associate Into dimers than human 
Insulin, and hence more rapid absorption and onset
Aspart B28 = Asp Less likely to self-associate Into hexamers than 
human Insulin, and hence more rapid absorption and 
onset
Glulisine B3 - Lys, B29 = glutamic 
acid
Less likely to self-associate Into hexamers than 
human Insulin, and hence more rapid absorption and 
onset
Glargine A21 = Gly, B31 = Arg, B32 = 
Arg
Formulated at pH 4.0. In subcutaneous Injection 
forms micropreclpltates at physiological pH which 
slows absorption, giving long-acting insulin
Detemir B30 removed, B29 acylated 
with a 14-carbon fatty acid.
Associates with the fatty acid binding sites of albumin 
In the blood and peripheral tissues, reducing Its 
effective plasma concentration and producing 
long-acting Insulin
Degludec One amino acid removed, 
and conjugated with 
hexadecanedlolc acid at 
B29
Basal Insulin that forms soluble multlhexamer 
assemblies, giving an ultra-long action profile.
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Insulin manufacturers adjust their formulations to control absorption after injection, but 
many other factors affect the rate of absorption in an individual. These include the site of 
injection (absorption is fastest from the abdomen, then the arm, then the leg) and the 
skin blood flow (affected by exercise, temperature and massage). Other variables include 
the fraction of the dose absorbed, the dosage (increased doses extend insulin action), the 
rate of elimination, the time to reach the target sites and bind to its receptors, and the rate 
of glucose transportation and degradation. As a result each individual shows substantial 
variation in their response: up to 25% in their reaction to regular insulin and up to 50% 
to longer-acting insulins, although detemir has been found to have a lower 
within-subject variability, and hence a more predictable glucose-lowering effect.
Insulin manufacture is subject to commercial, as well as clinical, influences. Some 
manufacturers are tending to promote the use of analogue products (which are more 
expensive), and animal insulins have largely been w ith d ra w n d e s p ite  concerns, often 
from patient-interest groups, about the restriction of patient choice and the safety of the 
newer products. Balanced against this are the purported benefits of the analogue 
insulins: a greater flexibility over mealtimes, and a reduced risk of hypoglycaemia, 
particularly at night.
1.4 Research aims and hypotheses
The introduction of analogue insulins extended the choices available to clinicians, while 
the reduced availability of animal insulins may have encouraged (or required) patients to 
switch to either human or analogue products. In addition, given the importance of tight 
glycaemic control, the relative risk of hypoglycaemia with different types of insulin is of 
clinical interest. The impact on hypoglycaemia of the different insulins has been widely 
considered, and is discussed in the Literature Review section. However, most published 
comparisons of insulins were from clinical trials, which involve selected groups of 
patients under controlled conditions. Such trials do not necessarily reflect the day-to-day
Novo Nordisk Pharmaceuticals Ltd discontinued their animal insulin products at the end of 2007, and by 
2009 only one manufacturer, Wockhardt, supplied animal insulins in the UK.
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experience of insulin-using patients, and the benefits observed in trials may not be 
attained in "real-life" practice.
In the UK health care is accessed primarily through General Practitioners; their 
importance in the management of patients with diabetes was recognised in the Quality 
and Outcomes Framework for Diabetes and the NICE Diabetes Pathway. In general,
GPs are responsible for the initial diagnosis and subsequent reviews, for instigating and 
reviewing treatments, and for referrals to specialist services.
The General Practice Research Database (GPRD) is a database of primary care 
information collected from participating UK GPs. Given the central role of GPs in the 
management of patients with diabetes, the aims of this study were, using GPRD data, to 
assess the impact of the introduction of analogue insulins on prescribing in the UK, and 
to ascertain whether, in the normal day-to-day management of their diabetes, analogue 
insulins were of benefit to patients in terms of their risk of hypoglycaemia.
It was hypothesised:
A: That GP’s insulin prescribing practices would change following the introduction of
analogue insulins, and that GPRD prescription records could be used to track those 
changes.
B: That GPs would be selective in their use of analogue insulins, choosing between
human or analogue products based on the patient’s characteristics, and hence that 
the GPRD data could be used to predict the chosen insulin.
C: That GP’s would change a patient’s insulin regime depending on their medical
history and characteristics, and that GPRD data could be used to predict such 
changes.
D: That GPRD records could be used to determine differences in the "real-life" risk of
hypoglycaemic events between patients using analogue and human insulins.
These hypotheses were tested in studies on insulin-using patients with diabetes using 
data from the GPRD.
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1.5 Data Source: the General Practice Research Database
All the data used in this study was taken from the UK General Practice Research 
Database (GPRD), a research database containing primary care medical records 
collected from over 400 UK GP practices.
E v o l u t io n  o f  t h e  GPRD
The GPRD evolved from a system initially developed by Dr Alan Dean, a GP who 
commissioned software to manage his own general practice. In 1987 Dr Dean formed a 
company -  Value Added Medical Products (VAMP) -  to introduce this software into 
other general practices and so generate a research database (the VAMP Research 
Databank). Participating GPs received practice computers and the VAMP software in 
return for submitting anonymised patient data. In November 1993 VAMP was taken over 
by Reuters and in 1994 the database was given to the UK Department of Health (DoH), 
who renamed it the "General Practice Research Database".
Management of the GPRD originally resided with the Office of Population Censuses and 
Surveys (OPCS), which was later merged into the Office for National Statistics (ONS). In
1999 management of the GPRD was transferred to the Medicines Control Agency 
(MCA) and in April 2003 the Department of Health created the Medicines and 
Healthcare products Regulatory Agency (MHRA), of which the MCA formed part. A 
not-for-profit agency of the MHRA (also called the "GPRD") assumed responsibility for 
the database and issued licences for its use.** Development continued, and in October
2000 the MHRA launched a restructured database as the Full Feature GPRD (FF 
GPRD). This was available on-line (in a version updated every few weeks) as well as a 
"snapshot": a copy of the data at a particular time which was not then updated. Although 
not as up-to-date as the MHRA on-line system, such snapshots allow more flexible 
access to the data and, since they do not change, mean that analyses conducted over the
There was a further change of responsibility after the data for this study had been extracted. In April 
2012 the GPRD was placed under a new agency: the Clinical Practice Research Datalink service 
(GPRD). This was formed by the Department o f Health’s National Institute for Health Research (NIHR) 
in partnership with the Medicines and Healthcare products Regulatory Agency (MHRA), as part of the 
government’s strategy for the development of electronic medical records. After this merger the preferred 
database name became the "Clinical Practice Research Datalink" (CPRD) rather than the GPRD, how­
ever, as the data was extracted before this change, in this thesis the original name will be used.
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lifetime of a project are consistent.
The University of Surrey licensed access to the FF GPRD, and received "snapshots" of 
data at approximately yearly intervals, which were loaded into an ORACLE relational 
database. This study used a snapshot containing entries up to February 2009 (which will 
be referred to as GPRD2009).
G P R D  DATA STRUCTURE
The GPRD database had 3 main data tables; a "Patient" table containing demographic 
data; a "Medical Record" table with coded symptoms, diagnoses and observations; and a 
"therapy" table holding coded prescription and device data. Other tables held the full 
GPRD clinical and product dictionaries as well as supplementary information such as 
referrals, test and screening results, vaccinations, and records of height, weight, smoking 
and alcohol use. Patients were fully anonymised, and identified within the database by a 
unique identifier.
I n f o r m a t i o n  c o l l e c t e d  f r o m  GPs
From its inception, each participating practice has been required to meet certain 
standards of accuracy and completeness before its data were considered to be "of a 
standard suitable for research". Up to 1997 regular audits were carried out and practices 
were assessed on quality criteria including the percentage of prescriptions with 
associated clinical indications; levels of recording of deaths, pregnancy outcomes and 
contraception; and the consistency of trends in consultations and prescriptions. While 
the procedures changed with the transfer to the MCA, the validation criteria remained 
broadly the same. To reach the research standard practices must have been using the 
software for at least one year and must enter at least 95% of a defined set of "research 
information"^®:
• Patient demographics for all active patients, including sex, year of birth (full date for 
children aged under 5), date of registration, registration s ta tu s a n d  a family number.
• Every prescription issued, whether by the GP, health visitor, district nurse or 
specialist nurse.
Examples of registration statuses include "permanent", "temporary", "death", and "left practice"
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• All "significant" morbidity events, including the initial indication for a drug or other 
treatment (and the original indication for repeated treatments); drug or treatment 
adverse reactions and withdrawals; hospitalisations or referrals to a specialist.
• All diagnoses and procedures communicated by hospitals or other specialist units.
• The date of the original onset of a chronic or recurrent condition (although full 
history summaries are not mandatory).
• Death, including the date and (where known) the cause.
• The outcome of pregnancy, with the condition of the newborn also entered in the 
child’s own record.
When the standard is reached, the practice is assigned an up-to-standard (UTS) date, 
from which time their data are considered suitable for research. Once a practice has 
achieved UTS status it is never revoked (Personal communication, R Williams, 2008).
GPs have considerable discretion in how they use the software, and many also record 
additional information, such as test and pathology results, height, weight and blood 
pressure, and "lifestyle" factors such as smoking status and alcohol usage. These are not 
obligatory. However, recording has increased in recent years, partly due to increased 
automation in (for example) the receipt of laboratory test results, and partly due to the 
inclusion of various monitoring standards in the Quality and Outcomes Frameworks 
(QOF) introduced in 2004 as part of the revision of NHS contracts for General Medical 
Services.
To aid consistency, the diagnoses, symptoms and any drugs or devices prescribed are 
selected from dictionaries encoded within the GPRD software. The "clinical" dictionary 
contains Read Clinical Terms, while drugs and devices are coded using the multilex 
product code (as used by the Prescription Pricing Authority^^) and British National 
Formulary (BNF) subsection.
GPRD POPULATION
GPRD2009 contains data from 1987 onward, albeit for a limited number of practices and 
with relatively few patients achieving the required quality standard. By 1992 1.5 million
The Prescription Pricing Authority is a Special Health Authority within the NHS responsible for pay­
ments to pharmacists, appliance suppliers and GPs for prescribed drugs and other materials.
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patients were contributing, and patient numbers peaked in 2005/6 at around 3.6 million. 
(Figure 1.3). Overall 6 .8  million individual "valid" patients with "non-temporary" 
registrations from 477 practices contributed to GPRD2009 at some point.
0  0 ) 0 ) 0 )
Calendar year
Figure 1.3: N u m b e r  o f  v a l id ,  n o n - t e m p o r a r y  p a t i e n t s  c o n t r i b u t i n g  t o  
GPRD2009 BY CALENDAR YEAR
Recruitment for the GPRD was national, and the age and sex distributions of patients 
were close, although not identical, to the UK population estimates by the Office for 
National Statistics (ONS), as illustrated by the comparisons for 2008 shown below. In 
2008 3.4 million "valid", non-temporary patients contributed to GPRD2009, ~ 6 % of the 
UK population, although with some over-representation of England and Wales and 
under-representation of Scotland (Table 1.5).
Table 1.5: UK p o p u l a t i o n  in m id 2008: c o m p a r i s o n  o f  O f f i c e  f o r  
N a t i o n a l  S t a t i s t i c s  m id - y e a r  e s t i m a t e s  w i t h  GPRD2009
Source England Wales N.Ireland Scotland Female Male
ONS®^ 83.8% 4.9% 2.9% 8.4% 50.9% 49.1%
GPRD2009 87.0% 6.7% 2.7% 3.7% 51.3% 48.7%
GPRD2009 had a marginally lower proportion of males, and a correspondingly 
marginally higher proportion of females than the ONS estimates (Table 1.5). Similarly 
there were slight differences in the age distribution (Figure 1.4), with GPRD2009 
containing slightly more older people, and slightly fewer younger people than the
26
1. Introduction Data Source; the General Practice Research Database
national estimates.
The MHRA have themselves compared the GPRD and UK populations, taking the 
GPRD population on the date of the UK national census (27^  ^March 2011) and 
comparing it to available census, mortality and practice data. They found that the 
practices contributing to the GPRD tend to be larger than the national average, and also 
reported the under-representation of younger age groups and of men. They concluded 
that the GPRD was generally representative of the UK population.
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Figure 1.4: U n i t e d  K in g d o m  m id - y e a r  p o p u l a t i o n  in 2008: c o m p a r i s o n  o f  t h e  
AGE d i s t r i b u t i o n  IN THE OFFICE FOR NATIONAL STATISTICS’ 
ESTIMATES®^ WITH GPRD2009
These differences are slight, and were not considered to affect the validity of the GPRD 
data for this study.
D a t a  c e n s o r i n g
GPRD data are dynamic. Contribution to the GPRD is voluntary: practices enter and 
leave the scheme, and individual patients start and cease contributing data. Accordingly, 
GPRD data are both left and right censored.
A patient has a left-censor date of the latest date of the practice’s UTS date and the date 
they join the practice, and a right-censor date of the earliest of the date they die, transfer 
out of the practice, or the last date on which the practice exported data, as illustrated in
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Figure 1.5.
Practice
Patient A
Patient B
f P ractice ach iev es  up-to-standard  sta tu s
4  Jo ins practice 
LEFT CEN SOR
Last d a ta  collection date
RIGHT CEN SOR
LEFT CEN SOR
4  leaves  practice 
RIGHT CEN SOR
Figure 1 .5 :  P a t i e n t  c e n s o r i n g  in t h e  GPRD
Accordingly, the patient’s UTS time is bounded by their left and right censor dates, and, 
although their GPRD record may contain events outside this period, these are not 
considered reliable enough for research. In particular, censoring means that the date 
when a condition was first diagnosed (it’s "index date") cannot be accurately found for 
patients who developed the condition before their left-censor date (these are referred to 
as "prevalent" patients, meaning they already had the condition at the start of their 
up-to-standard data period).
Data validity
There have been a number of studies of the validity of the GPRD data. Drug safety 
studies by the Boston Collaborative Drug Surveillance Program (BCDSP) in 1991 and 
199290 cross-referenced a sample of GPRD data to the paper records. The studies found, 
respectively, that 87% of consultants’ letters had a corresponding clinical diagnosis in 
the GPRD and 93% of patients with inpatient referrals had a matching diagnostic code. 
The BCDSP concluded that the GPRD prescribing data and clinical recording of 
illnesses was "reasonably complete".
One of the GRPD software’s functions is prescription management, and a study by 
Walley and Mantgania®^ found that 95% of prescriptions were recorded.
A 1997 study by Hollowell^^ for the ONS compared consultation rates and prescribing 
in two acute (chicken pox and hay fever) and two chronic (asthma and diabetes)
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conditions with data from the 4th National Morbidity Survey in General Practice^^
(MSGP4). She found records of consultations for chronic conditions to be lower in the 
GPRD than in MSGP4, but thought that this might be because the GPRD, unlike 
MSGP4, does not require every consultation to be recorded. A further study by this 
group (Hansell et a l  compared event and prescribing rates derived from GPRD and 
MSGP4 data for various respiratory conditions, and found them to be generally similar.
Overall, they considered the GPRD to be a useful source of morbidity data.
While these studies are of interest in confirming the general completeness of GPRD data, 
of more direct relevance to this study is the work by van Staa et a l  on the recording of 
various conditions including hypoglycaemia and other diabetic complications. Overall 
they found 90.7% of hospitalisations for hypoglycaemia were recorded in the GPRD, 
with similar high levels for other diabetic complications. They also found good 
agreement between the duration of diabetes from the GPRD and those from patient 
questionnaires (89.0% concordance overall, 96.0% for diabetes of less than 5 years 
duration). GPRD records of smoking status and alcohol usage status (where recorded) 
also agreed closely with the questionnaire, with 94.9% concordance for smoking and 
97.3% for alcohol abuse.
The GPRD is the world’s largest source of longitudinal primary care data, and its 
population can be taken as representative of the UK population. It has been widely used 
in epidemiological studies, including those in diabetes, and over 400 papers based on its 
data have been published in peer-reviewed journals.
Overall, the quality of the prescription and clinical data, and its coverage of the UK 
population, mean that the GPRD is an appropriate source of data for this study.
A survey carried out approximately every 10 years by the ONS jointly with the DoH and the Royal Col­
lege of General Practice. MSGP4, carried out during 1991-1992, collected morbidity data from 60 gen­
eral practices in England and Wales.
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2.1 Objectives and Strategy
O b j e c t iv e
One of the hypotheses driving the analyses presented in this thesis was that primary care 
data could be used to evaluate differences in the "real-life" risk of hypoglycaemic events 
between users of analogue and human insulins. To inform these analyses a review of the 
literature on the differences in the risk of hypoglycaemia between human and analogue 
insulins was carried out.
The objective of the review was to obtain estimates of the relative likelihood of 
hypoglycaemic events in patients using analogue insulin compared to those using human 
insulin.
S e a r c h  s t r a t e g y
The literature review strategy was, firstly, to search for authoritative reviews and 
meta-analyses. If found, these would, I believe, provide a rigorous and reliable indication 
of the balance of evidence over their search period. Relevant studies published after that 
date could then be obtained.
The on-line databases MEDLINE (via PubMed), EmBase and the Cochrane Library 
were searched for reviews or meta-analysis published from the 1st January 2002 onwards 
which referred specifically to human or analogue insulin and hypoglycaemia, were 
published in English and dealt with humans. The search terms used are summarized in 
Table 2.1. Citations without an abstract or without named authors were excluded, as 
were citations for conference or meeting abstracts. No attempt was made to locate
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unpublished studies. The last search date was 17th January 2014.
After removal of duplicate citations, the initial search produced 105 reviews or 
meta-analyses. Their abstracts were reviewed, and publications were excluded if they:
• did not involve direct comparison of human and analogue insulins
• did not report hypoglycaemia as an outcome (primary or secondary)
• were "clinical guidelines" or "briefing papers", i.e. publications that summarized a 
clinical area but did not critically review the evidence
• were restricted to pregnant women (as women with gestational diabetes were 
excluded from the studies in this thesis)
• included only patient groups that were felt to be atypical of the UK population, for 
example reviews of insulin use during Ramadan, or only in patients using insulin 
pumps
• were restricted to patients under special circumstances or with specific conditions, 
for example critically ill or hospitalised patients, cardio-vascular patients, or patients 
recovering from surgery
• were health economic, rather than clinical, studies
Fifty-seven publications were excluded at this stage: Appendix A, Table A .l lists them 
and the reasons for rejection. The full texts of the remaining reviews and meta-analyses 
were reviewed. Publications were retained if they reported risk or rates of 
hypoglycaemia in comparisons of human and analogue insulins: but rejected if they were 
found to meet any of the exclusion criteria listed above or if the publication:
• did not provide a quantitative comparison of hypoglycaemia in users of analogue and 
human insulins, for example publications that compared insulin (without 
differentiating by source) to other therapies (such as GLP-1 or oral antidiabetic 
drugs)
• only reviewed degludec, which was not available in the UK during the study period, 
or inhaled insulin (as few patients used this and it was withdrawn during the study 
period)
• was only available as an abstract (for example from conference proceedings), or the 
body of publication was not in English (even though an English abstract was 
available)
• was funded and written by an insulin manufacturer {i.e. without an external author), 
and included only their own trials
• reviewed only the results from "laboratory" metabolic studies, such as glucose 
clamps
To aid consistent reviewing, an adaptation of the criteria suggested by the Critical 
Appraisal Skills Program^® (GASP) was used; the versions of the questions in the GASP
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check-lists are listed in the Appendix, section A.L Twenty-nine publications were 
rejected after the full text review (listed, with reason for rejection, in Appendix A,
Table A.3); the 19 retained publications are listed in Table 2.2.
To obtain studies published after those included in the reviews and meta-analyses, the 
on-line databases were searched (using SCOPUS, which included Medline) for relevant 
observational studies and clinical trials published in 2009 or later (see Table 2.1). As 
before, their abstracts were reviewed against the criteria listed above, an in addition 
publications were rejected if they:
• were case study reports
• were felt to use an unrepresentative patient set, for example studies in only Japanese 
patients
• involved comparisons with novel analogue insulins, i.e. analogue products that were 
not commercially available during the study period
Sixty three publications were rejected after abstract review (listed in Appendix A,
Table A.2), and the full texts of the remaining publications were then reviewed. The full 
texts were reviewed against the above criteria, and were also rejected if they:
• did not state how and from where subjects were recruited, or did not specify the 
inclusion/exclusion criteria for study subjects
• did not (quantitatively) compare hypoglycaemia in at least one group of patients 
using only analogue insulin to at least one group using only human insulin
Twenty-four publications were rejected at full text review, and 11 retained. The overall 
process is outlined in Figure 2.1.
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Table 2.1 : O n - l i n e  d a t a b a s e  s e a r c h  t e r m s
Reviews and meta-analyses
Medline 1 "hypoglycaemia"[AII Fields] OR "hypoglycemia"[MeSH Terms] OR "hypoglycemia"[AII 
Fields]
2 "insulin/analogs and derivatives"[MeSH Terms] AND ((Review[ptyp] OR 
Meta-Analysislptyp]) AND English[lang] AND ("2002/01/01"[PDAT] : "3000/12/31 "[PDAT]) 
AND "humans"[MeSH Terms])
3 (#2) AND (systematicfTltle/Abstract] OR meta-analysis[Tltle/Abstract]) NOT 
(receptorfTltle] OR pharm acokinetics [Title] OR "growth factor" [Title] OR pharmacokinetic 
[Title] OR intranasal [Title] or d esign  [Title] or oral [Title] or peptide-1 [All Fields] OR 
pregnancy [All Fields] OR cancer [All Fields] OR malignancy [All Fields])
4  (# 1 )A N D (# 3 )
EMBASE 1 ’insulin derivative’/exp/mj AND ([meta analysis]/lim OR [system atic review]/lim) AND
[humans]/lim AND [english]/lim AND [abstracts]/lim AND ([embase]/lim  OR [em base  
classic]/lim ) AND [2002-2014]/py
2  exenatide:ti OR glyburiderti OR pioglitazone:ti OR pumprti OR gestational:ti OR 
inhibitors:tl OR GLP-1 ;ti OR pregnancy:ti OR infusiomti OR agonists:ti OR ’growth 
factor’:ti OR ’glucagon like’iti OR sulphonylureas:ti OR metforminiti OR pumprti OR 
incretingdi OR acarboserti AND [humans]/lim AND [english]/lim AND [abstracts]/lim AND 
([em base]/lim  OR [em b ase classic]/lim) AND [2000-2014]/py
Cochrane 1 Review titles, abstracts and keywords search ed  for "diabetes" OR "insulin", limited to
Library reviews.
2 Review sum m aries w ere reviewed, identifying th ose  comparing types of insulin.
Additional clinical trials and observational studies
SC O PU S 1 Search on titles, abstracts and keywords(TAK) for hypoglycaem ia OR hypoglycem ia AND 
insulin, restricted to journal articles published in English in 2009  or later
2  (#1) AND (lispro OR aspart OR glulisine OR glargine OR detemir OR degludec)TAK AND
(regular OR nph OR isophane OR ultralente)
3 (#2) AND NOT ["continuous g lu cose  monitoring") OR CSII OR "pump therapy" OR "case
study" OR "gestational diabetes" OR "hyperglycemia" OR "hyperglycaemia" OR  
"pregnancy" OR "health care costs" OR meglitinide OR sitagliptin OR peptide OR 
ramadan or DPP-4
4 The article titles w ere then reviewed. Publications w ere rem oved if the title indicated they  
were: an in-vitro or animal study; a  health econom ic study; a  case-study; w as a  m etabolic  
or pharmacokinetic study; dealt with nursing m anagem ent, or with the care of hospitalised  
or post-surgical patients; involved inhaled insulin; or w ere clearly briefing or information 
papers rather than reports of clinical studies. Citations without abstracts or without nam ed  
authors, and duplicates of previously extracted publications, w ere a lso  rem oved.
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Articles retained for 
full-text review  
n =  35
R ejected  a t  full-text review  
n = 29
R ejected  a t  a b s tra c t review  
n = 57
R etained  rev iew s and  
m e ta -an a ly ses  
n  = 19
R ejected  a t  full tex t review 
n = 24
R ejected  a t  a b s tra c t review  
n = 63
R eview s an d  m e ta -an a ly ses  
re ta ined  for full-text a pp ra isa l 
n = 48
R etained  clinical trials and  
observational s tu d ie s  (not included 
in retained  review s o r m e ta -an a ly ses) 
n = 11
S ea rch  on-line d a ta b a s e s  for review s 
and  m e ta -an a ly se s  relating to  
hypoglycaem ia an d  an a lo g u e  insulins 
n = 105
S earch  on-line d a ta b a s e s  
for clinical trials an d  observational 
s tu d ie s  published after th e  review  or 
m eta-ana ly sis  inclusion d a te s  
n  = 98
Figure 2.1: S y s t e m a t i c  o f  l i t e r a t u r e  a p p r a i s a l  p r o c e s s ,  w i t h  n u m b e r s  o f
PUBLICATIONS
2.2 Retained publications
The 20 reviews or meta-analyses and 11 additional articles retained for the review are 
listed in Tables 2.2 and 2.3 respectively.
More studies involving longer-acting analogue insulins than shorter-acting analogues 
were found. This probably reflects the literature search period: longer-acting insulins 
were the newer products, and the search period covered the release of a number of 
manufacturer-sponsored trials, including non-inferiority evaluations.
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2.3 Literature review: rapid(fast)-acting analogue insulin compared with 
human insulin
R e v i e w s  a n d  m e t a -a n a l y s e s
Two of the retained reviews and 4 meta-analyses compared the risk of
hypoglycaemia in users of rapid-acting analogue insulins and human insulin. The 
findings of the meta-analyses are summarized in Table 2.4.
Heller et a l  in a study funded by Novo Nordisk (who also helped prepare the 
manuscript), compared aspart and regular human insulin (both with NPH insulin as the 
basal component) in RCTs of at least 12 weeks duration, in adults (excluding pregnant 
women). They reported a statistically significant (at 95%) ~24%  reduction in the risk of 
nocturnal hypoglycaemia (defined as events between midnight and 6am) with aspart 
compared with regular human insulin, corresponding to an average of 4.4 episodes/year 
in patients using aspart compared with 5.8 episodes/year in those using regular human 
insulin. No statistically significant difference was found in the risk of "all" 
hypoglycaemic episodes (where the pooled data gave an average of 31.1 episodes/year 
with aspart and 32.9 with regular insulin). A fixed-effects model was used to produce 
summary measures, although the authors did not indicate the heterogeneity of the 
studies. Further concerns are that the analysis combined patients with Type 1 and Type 2 
diabetes, and the data sources used were not specified. No sources were given for the 5 
(of 10) studies that were unpublished.
The analysis by Plank et a l  included RCTs comparing aspart or lispro and regular 
human insulin with durations of 4 weeks or more, in adults (excluding pregnant women), 
where the study arms used the same basal insulin. Their approach seemed rather more 
rigorous than Heller’s, however their study was also funded by Novo Nordisk, who 
assisted in the preparation of the manuscript, and one of the authors was on the Novo 
Nordisk advisory board. Their analysis of all hypoglycaemic events found no differences 
between analogue and human insulins in the standardised rate of hypoglycaemic episodes 
(as episodes/patient-month). However, their analysis did not distinguish between aspart 
and lispro, or between patients using insulin pumps and those manually injecting.
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Given the level of manufacturer involvement with these analyses, the results of the Heller 
and Plank reviews need to be treated with caution.
The meta-analysis by Mannucci et a l  compared short-acting analogues and regular 
human insulin in patients with Type 2 diabetes in RCTs of at least 12 weeks duration. 
Mantel-Haenszel (MH) odds ratios for the risk of severe hypoglycaemia were derived 
using a random effects model: no difference was found between patients using analogue 
and those using human insulin (ORmh0.61 Cl95[0.25,1.45]). However, severe 
hypoglycaemia was rare: only 13 patients using analogue insulin, and only 21 patients 
using human insulin (of a total of 3,466 study participants) had one or more severe 
episodes. The authors did not distinguish between the analogue insulins (which included 
glulisine) in their analysis, nor did they provide any information on nocturnal or overall 
hypoglycaemia. The funding source for the study was not stated.
The Singh et meta-analysis covered a broad range of RCTs. It included adults, 
children and adolescents; Type 1, Type 2 or gestational diabetes and all insulin types 
except glulisine. The study was publically funded (by Health Canada). Study quality was 
assessed independently by two reviewers, and the heterogeneity of the studies was 
evaluated. All of the studies were open-label, but otherwise varied considerably: 
durations were from 4 weeks to 30 months, and the numbers in each study varied from 7 
to 1008. The authors rated the methodological quality of most of the trials as poor.
Depending the data available within the included studies, hypoglycaemia was analysed 
using either the relative risk of a patient experiencing 1 or more episodes during the 
study period, or the rate ratio of the frequency of episodes (as
episodes/patient/unit-time). The meta-analysis found statistically significant reductions 
in the risk of nocturnal hypoglycaemia in adults (by 49%) and adolescents (by 39%) in 
patients using lispro rather than regular human insulin; and a statistically significant 2 0 % 
reduction in severe hypoglycaemia in adults with lispro. No difference in the risk of 
severe or nocturnal hypoglycaemia was found between aspart and regular human insulin.
In addition to the meta-analyses, systematic reviews by Siebenhofer et a l  (for the 
Cochrane Collaboration) and Gough compared short-acting analogues with regular 
human insulin in RCTs.
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Sibenhofer^®^ reviewed 49 studies (of duration 4 weeks or longer), covering Type 1,
Type 2 or gestational diabetes, in any age and sex, and patients using insulin pumps as 
well as only manual injection. Hypoglycaemia was reported in 10 of these (with 4,266 
patients) in Type 1 diabetes, and 5 (with 2,617 patients) in Type 2 diabetes. For these 
studies Siebenhofer derived the weighted mean difference (WMD) in hypoglycaemic 
episodes/month between the analogue insulin and human insulin arms: no statistically 
significant diflferences were found in either Type 1 (WMD -0.23 [CI95- I .I 4 , 0.69]) or 
Type 2 diabetes (WMD -0.17 [CI95-O.4 6 , 0.12 ]). These results did not differentiate 
between lispro, aspart and glulisine, or between patients using insulin pumps and those 
manually injecting. Sibenhofer found most of the included studies to be "of poor 
methodological quality", and noted that many studies did not report on potential 
confounders or potentially important covariates such as co-medication or disease 
severity.
Gough’s review was wide-ranging, including both Type 1 and Type 2 diabetes, and 
longer-acting as well as fast-acting analogues. The review updated a previous 
meta-analysis (and included all its studies), with new publications up to 2005; they also 
contacted insulin manufacturers for details of abstracts or papers in press. The stated 
selection criteria were for at least 50 patients in each treatment group (although one 
study with 28 per arm was included), a treatment duration of at least 3 months, and 
studies involving CSII were excluded. However, no information is given on the numbers 
of studies evaluated, or the quality criteria used for inclusion or rejection. Six of the 
included studies were available only in abstract form. Accordingly, this cannot be 
considered a systematic review. Four of the studies reported by Gough compared 
fast-acting analogues with human insulin in basal-bolus regimes, but only 1 of these 
reported on hypoglycaemia: it found a statistically significant reduction in the rate of 
hypoglycaemia in patients using lispro compared with those using human insulin (3.18 
episodes/patient/30days with lispro, 3.34 with human insulin, p<0.02). In 5 trials 
comparing pre-mixed analogue insulins with pre-mixed human insulins in Type 2 
diabetes (2  of which were based on the same study) found a statistically significant 
difference in the nocturnal hypoglycaemia, with a relative risk of 0.74 (p=0.020) with 
biphasic aspart compared with biphasic human insulin.
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A d d i t i o n a l  c l i n i c a l  t r i a l s
Brock-Jabcobsen et a l  carried out a randomised, double-blinded cross-over trial (two 
periods of 8 weeks) in 16 adults who had had Type 1 diabetes for at least a year, in a trial 
sponsored by Novo Nordisk. The treatment regimes were three daily injections of human 
soluble insulin or aspart in addition to NPH insulin twice daily. The study was primarily 
interested in the counter-regulatory hormone responses, but also reported on the 
frequency of hypoglycaemia (as events/patient-week) defined as a blood glucose level 
<3.5mmol/l. Overall, there were 1.1 ± 0 .2  hypoglycaemic episodes/patient-week in 
patients on human insulin compared to 0.9 ± 0 .1  per week in patients using aspart: the 
difference was not statistically significant (p = 0.34). This study had relatively few 
patients (and 2  of the 16 did not complete the study), but did have the advantage of being 
double-blinded (many of the trials reported in the reviews and meta-analyses were not 
blinded, sometimes due to visible differences between insulin preparations). There did 
not seem to be a "wash-out" period between the two exposure periods: however, given 
the rapid degradation of insulin once in circulation (its half-life is estimated at 4-6 
minutes ^^ )^ it seems likely that there would be little "carry over" from the first treatment 
group.
The multi-centre RCT by Brunetti et a l  was one of the few that had severe nocturnal 
hypoglycaemia as its primary endpoint. They compared lispro and regular human insulin 
in 95 patients using glargine as basal insulin, over a 16 week exposure period with a 
further 2 weeks follow-up. The study subjects were adults (18-60 years) who had had 
Type 1 diabetes for at least 3 years. Women at risk of pregnancy were excluded. Severe 
hypoglycaemia was defined as events needing 3rd party assistance (including glucagon 
or intravenous glucose administration), or the administration of oral carbohydrate -  a 
rather broader definition than used in many studies. Nocturnal hypoglycaemia was 
defined as events while the patient was asleep, between bedtime and getting up in the 
morning. The study compared the proportion of patients with severe nocturnal 
hypoglycaemia: this was a non-inferiority trial, and the results were analysed using a 
one-sided 95% CL No statistically significant difference was found between the lispro 
and the regular human insulin groups.
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O b s e r v a t io n a l  s t u d ie s
One of the disadvantages of clinical trials, which are often of relatively short duration, is 
that they generally report a very low rate of severe hypoglycaemic events. Observational 
studies, particularly those based on longitudinal data sources such as primary care 
databases, may offer a better approach to studying these uncommon events. Accordingly, 
recent observational studies that reported on hypoglycaemia were reviewed.
Hermansen et a l  carried out a sub-group analysis in the PREDICTIVE study* on 
2,923 patients on a basal-bolus regime at the start of the study who were switched to a 
regime of detemir with either a human (500 patients) or analogue bolus component 
(2,423 patients)/ram a NPH + human bolus (849 patients), a NPH + analogue bolus 
(1,144 patients), or glargine + analogue bolus regime (704 patients). The analysis, which 
was funded by Novo Nordisk (who also provided editorial support for the production of 
the manuscript), looked at the reduction in the mean incidence of hypoglycaemia 
following the switch. Hypoglycaemia (as recalled by the patient) was recorded in the 4 
weeks before the switch, and in the 4 weeks "before follow-up" (26 weeks). The analysis 
found statistically significant reductions (all with p<0 .0 0 1 ) in the mean incidence of 
hypoglycaemia at 26 weeks in all 4 patient groups, however, there are a number of 
methodological concerns with this analysis. Apart from the risk of recall bias, the 
follow-up period in the original PREDICTIVE study protocol was between 12 and 52 
weeks: this study did not report how many patients on a basal-bolus regime at baseline 
dropped out before the 26 week follow-up. It is possible that patients may have 
discontinued detemir as they experienced adverse events, including hypoglycaemia. In 
addition, the analysis included only those patients who had both baseline and end-point 
data on hypoglycaemia: the observed numbers of hypoglycaemic events were not stated, 
and it is unclear whether or not patients with no reported hypoglycaemia at baseline were 
included in the analysis. The comparison of the risk of hypoglycaemia did not adjust for 
patient characteristics such as body mass or duration of diabetes (although this 
information was available), and included both Type 1 and Type 2 patients. Overall, while 
this study suggests a reduction in the risk of hypoglycaemia following a switch to
The PREDICTIVE study was a multinational, observational study, sponsored by Novo Nordisk, evaluat­
ing detemir in Type 1 and Type 2 diabetes
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regimes including detemir, the results must be treated with caution.
The frequency of hypoglycaemic episodes in patients with diabetes was estimated by 
Kristensen et a l  using a questionnaire sent to unselected Type 1 patients from 6 
Danish diabetes clinics. Patients were asked to report severe and mild episodes in the 
preceding year, and 3,861 (of 6,112, 63.2%) returned the questionnaire. In an adjusted 
regression analysis the authors found no statistically significant differences in the risk of 
severe hypoglycaemia in patients using rapid-acting analogue or short-acting human 
insulin (patients using both were excluded from the analysis). There are clear risks of 
bias in such self-selected data, and the authors noted that a large proportion of the severe 
episodes were accounted for by a minority of subjects.
The effect of insulin type on severe hypoglycaemic events requiring hospital inpatient or 
emergency department treatment was evaluated by Solomon et a l  in an observational 
study (in the United States) using administrative data from self-insured employers. The 
study subjects were 8,626 adults between 18 and 65 years of age with Type 2 diabetes 
(and private health insurance) with no history of severe hypoglycaemia before the start of 
their insulin therapy and who were in their first year of insulin use. Follow-up was for at 
least one year (although the authors do not give information on the actual follow-up 
periods). The study included all types of analogue insulins: 1,930 patients used 
fast-acting analogues, of whom 50 had a severe hypoglycaemic event. Using adjusted 
Cox proportional hazard models the authors found a greater risk of severe 
hypoglycaemia in users of rapid-acting insulin compared with a reference group of 
patients on a basal-bolus regime (HRadjl-9 CIg5 [1 .4 , 2.7]), but the specific insulins used 
by the reference group were not defined. Severe hypoglycaemia was rare, seen in only 
2 .6 % of those using rapid-acting analogue insulin, with an observed event rate of 0.82 
events/100-patient-years. Like all observational studies, there are some methodological 
concerns. The patients, as employed people with private health care, may not have been 
representative of the general US population. The assignment to insulin groups for 
analysis may also have introduced bias. Patients were partitioned into users of detemir, 
glargine, rapid-acting, premixed, or NPH insulin. Patients who experienced a severe 
event were grouped according to the insulin they were using immediately prior to the 
event, but where patients used more than one insulin they were assigned based on the
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highest cumulative days of usage since the start of their insulin therapy (as were all those 
who had no events). Patients were also divided into "basal-bolus" or "rapid-only" 
regimes based on the proportion of rapid-acting insulin in their cumulative insulin use:
<25% defined them as rapid-only. There was, therefore, no clear distion between the 
patient groups. This, together with the lack of information of patient compliance, must 
increase the risk of incorrect assignment of exposure. Although the authors conclude 
that the reductions in severe hypoglycaemia seen with glargine were "substantial and 
clinically significant", this was an overstatement of the results of the study.
2.4 Literature review: longer-acting analogue insulin compared with human 
insulin
R e v ie w s  a n d  m e t a -a n a l y s e s
Nine reviews ^ 8;99;100;101;104;126;111;112;113 y meta-analyses 96;97; 103; 106; 126; 108; 110
compared the longer-acting analogue insulins glargine and detemir"! to human insulins, 2  
of which (Singh and Sanches ^ !^^ ) also reviewed short-acting insulins, and were 
discussed above.
The finding of the meta-analyses, apart from Home^^^  ^ and the Monami Type 2 
analysis, are summarized in Table 2.5, which also includes the summary measures 
from the Horvath and Vardi reviews. The Home meta-analysis structured their results in 
a different way to most of the other meta-analyses, so the results could not be easily 
tabulated. The Monami Type 2 meta-analysis only reported the hypoglycaemia results 
(as Mantel-Haenzel hazard ratios) graphically, so the exact numerical values were not 
available.
 ^ The ultra-extended analogue insulin, degludec, was not available in the UK during the study period.
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The meta-analysis by Sanches et a l  was unusual in that it included only 
double-blinded, non-crossover clinical trials: most of the other studies also included 
open-label and cross-over trials. Sixteen RCTs of least 4 weeks duration in adults with 
"established" (which was not defined) Type 1 diabetes were included. Pooled data was 
analysed using random-eifects models to estimate the odds-ratio of (any episode of) 
hypoglycaemia for patients using (amongst other comparisons) analogue insulin 
compared with those using human insulin. No statistically significant differences were 
found between users of lispro or aspart and users of human insulin. Sanches found no 
statistically significant differences in the odds-ratio for any hypoglycaemic episode 
between glargine and NPH or between detemir and NPH. However, the authors noted 
high heterogeneity in these studies.
Bi et a l  reported on RCTs with a duration of 12 weeks or more in insulin-naive adults 
(aged 18 or older) with Type 2 diabetes. One arm of their meta-analysis compared 
long-acting analogue insulin with human insulin (the other 3 compared long-acting 
analogue insulin with rapid-acting analogue insulin, biphasic analogue insulin, and 
GPL-1), and the outcome measures included the incidence of total, nocturnal and severe 
hypoglycaemia. The authors derived odds ratios for the risk of the various classes of 
hypoglycaemia using a random effects model. They found statistically significant 
reductions in the risk of both nocturnal (by 54%) and overall (by 43%) hypoglycaemia in 
patients using long-acting analogue insulins compared with those using NHP insulin.
They did not, however, distinguish between the different types of long-acting analogue 
insulins.
Home et a l  carried out a meta-analysis of 5 RCTs comparing the risk of 
hypoglycaemia in patients with Type 2 diabetes using glargine to those using NPH 
insulin, with study durations of 24 weeks (3 studies), 28 weeks (1 study) and 52 weeks (1 
study). Using patient-level data they estimated the odds ratio of the proportion of 
patients in the study arms with at least one hypoglycaemic event, adjusted for changes in 
the patient’s HbAic over the study period. For analysis the patients were divided into 
two pools depending on whether their glargine was given in the evening (pool 1, 2,711 
patients) or morning (pool 2,470 patients). The authors categorised hypoglycaemic 
events as symptomatic with PG <2.0 mmol/1; symptomatic with PG <3.9 mmol/1; or
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severe (using the definitions in the study protocols), and reported their results in each of 
these categories by "daytime", "nocturnal" and "total" hypoglycaemic events. The 
comparison of glargine with NPH insulin found no difference in either patient pool in the 
day-time risk of (any category of) hypoglycaemia, and no difference in pool 2  (morning 
glargine) in total hypoglycaemic events. However, there was a statistically significant 
reduction in the risk of (both categories of) symptomatic nocturnal hypoglycaemia in 
patients receiving evening glargine (pool 1) ORadjO.44 Cl95[0.25,0.76] for PG < 2  
mmol/1; ORadjO.52 CI95 [0.35.0.76] for PG <3.9 mmol/1). Patients receiving morning 
glargine (pool 2) had a reduced risk of the <3.9 mmol/1 category of symptomatic 
nocturnal hypoglycaemia (O R adj0.20 CI95fO.ll, 0.34], but no difference was found in 
the <2.0 mmol/1 category of symptomatic nocturnal hypoglycaemia. The authors also 
calculated the number needed to treat (NNT) with glargine to prevent a single episode of 
hypoglycaemia. They estimated the NNT as 8 for pool 1 patients and 5 for pool 2  
patients, relatively low numbers that the authors suggest is a clinically important result.
While the authors note that the patients in their studies were well matched in their 
baseline characteristics, they also noted that the studies were open-label, that 
hypoglycaemia was not a primary end point in any of them and that the methods of 
collection of hypoglycaemia data on varied. The authors concluded that glargine offers 
clinical benefits, however the review was funded by Sanofi-Aventis, their publications 
department provided "editorial support", and one of the authors was an employee of the 
company.
Szypowska^^^ analysed open-label RCTs with a duration of at least 12 weeks that 
compared detemir with NPH insulin in basal-bolus regimes in patients who had had 
Type 1 diabetes for at least a year. In addition to published studies, unpublished trials 
from the Novo Nordisk research database were included (3 of the total of 10 retained 
trials). All but one of the studies used aspart as the prandial insulin. The meta-analysis 
found statistically significant reductions in the risk of nocturnal (22%), severe (34%) and 
total (2 %) hypoglycaemic episodes in patients using detemir compared with those using 
NPH insulin, although the result for total episodes might be considered marginal. The 
authors noted that all of the studies were open-label, and the 3 Novo Nordisk trial reports 
did not include details of randomization. While the study was sponsored by the Medical 
University of Warsaw, Novo Nordisk funded a medical writing company to edit the
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paper, and one of the authors was a shareholder in a consulting company associated with 
Novo Nordisk.
The meta-analysis by Bazzano et a l  compared glargine and NPH insulin in RCTs with 
a minimum duration of 4 weeks in patients with Type 2 diabetes. Although the primary 
outcomes for the meta-analysis were changes in fasting plasma glucose, HbAic and body 
weight, where data was available the authors calculated the mean percentage of patients 
experiencing a given type of hypoglycaemic events, weighted by study size. The authors 
noted "substantial differences" in the definitions of hypoglycaemia across the studies.
They found statistically significant reductions in nocturnal, severe and "any" episodes of 
hypoglycaemia in users of glargine compared with users of NPH insulin. The reported 
results for hypoglyaemia give the number of trials that reported on symptomatic, 
noturnal, severe or "any" hypoglycaemia, but do not state which trials they were. Hence, 
the numbers of patients in these comparisons was unknown.
Monami has published two meta-analyses comparing longer-acting analogue insulins to 
NPH insulin in 18 RCTs in Type 1 and Type 2^^^ diabetes respectively, both of which 
reviewed RCTs of at least 12 weeks duration, and both of which used summary data from 
the study for the analysis. The Type 1 study included 20 RCTs, 4 of which were 
unpublished studies from trial registries. 15 trials reported on severe hypoglycaemia, 13 
on "any" hypoglycaemia, and 14 on nocturnal hypoglycaemia. There were substantial 
differences between the studies included in the analysis: study durations varied from 12  
weeks to over 104 weeks, the mean age of the subjects ranged from 13.5 to 42.9, and 
their duration of diabetes from 4 months to over 18 years; but the authors do not discuss 
heterogeneity. The meta-analysis reported a statistically significant 27% reduction in the 
risk of overall hypoglycaemia, and a statistically significant 31% reduction in the risk of 
nocturnal hypoglycaemia in patients using long-acting analogue insulin compared with 
those using NPH insulin. The meta-analysis did not distinguish between glargine and 
detemir. Monami’s Type 2 meta-analysis included 14 RCTS, all published studies, 
that compared glargine or detemir with NPH insulin. Eight of the studies reported on 
severe hypoglycaemia, although in 2  studies no events were recorded in either trial arm.
Seven reported symptomatic hypoglycaemia, and 10 nocturnal hypoglycaemia, all as the 
number of patients with at least one event. No information was given on how
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hypoglycaemia was defined in the trials. The patients in the trials were reasonably 
homogeneous, with mean ages of between 56-61 years and mean duration of diabetes 
7-13 years, although the authors did not discuss the data heterogeneity. This analysis 
was not included in Table 2.5 because the results for hypoglycaemia were shown only as 
a forest plot {i.e. no numerical values for the HR and Cl were given). The plot did not 
show any statistically significant difference between long-acting analogue and NPH 
insulin in the risk of severe hypoglycaemic, but did show statistically significant 
reductions in risk for nocturnal and symptomatic hypoglycaemia of (approximately) 55% 
and 25% respectively. The results did not distinguish between glargine and detemir.
Neither analysis gave information on how the various classes of hypoglycaemia were 
defined in the trials but both noted that "the only consistent definition ... was that of 
severe hypoglycaemia".
In addition to the meta-analyses, a number of reviews compared longer-acting analogues 
to human insulin.
Vardi et and Horvath et al. were systematic reviews for the Cochrane 
Collaboration. Vardi compared intermediate-acting (NPH or lente) and long-acting 
insulin (glargine, detemir or ultralente) patients with Type 1 diabetes, while Horvath 
compared long-acting analogue insulin to NPH insulin in Type 2 diabetes. As Cochrane 
reviews, both included only randomised controlled trials.
Vardi et al. reviewed 25 RCTS, 17 of which reported on hypoglycaemia. Hypoglycaemia 
was classified as "usual", "nocturnal" or "severe"; the author noted that studies differed 
in their definitions of hypoglycaemia, and that most authors tended to emphasise severe 
events. He also commented that the quality of the studies was "at best, intermediate". 
Hypoglycaemic event rates were estimated as both the percentage of patients 
experiencing events and the number of events per patient per 100 follow-up days. The 
authors derived Mantel-Haenzel odds ratios based on the percentage of patients 
experiencing hypoglycaemia, and found a statistically significant reduction in risk 
(shown in Table 2.5) in users of analogue insulin. The reported results did not 
distinguish between the various analogue products. Vardi was cautious in his 
conclusions, suggesting the analogues offered "only a modest clinical benefit" compared
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to human insulins, although noting the benefits for nocturnal hypoglycaemia,
Horvath reviewed 8 open-label clinical trials that compared long-acting analogues with 
NPH insulin in patients with Type 2 diabetes, and, unusually, considered hypoglycaemia 
as a primary outcome. "Overall", "severe" and "nocturnal" hypoglycaemia were analysed 
using the Peto-Odds ratio (as event rates were low). Horvath found statistically 
significant reductions in the risk of overall and nocturnal hypoglycaemia in uses of 
analogue insulins compared with human insulins: the odds-ratios are shown in Table 2.5.
The methodological quality of all the included studies was rated "low", and Horvath 
notes that information on potentially important confounders or covariates was rarely 
provided. Like Vardi, Horvath was cautious in his conclusions, suggesting "only a minor 
clinical benefit" in symptomatic nocturnal hypoglycaemia with longer-acting analogue 
insulins.
The review by Duckworth and Davis which was sponsored by Sanofi-Aventis, 
compared glargine and NPH insulin in Type 2 diabetes. It included 8 clinical trials that 
reported on hypoglycaemia, one of which was only available as a conference abstract and 
one was an unreported trial from the Sanofi-Aventis database. The included studies 
varied in duration from 4 weeks to 1 year, and all were open label. No information was 
given on the studies’ criteria for hypoglycaemic episodes. Statistically significant 
reductions in nocturnal hypoglycaemia were reported in 6 of the trials (one did not report 
on nocturnal hypoglycaemia, and in one the result was not significant). For "overall 
symptomatic" hypoglycaemia, 5 trials reported statistically significant reductions,
(results were not significant in 3 trials). Where significant reductions were seen, there 
was substantial variation in the observed rates: the percentage of patients experiencing 
symptomatic hypoglycaemia (in the 4 trials that reported this) varied from 13.7% to 46% 
of those on glargine, and 1.7% to 60% of those using human insulin. The 5th study 
reported 5.5 episodes per year in glargine users compared with 8.0 episodes in users of 
human insulin. Confidence intervals were not given. Only 2 trials reported on severe 
hypoglycaemia, and no statistical comparisons for this were included in the review.
While the authors concluded that although glargine and NPH insulin were equally 
effective in achieving glycaemic control (they also analysed HbAic and FPG), glargine 
was associated with "a significantly lower risk of hypoglycaemia", this was not fully
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supported by the data they reported. The p-values in the 5 trials that reported reductions 
on overall hypoglycaemic events were 0.04,0.002, "<0.02" and, in two trials, "<0.05"; 
none of which gives a very strong presumption against the null hypothesis, and 3 of the 
studies found no differences between glargine and NPH insulin.
Wang et al. conducted a wide-ranging review comparing glargine and human NPH 
insulin. They searched for all clinical trials of glargine with 100 or more patients, and 
included 14 trials comparing glargine with NPH insulin. All the trials were open-label, 
with durations of between 4 to 52 weeks, and the incidence of hypoglycaemia was a 
secondary endpoint. In the 7 trials in patients with Type 1 diabetes, 3 found a statistically 
significant reduction in the risk of symptomatic hypoglycaemia with glargine compared 
with NPH insulin while 1 showed a reduction with NPH insulin. Four of the 5 Type 1 
trials that reported nocturnal hypoglycaemia showed a statistically significant reduction 
with glargine, while only 1 trial (of 5) found a statistically significant reduction in severe 
hypoglycaemia with glargine. Of 8 trials in patients with Type 2 diabetes 4 reported on 
symptomatic hypoglycaemia, of which 3 reported statistically significant reductions in 
risk in glargine users. 6  Type 2 trials reported on nocturnal hypoglycaemia, all but one of 
which showed a statistically significant reduction with glargine, while the 1 trial that 
reported on severe hypoglycaemia also showed a statistically significant reduction in risk 
with glargine. Wang noted some problems with the trial data: 7 of the trials were 
available only as abstracts, and 2  were of different aspects of the same trial; most of the 
studies were statistically underpowered, and differed in how they defined hypoglycaemia.
Garg et al. reviewed 27 RCTs, of which 10 studies (or study arms) compared 
hypoglycaemia in patients with Type 1 diabetes using glargine (sometimes in 
combination with lispro) or NPH insulin. Of the 8 studies that reported symptomatic 
hypoglycaemia, 4 found no statistically significant difference, while 4 reported a 
reduction in events with glargine. Five of the 6 studies that reported on nocturnal 
hypoglycaemia showed statistically significant reductions in patients using glargine, as 
did 3 of the 4 that reported severe hypoglycaemia.
A review by Frier et al. compared detemir with NPH insulin in trials of at least 12 weeks 
duration. It included 14 RCTs which reported hypoglycaemia In Type 1 diabetes 3 (of 9)
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trials showed statistically significant reductions in the risk of overall hypoglycaemia in 
patients using detemir compared with those using NPH insulin (although in one trial the 
p-value was 0.036). In Type 2 diabetes 4 of 5 studies found a reduction in the risk of 
overall hypoglycaemia with detemir. In addition, the authors conducted a pooled analysis 
of the data for patients with Type 1 diabetes, and found the relative risk of 
hypoglycaemia to be 22% lower in patients receiving detemir. They also used a 
mathematical model to predict confirmed hypoglycaemia from a 26 week trial in patients 
with Type 2 diabetes, which predicted a lower incidence of major and minor 
hypoglycaemia in patients using detemir. This review was sponsored by Novo Nordisk, 
an insulin manufacturer, and the paper notes that Novo Nordisk "had a role in the review 
of the manuscript". The authors conclude that detemir offers a "similar or lower 
frequency of hypoglycaemia" compared with NPH insulin: however, given the 
involvement of Novo Nordisk, it is possible that this study would not have been 
submitted for publication had the finding been unfavourable to detemir.
The Gough review (which was discussed in the section on short-acting insulins) also 
included studies comparing longer-acting analogue insulins and NPH insulin. Of the 6 
studies that compared glargine to NPH in Type 1 diabetes, 4 found no statistically 
significant differences in the risk of hypoglycaemia, while the two other studies reported 
a benefit with glargine in both nocturnal and symptomatic/mild hypoglycaemia. 6 
studies comparing glargine with NPH insulin in Type 2 diabetes all reported statistically 
significant reductions in nocturnal hypoglycaemia with glargine. Gough also reported on 
8 studies in Type 1 diabetes and 1 study in Type 2 diabetes that compared detemir and 
human insulin. In Type 1 diabetes, 6  of 8 studies found statistically significant 
differences in the risk of nocturnal hypoglycaemia, and the 3 studies that reported 
hypoglycaemia other than nocturnal, reported statistically significant reductions.
A d d i t i o n a l  c l i n i c a l  t r i a l s
Bolli et a l  conducted an open-label, multi-centre RCT in Italy, comparing glargine 
and NPH insulin in 175 patients with Type 1 diabetes (85 glargine, 90 NPH), funded by 
Sanofi-Aventis. The subjects were adults (age 18-60) who had had Type 1 diabetes for at 
least 3 years, and who were on intensive insulin therapy with lispro at mealtimes. The 
study evaluated changes from baseline to the end of the study period (30 weeks). There
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were no statistically significant differences between the treatment groups in age, BMI,
HbAic, duration of diabetes, duration of insulin therapy or the ratio of the sexes. While 
the primary outcome was mean fasting blood glucose, hypoglycaemia^ (identified from 
patient diaries) was also evaluated. The trial found no statistically significant differences 
in the incidence of "overall" or "serious" hypoglycaemia between patients using glargine 
and those using NPH insulin, however the incidence of nocturnal hypoglycaemia was 
significantly lower in the glargine group (-0.19 CI95 [-0.32,-0.05] p=0.006), (but not in 
the NPH group). The study findings of reduced nocturnal hypoglycaemia in patients 
using glargine is in line with the finding reported in the reviews and meta-analyses.
While there were no obvious flaws in the study methodology, the authors had calculated 
they needed 312 patients to reach a power of 90% for their primary outcome, so the 
study was underpowered. The paper notes the involvement of a Sanofi-Aventis employee 
(not listed as an author) in the "realization and analysis of the study".
The open-label RCT by Hsia^^^! compared glargine and NPH insulin in insulin-naive 
Hispanic or African-American adults with Type 2 diabetes. This American study, which 
was funded by the US National Institutes of Health, recruited patients from a Diabetes 
Speciality Clinic in Los Angeles that served predominantly low-income and low 
education level patients. There was a high drop-out rate, with just 60% of the subjects 
completing the study; many were excluded for non-compliance with the insulin protocol. 
Hypoglycaemia, a secondary outcome of the study, was defined as the occurrence of the 
"classic" symptoms, with or without corroborating blood glucose measurements, as 
recalled at weekly visits during the study period, and reported as the proportion of 
subjects reporting any hypoglycaemia. The study found no statistically significant 
differences in mean number of hypoglycaemic events per patient over the study period 
between users of NPH or glargine except for "pre-supper" events (although the author 
notes that the study may have been underpowered to detect smaller differences in 
nocturnal hypoglycaemia). Patients using glargine in the morning had more "pre-supper" 
hypoglycaemic events than those using NPH insulin or glargine at bedtime 
(Kruskal-Wallis test of event rate p=0.007). This study was unusual in focussing on a
* The Bolli study defined hypoglycaemia as blood glucose (BG) < 4 .0  mmol/1 and "serious" hypogly­
caemia as BG <2.3 mmol/1).
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relatively disadvantaged, ethnic minority population, although this does limit the validity 
of the study.
Thalange et al. carried out a multinational (35 sites in 11 countries), open-label, RCT 
comparing detemir to NPH in 347 children (median age ~10 years) who had had Type 1 
diabetes for at least a year. The study was funded by Novo Nordisk, who were also 
responsible for the analysis and reporting of the study. The study period was 52 weeks, 
and all patients also received insulin aspart. The study duration was 52 weeks, and the 
primary outcome was HbAic. Hypoglycaemia was a secondary outcome, classified as 
"mild" (self-treated), "moderate" (required assistance, but responded to oral 
hypoglycaemic drug treatment) and "severe" (patients were semi- or unconscious or in a 
coma). These definitions differed from those used in many trials, where "severe" 
hypoglycaemia was defined as needing 3rd party assistance: so it is likely that at least 
some of the events recorded as "moderate" in this trial would have been "severe" in 
others. Hypoglycaemic events were recorded in patient diaries (and also included blood 
glucose measurements of ~ 3 .6  mmol/1) and the number of hypoglycaemic episodes per 
patient was analysed to give an adjusted rate ratio between the treatment groups. The 
study found a statistically significant reduction in the risk of nocturnal hypoglycaemia in 
patients treated with detemir compared to NPH insulin (RRadjO.62 CIg5[0.47,0.84], 
p=0.002). While no significant difference was found the risk of day-time hypoglycaemia, 
there was an overall (24-hr) reduction in risk: RRadjO.76 CI95[0.60,0.97], p=0.28. This 
was one of the few RCTs dealing with children, a group not often included in clinical 
trials: it was used as the basis of gaining regulatory approval from the European 
Medicines Agency for the use of detemir in children.
O b s e r v a t io n a l  s t u d ie s
Haukka et aO^^ used data on insulin prescriptions from the Finnish Registry for 
Reimbursed Medication correlated with data from the Finnish Hospital Care Register 
(which records all hospitalisations and outpatients visits) to estimate the risk of 
hypoglycaemic coma in patients newly-starting insulin therapy. In their population of 
75,682 patients (including Type 1 and Type 2 patients), with a mean follow-up period of
4.1 years, they found the incidence of a first hypoglycaemic coma to be between 1.8 and
2.1 events/ 100  patient-years, and the overall incidence of all hypoglycaemic comas to be
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between 2.2 and 3.3 events/100 patient-years. When stratified by the type of insulin 
(where this was known), they found a statistically significant 21.7% reduction in the risk 
of a first hypoglycaemic coma in users of detemir compared with NPH insulin 
(01959.6,32.1%, p < 0.001), and a 9.9% reduction (Cl95l.5,17.6%, p = 0.022) with 
glargine vs. NPH. The risk for the recurrence of hypoglycaemic coma was 36.3% 
(01958 .9 ,5 5 .5%, p = 0.014) lower for detemir vs. NPH, but there was no statistically 
significant difference between glargine and NPH insulin.
The Solomon et a l  observational study discussed earlier also reported on 
longer-acting analogue insulins using administrative data from self-insured employers in 
the United States. The study subjects were 8 ,626  adults between 18 and 65 years of age 
with Type 2 diabetes (and private health insurance) with no history of severe 
hypoglycaemia before the start of their insulin therapy and who were in their first year of 
insulin use. Follow-up was for at least one year (although the authors do not give 
information on the actual follow-up periods). 186 patients had a severe hypoglycaemic 
episode during the follow-up period, with a mean time to event of 38 .4  months. Using 
adjusted Oox proportional hazard models, the authors found that patients using 
premixed, rapid-acting or N P H  insulins were at statistically significant higher risk of 
severe episodes than were patients using glargine (H R adj2.12 0 X95(1 .2 6 ,3 .5 5 ] , 2 .75  
CI95 [1 .88-4 .04] and 2 .02  C l95[ 1 .25 ,3 .26] respectively), although no difference was 
found with detemir.
The effect of a change from NPH to glargine was investigated in a retrospective, 
registry-based study of adults with Type 2 diabetes in Spain by Delado. The study 
compared patients who switched to glargine (at their physicians discretion) in the 
preceding 4-9 months to those who were maintained on human insulin. Their final study 
population was 1,482 patients, and hypoglycaemic events were determined from 
self-monitored blood glucose values in the patient records (defined as <3.9mmol/l). The 
study reported that the proportion of patients experiencing documented hypoglycaemia 
was lower in the glargine group (p<0.0001). The authors noted that there were 
differences between the treatment groups, for example the glargine group had poorer 
glycaemic control before the switch in insulin, and that they could not be sure that the 
recording of hypoglycaemia was consistent across the study centres, and that the results
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should, accordingly, be treated with caution.
The Kristensen et al. questionnaire study mentioned earlier also compared 
longer-acting insulins. An adjusted regression analysis found that long-acting analogue 
insulin was associated with a 2 2 % higher risk of severe hypoglycaemia than long-acting 
human insulin (CIg59-36%). Similarly, the rate of milder episodes was higher in users of 
longer-acting analogue than longer-acting human insulin (p<0.001). These findings are 
contrary to the findings of most RCTs, where, if any differences were seen, they tended 
to favour analogue insulins. While the study results must be treated with caution (and the 
authors note they cannot rule out confounding by indication) they do, perhaps, suggest 
that the results of RCT cannot automatically be extrapolated to "real-life" practice in the 
general population.
Tentolouris et al. in a retrospective study funded by Sanofi-Aventis, compared adults 
with Type 2 diabetes who switched from biphasic human insulin to glargine with 
patients who continued on human insulin. The study was carried out in 10 centres in 
Greece, and involved 142 "switching" patients and a control group on 159 patients. 
Hypoglycaemia was recorded as "nocturnal", "severe" (requiring 3rd party assistance), 
or mild/moderate", which included all other hypoglycaemic episodes. Data for the 6-12 
month period prior to the switch was obtained from medical records for the switching 
group, and compared with data over the same period in the same trial centre for the 
control group. How controls were assigned is unclear from the study description, as was 
how hypoglycaemia events were included in the patient’s record. There were some 
statistically significant baseline differences between the switching and control groups, 
with the switching patients having a lower BMI and higher initial HbAic and fasting 
plasma glucose than the control group, as well as differences in the treatment regimes 
(such as the use of oral hypoglycaemic drugs). Hypoglycaemia rates were compared by 
estimating the relative risk in the treatment arms. They found no statistically significant 
difference in the relative risk of a patients having at least one hypoglycaemic event (of 
any category) between patients who remained on human insulin and those who switched 
to glargine. The authors state their study was adequately powered to detect a difference 
in their primary outcome (HbAic), although they only recruited 301 of the 334 patients 
their power calculation required. The authors also noted that detailed information on
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hypoglycaemic episodes was not available, and the number of mild/moderate events may 
have been underestimated.
2.5 Summary of findings
While studies which reported hypoglycaemia as an outcome generally did so in 3 
categories: symptomatic, nocturnal and severe, the specific definitions used varied 
between studies. Severe hypoglycaemia was commonly defined as "requiring assistance 
from another person", although some studies gave more specific definitions. Thirty-five 
of the studies included in the Siebenhofer Cochrane review defined severe 
hypoglycaemia: 25 as events needing 3rd party assistance; 9 as events requiring 
glucagon, intra-venous glucose or resulting in unconsciousness or coma; and 1 study 
defined it as a blood glucose measurement of < 2.8  mmol/1.
Definitions of nocturnal hypoglycaemia were generally defined by either a time range, 
for example midnight to 6am, or in terms of patient activity: e.g. "while asleep 
between bedtime and getting up in the morning" or "between the evening and morning 
insulin injections". While the definitions nocturnal and severe hypoglycaemia were, 
relatively, consistent, the more general group, of symptomatic (or "all" or "minor") 
events were more broadly defined. For example, Heller’s meta-analysis defined as 
"symptom-only" any event where the patient could self-treat and their blood glucose was 
>2.8 mmol/1 (or there was no blood glucose measurement). Even when a study required 
hypoglycaemia to be confirmed by blood glucose measurement, the chosen values 
varied. Thirty-three of the 49 studies included in the Siebenhofer^!!^ Cochrane review 
gave blood glucose level definitions for "overall" hypoglycaemia; the values ranged from 
2.0 mmol/1 (1 study) to 3.9 mmol/1 (1 study), with the most common value being 3.0 
mmol/1 (12  studies).
Such variations complicated comparisons across studies, particularly for symptomatic 
episodes and in open-label trials. Horvath noted that definitions of hypoglycaemia 
often allow some degree of subjective interpretation, and hence were potentially subject 
to influence, particularly since many studies did not require corroboration by blood
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glucose measurement. In addition, the poor methodological quality of many studies was 
noted by reviewers.
A further complication in clinical trials was that severe hypoglycaemia was relatively 
rare, and, given that clinical trials may not have long durations, not enough events may 
occur for robust analysis. Observational studies, which tend to have longer follow-up 
periods, are more likely to capture such events, but it is more difficult (particularly in 
retrospective, database based studies) to impose rigorous and consistent definitions of 
hypoglycaemia. Blood glucose measurements are less likely to be available, and 
researchers may have to rely on patient recall or clinician reporting of episodes.
Furthermore, many of the studies were funded by the insulin manufacturers (sometimes 
in pursuit of regulatory approval). In some cases the manufacturer was directly involved 
in the preparation of the manuscripts or the analysis of the data. For example. Novo 
Nordisk funded the Heller, T h a l a n g e a n d  P l a n k s t u d i e s ,  was involved in the 
preparation of their manuscripts, and the studies had at least one author closely 
associated with that company. Similarly, the Bolli review and the Solomon 
observational study and were both funded by Sanofi-Aventis (and one of the Solomon 
authors was a Sanofi employee). While this does not necessarily invalidate the findings, 
it could be argued that the studies may not have been submitted for publication, or 
unpublished studies may not have been suggested for inclusion in a meta-analysis, had 
they not shown some benefit with the manufacturers products.^
Despite the variations between studies, the overall balance of evidence suggested a 
statistically significant reduction in the risk of nocturnal hypoglycaemia both in patients 
using fast-acting analogue insulin (with reductions of between 24 and 49% compared to 
those using regular human insulin), and in those using longer-acting analogue insulins 
compared to regular human insulin (with observed reductions of between 8 and 46%).
This wide variation in effect size may reflect underlying differences between patients 
such as duration of diabetes, as well as factors such as co-therapy and treatment regime.
Although the Plank analysis did not find any difference in the rates of hypoglycaemia, this was a sec­
ondary outcome; the primary outcome was attained H bA ic and it did find a statistically significant ben­
efit with analogue insulins in post-treatment H bA ic levels in Type 1 diabetes.
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The evidence for an effect on severe hypoglycaemia was less clear: many studies did not 
find any statistically significant differences in risk between analogue and human insulins, 
although, in those that did, the risk was lower in analogue insulin users. Equally, the 
majority of studies found no statistically significant difference between analogue and 
human insulin where all hypoglycaemic episodes were taken into account.
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3.1 Study design
This thesis presents retrospective observational studies using data from the UK General 
Practice Research Database testing the research hypotheses (pg. 21).
S t u d y  s u b j e c t s
The study subjects were a cohort of "valid"* patients from GPRD2009 who were 
prescribed insulin during the study period.
A "base study population" of patients who met various inclusion criteria was identified 
as described in section 3.3, and appropriate sub-groups of these patients, described in 
section 3.3, were used for the analyses.
S t u d y  p e r i o d
GPRD2009 contained data from 1987 onward, although for few practices before 1992 
(see Figure 1.3, page 26). The final data collection was on the 18^ ^^  February 2009; 
however, not all practices were harvested then, so there was relatively little data for 2009.
Preliminary examination of the numbers of insulin prescriptions showed there was 
relatively little use of analogue insulin before 1998. Accordingly, while secular trends in 
insulin use are described from 1992 to 2008 (the last full year of GPRD data), the 
quantitative analyses used data from January 1999 to the 18^ ^^  February 2009.
Patients whose GPRD records met certain minimum data quality standards relating to the recording 
of gender, age, registration details and event dates, such as having no event records before their date of 
birth. ’128
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VARIATES
Patient characteristics, including their age, sex, UK geographical region (of the GP 
practice), duration of diabetes, frequency of clinical contacts, history of diabetic 
comorbidities, prescriptions for oral hypoglycaemic drugs, and, where available, their 
alcohol usage status, smoking status, ethnicity, BMI and HbAic level, were included as 
covariates in the analyses. Section 3.8 describes how these were identified and classified.
Insulin exposures were found by mapping the insulin prescriptions (section 3.5), and the 
mapped exposures were used to identify changes ("switches") in insulin exposures, and 
hence a sub-group of "switching" patients (section 3.6).
The process used to identify hypoglycaemic events is described in section 3.7, which 
also defines the term "serious" hypoglycaemic events used in this thesis.
E t h i c a l  a p p r o v a l
This study received ethical approval from the Scientific and Ethical Advisory Committee 
(SEAC) for the GPRD: Protocol number 744.
3.2 Testing the hypotheses: analyses and statistical methods
H y p o t h e s i s  (A)
That GP’s insulin prescribing practices would change following the introduction of 
analogue insulins, and that GPRD prescription records could be used to track those 
changes
Secular trends were examined in the base study population and in patients newly-starting 
insulin therapy. Changes in insulin exposure were examined in the base study 
population, and secular trends in were examined in "switching" patients. Chapter 4 
presents the results.
H y p o t h e s i s  (B)
That GPs would be selective in their use of analogue insulins, choosing between 
human or analogue products based on the patient’s characteristics, and hence that
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the GPRD data could be used to predict the chosen insulin.
The objective of the analysis was to identify factors that influenced the initial choice of 
human or analogue insulin in patients newly-starting insulin therapy. The "outcome" was 
binary: the initial choice of either human insulin (coded as 0) or analogue insulin (coded 
1 = "success"), so multivariate logistic regression was used, evaluating the likelihood 
that a patient would start on analogue rather than human insulin. The results are 
presented in Chapter 5.
The analysis subjects were "new" insulin users with a first insulin prescription between 
1999 and 2008, who started on insulin after their practice first prescribed analogue 
insulin, who started on only analogue or only human insulin, and who were aged 1 year 
or older at their first insulin prescription (as GPs sometimes record dummy prescriptions 
in the patient’s year of birth). Separate analyses were carried out in patients with Type 1 
and Type 2 diabetes.
L o g i s t i c  r e g r e s s i o n  m o d e l l i n g
Statistically the outcome can be considered as a random variable Yi that can take the 
values 0 or 1; and the outcomes for n  study subjects considered as a set of n  independent 
Bernoulli observations of that variable: y i,i  — 1 ,2 , . .  .n .  Taking the probability that the 
i th  individual was a "success" as pi, then the random component of the probability of 
the i th  outcome is generated by a Bernoulli distribution with parameter pi and 
probability mass function:
p K  =  V i )  =
Multivariate logistic regression fits k  independent variables to the binary outcome via a 
logistic link function. It models the dependence of pi on the set of k  independent 
(explanatory) variables:
The ratio is the odds of success, so the model estimates the log odds of success. 
Statistical software (in this case Stata) uses maximum likelihood estimation to
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approximate the values of a  and the A: /3s from the observed covariate values. These are 
partial regression coefficients, indicating the effect on the log odds of "success" if all the 
other explanatory variables are held constant.
The regression results in Chapter 5 are given as odds ratios (OR), which compare the 
probability of success between groups. For example, consider a dichotomous variable x  
that can take the values 0 or 1, and let po and p i be the probabilities of success when 
x =  0 and X =  1 respectively. The odds ratio estimates how much more (or less) likely a 
"successful" outcome is in a subject with x  = I compared to a subject with x =  0:
OR =
P o /(l -p o )
In terms of the logistic regression model:
( î^ )  “
=  (a -  ^Xi) -  (a  -  /3xo)
=  (cK — /3) — (cK — 0)
Hence, the regression coefficient (3 gives the log of the odds ratio (and exp(^)  gives the 
odds ratio) of the likelihood of a success in subjects with one value of the explanatory 
variable compared to another. For categorical variables, as in the example above, exp(/3) 
is the odds ratio for one level of the variable compared to the reference level, while for 
continuous variables exp{/3) is the odds ratio for a unit increase in the explanatory 
variable.
Logistic regression of individual covariates was used to produce the "unadjusted" odds 
ratios. Covariates were selected for inclusion in the multivariate models using stepwise 
analysis to identify potentially significant contributors (with significance level 0.1 for 
removal/addition); by testing covariate interactions for statistical significance; and by 
examining the prediction rate of various models.
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A n a l y s i s  c o v a r i a t e s
The covariates considered for the multivariate model included the patients’ age, sex, 
duration of diabetes, HbAic level, clinical care contact rate, oral hypoglycaemic drug 
prescribing, history of diabetic comorbidities, and (where available) their smoking 
status, ethnicity, UK geographical region, socio-economic status and HbAic level. For 
time-varying covariates the value at the patient’s first insulin prescription was used. The 
extraction and classification of the covariates is described in section 3.8.
It was recognised, here and in the other analyses, that the high number of patients with 
"unknown" values for some of the covariates may bias the outcome, so an additional 
analysis of "complete cases" (patients who had known values for socio-economic status, 
body-mass index, HbAic level, smoking status and alcohol usage at their first insulin 
prescription) was carried out in patients with Type2 diabetes. There were too few 
"complete case" patients with Type 1 diabetes for stable analysis. Socio-economic status 
was only available for patients in English practices, so this analysis excluded patients 
from Wales, Scotland and Northern Ireland.
H y p o t h e s i s  (C)
That GP’s would change a patient’s insulin regime depending on their 
characteristics and medical history, and that GPRD data could be used to predict 
such changes.
This was examined in a case-control study that looked at patients in the period leading 
up to a change in insulin exposure. The cases were qualifying "switching" patients, 
identified as described in section 3.6. The results are presented in Chapter 6 .
The logistic regression analysis that tested hypothesis B in new insulin users found that 
the best predictor of the choice of analogue insulin was the calendar year in which 
therapy started. The match over the case’s calender time of exposure was included to 
remove the effect of the calendar year.
One of the criteria for "eligible" switches was that the pre-switch exposure had to be at 
least 6  months long. As the analysis was concerned with what happened in the lead up to 
a change in exposure, and to avoid excessively restricting the number of potential
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controls, it was decided to limit the analysis to at most the last 18 months of a case’s 
pre-switch exposure. Accordingly, the exposure period for each case (their "contributed 
time") was between 6 and 18 months.
For this analysis cases were matched to controls drawn from the base study population 
on insulin exposure, sex, type of diabetes, year of birth (±3 years) and the calendar dates 
of the case’s exposure period. Patients in the base study population were eligible as 
potential controls if they met the matching criteria and all of a case’s contributed time 
fell within a period of the same insulin exposure over the same calendar dates. Cases 
were eligible to be controls provided the switch date of their potentially matching case 
was at least 1 month before their own switch date. The data was analysed using 
conditional logistic regression.
Each case was matched with up to 4 controls, and controls were not reused. Matches 
were randomly selected within eligible controls using a computer program written by the 
author. Lists of cases and potential controls (all patients in the base study population) 
were generated, sorted on a "key" field coding for the non-varing matching criteria (sex, 
type of diabetes and insulin exposure). The computer program read in each list, creating, 
to speed up searches, hash tables for the distinct control key values. The program then 
iterated through the cases 4 times (one for each control match), randomly selecting a 
potential control from those matching the case’s key. If the control had not previously 
been selected and the UTS exposed calendar time and year of birth (±3 years) matched 
the case’s, the control was accepted and marked as "used"; otherwise another potential 
control was randomly selected. Selection was repeated until either a match was found, or 
no further unused potential controls were available. Cases that could not be matched 
were excluded from the analysis.
C o n d i t i o n a l  l o g i s t i c  r e g r e s s i o n  a n a l y s i s
Case-control studies compare "cases": patients with the event of interest -  in this 
analysis those who switched insulin exposure -  to "controls": patients similar to the 
cases but whose insulin exposure did not change.
Conditional logistic regression was used to analyse the data, with the "outcome"
68
3. Methods Testing the hypotheses: analyses and statistical methods
indicating whether the subject was a case (coded 1) or a control (coded 0). Unlike the 
"unconditional" logistic used for the analysis of Hypothesis A (above), in conditional 
logistic regression the data are grouped: a group (or stratum) consisting of a case and its 
matched controls.
H y p o t h e s i s  (D)
That GPRD records could be used to determine differences in the "real-life” risk of 
hypoglycaemic events between patients using analogue and human insulins.
This was tested by two survival analyses that evaluated the risk of serious hypoglycaemic 
events in, firstly, patients newly-starting insulin therapy and, secondly, in patients who 
switched from human insulin. In both analyses the objective was to evaluate the risk 
associated with different initial insulin exposures.
Survival analysis
Survival analysis models the time from a defined origin time to one or more "events" (for 
these analyses the events were serious hypoglycaemic episodes). The analysis in new 
insulin users used recurrent event survival analysis, while the analysis in switching 
patients analysed survival to the first hypoglycaemic event after a switch in insulin 
exposure.
Data censoring
Patients contributed "survival time" to the analysis: the elapsed time from an origin time 
to a right-censor point. This censor point may be the date of an event (for single-event 
survival analysis), or the end of the period of "eligible time" for that patient.
For new insulin users the origin time was the date of their first GPRD insulin 
prescription. The initial censor point was the earliest of their UTS right-censor date and 
the date of their first switch in insulin exposure.
For insulin switchers the origin time was the date of their "qualifying switch" (described 
in section 3.6), and initial the censor point was the earliest of their UTS right-censor date 
and the date of their first subsequence change in insulin exposure.
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In both groups of patients a further adjustment of the censor date was made following 
preliminary analyses to check the proportional hazards assumption in the models.
Adherence to the proportional-hazards assumption was investigated in two ways: (a) by 
comparing the Kaplan-Meier observed and Cox predicted survival curves - the closer the 
observed and predicted values, the more likely that the proportional hazards assumption 
holds and (b) by inspecting the plots of ln(ln(survival time)) against ln(patient time) for 
nominal covariates, where parallel lines indicate the proportional hazards assumption 
had not been violated.
In new insulin users the proportional hazards assumption was valid for 48 months in 
patients with Type 1 diabetes and 60 months in patients with Type 2 diabetes, while in 
insulin switchers the assumption held for 60 months in both Type 1 and Type 2 diabetes. 
Patients with longer contributed times were censored at those points: hence any 
hypoglycaemic events after the censor date were not included in the analyses.
Single event survival analysis
For the analysis in patients following a change in insulin exposure, each patient 
contributed "survival time" (in days), measured from the date of their change in insulin 
exposure until either an event (a hypoglycaemic episode) occurred (coded as a "failure", 
value = 1), or (if they did not have an event) until their right-censor date was reached 
(coded as 0). The anaylsis data comprised one record per patient, giving the elapsed time 
from the switch date (in days), the failure marker (0  or 1), and the patient’s covariate 
values. For time-varying covariates the value at the switch date was used. For example:
ID, time, failure, <covariate values>
1, 24, 1, xl, x2, ... xk
2, 416, 0, xl, x2, ... xk
In the above example, patient 1 had an event on the 24^ *^  day after their switch date, while
patient 2  reached their censor date (416 days after their switch date) without having an
event.
The survival times can be considered as a random variable T , with the individual 
contributed times t  being the observed values of this variable. The hazard function gives 
the probability that a patient experiences an event at time t, having not had an event 
before then. The impact of explanatory variables on the hazard function was estimated
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using proportional hazards models, also known as Cox regression models. In the 
comparison of two (or more) groups of patients, these models assume that the risk of an 
event at a time t  for an individual in one group is proportional to the hazard at that time 
for a similar individual in the other (or the reference) group: this is the proportional 
hazard assumption.
Consider 2 groups of patients, a and h. Let ha{t) and /15(A) be the hazard of an event at 
time t  in patients in group a and group b respectively. Then the proportional hazard 
model defines:
ha{t) =  K  hb{t)
where iT is a constant, the hazard ratio (HR): in this case the ratio of the hazard of an 
event for patients in group a compared to those in group h. When iT =  1 the hazard is 
the same in both groups. A value of iC <  1 indicates a lower hazard in group a, while a 
value K  > 1 means a greater hazard in group a.
A proportion hazard multivariate regression model can be constructed by letting 
K  = exp{j3) (i.e. /3 is the log of the hazard ratio). If there are k  explanatory variables, 
the proportional hazards model for the i th  subject is:
hi{t) = exp [p ix i  +  132X2 +  . . .  +  /3fcXfc) /io(A)
where /io(A) is the baseline hazard function: a function nominally defining the hazard at 
baseline levels of the covariates, zero for continuous variables and the reference level for 
categorial variables. The model can be expressed as:
In =  A 3:1 +  P2X2 +  . . .  +  ^kXk
so the proportional hazards model can be regarded as a linear model for the log of the 
hazard ratio. The statistical software estimates the /3 values from the observed data using 
the method of maximum likelihood, and explicit evaluation of the baseline hazard 
function is not required. As with logistic regression the /3 coefficients are partial: they 
reflect the impact of a change in a covariate given the values of all the other covariates 
remain the same.
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Recurrent event analysis
The analysis of patients newly-starting insulin therapy used recurrent event survival 
analysis, including all of the serious hypoglycaemic episodes from the patient’s first 
insulin prescription to their censor date. This used an extension of the proportional 
hazard model that did not censor patients at their first event, instead allowing multiple 
records for each patient and accounting for all the patient’s time from their first insulin 
prescription to their right-censor date. Covariate values for a given patient were 
duplicated in the records, and for time-varying covariates the value at the patient’s first 
insulin prescription was used. The record structure is shown below:
ID, time, failure. <covariate values>
1, 261, 1, xl, x2. .. xk
1, 1183, 1, xl, x2. .. xk
1, 1185, 1, xl, x2. . . xk
1, 1460, 0, xl, x2. .. xk
2, 1950, 0, xl, x2. .. xk
In this example patient 1 had 3 events during the time they contributed to the survival 
analysis, coded by a "failure", at 261 days, 1,183 days and 1,185 days after their first 
insulin prescription. They then contributed a further 275 days without an event. Patient 2 
did not have any events in the 1,950 days from their first insulin prescription to their 
right-censor date.
The recurrent event model used in these analyses defined time from the origin date (other 
versions of recurrent event analysis use time defined since the previous event) and the 
proportional hazards function for the s th  event under this model, assuming that the 
events are independent and that all the covariates are fixed at the origin time, is given by:
h s { t )  =  e x p { ^ i s X i  -b ^ 2 s X2  +  . . .  +  ^ k s X k )  h Q s { t )
The statistical software used a stratum variable to track the individual events, and 
adjusted the estimates for the coefficients to account for the correlation of multiple 
observations on a subject.
Risk of serious hypoglycaemic events in new insulin users of human or analogue insulins
The risk of "serious" (defined in section 3.7) hypoglycaemic events in patients 
newly-starting insulin therapy was examined using a sub-group of new insulin users: 
those with a first insulin prescription in 1999 or later, who were aged 1 year or older at
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their first prescription, who started on only analogue or only human insulin, and whose 
first insulin exposure was at least 3 days long.
Cox proportional hazards models for recurrent event survival analysis were used to 
derive hazard ratios for the risk of serious hypoglycaemic events under different insulin 
exposures, adjusting for covariates. Patients with Type 1 and Type 2 diabetes were 
analysed separately, with a "complete-case" analysis for patients with Type 2 
diabetes.The results are presented in Chapter 7.
In preliminary analysis of the complete case patients, the inclusion of those with a 
post-switch exposure of only fast-acting analogue insulin (category 5) made the Cox 
model unstable. As combining these patients with another exposure category would have 
obscured the effect of the insulin exposure, they were omitted from the analysis.
Risk of serious hypoglycaemic events after a change in insulin exposure
In patients who switched from human insulin, the risk of serious hypoglycaemic events 
was evaluated using "switching" patients with pre-switch exposures to only human 
insulins. Twenty-one patients who switched to animal insulin were excluded, as they 
were felt to be atypical of insulin users in the study period. Patients who changed from 
one human insulin regime to another (for example from only human pre-mixed insulin to 
only human short-acting + long-acting insulins) were included. The pre- and post-switch 
insulin exposures, classified as in Table 3.5, were included as covariates in the analysis, 
as was the type of diabetes.
Cox proportional hazards models for single-event surival analysis were used to estimate 
the hazard ratios for the risk of a serious hypoglycaemic event under the different 
post-switch exposures. Analyses were carried out for all analysis subjects and for 
complete cases.
Preliminary analyses found that the proportional hazards assumption did not hold for the 
post-switch care provider contact rates, accordingly the analyses were stratified by this 
variable.
A preliminary analysis of patients switching from animal insulin was also carried out.
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However, there were only 716 such patients, and it proved impossible to produce a stable 
multivariate Cox model.
M o d e l  s e l e c t io n
In all analyses covariates were selected for inclusion or rejection in the multivariate 
models using stepwise analysis to identify potentially significant contributors (with 
significance level 0.1 for removal/addition); by testing covariate interactions for 
statistical significance; and by examining the prediction rate of various models.
Statistical analysis was carried out using Stata version 12.0.
3.3 Identification of the base study population
A base study population of people who contributed up-to-standard time to GPRD2009 in 
1992 or later, who had insulin prescriptions in that time and who met defined inclusion 
criteria were identified using the process outlined in Table 3.1.
Two processes applied during the extraction to improve the quality of the GPRD data are 
described below.
R e m o v a l  o f  i n v a l id  p r e s c r i p t i o n s
GPRD prescription records record the issue date of the prescription, the entry date on 
which the prescription was recorded in the GPRD, and a incrementing sequence number 
for repeat prescriptions. These were used to try to identify invalid records, such as lost 
prescriptions which were subsequently replaced, or prescriptions accidentally duplicated 
during data entry.
The earlier of two identical prescriptions on consecutive days was excluded if:
1) Both entry dates were the same as the issue dates. It was felt that these were likely 
to be replacements for lost prescriptions.
2) Both had the same entry date and the same sequence number. Again, these were 
felt likely to be replacements for lost prescriptions.
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Table 3.1 : S t e p s  in t h e  identification  o f  t h e  b a s e  s t u d y  po p u l a t io n  in GPRD2009
Step Process
Number after step 
Ins. Prsc. Patients
1 Extract all insulin prescriptions from GPRD2009 which were not 
dated 1 st January and were not marked as "not collected" or "not 
issued".
3,793,182
2 Remove duplicated, spurious and re-issued prescriptions (as 
described in sub-section Removal of invalid prescriptions).
3,790,330
3 From the insulin prescriptions, find all patients who met the 
GPRD data quality criteria {i.e. were "valid" patients), were 
specifically "male" or "female", had at least one year of UTS 
data, contributed UTS time in 1992 or later, and did not have a 
"temporary" GP registration. Remove insulin prescriptions for 
patients who did not meet these criteria.
65,127
4 Censor patients in truncated practices (as described in 
sub-section Adjustment of censor dates) and remove those 
where truncation meant they no longer had at least 1 year UTS 
time with at least one insulin prescription during that time.
3,225,827 58,719
5 Remove patients who did not have insulin prescriptions in UTS 
time in 1992 or later.
3,217,372 57,982
6 Remove patients where the only insulin prescriptions were 
during pregnancy (assumed to have gestational diabetes).
3,217,372 56,931
7 Count the number of separate days in UTS time on which each 
patient received either insulin or oral hypoglycaemic 
prescriptions (or both). Remove patients without prescriptions on 
at least 2 separate days.
3,215,411 56,330
8 Remove patients without at least 31 days UTS data after their 
first insulin prescription.
3,210,158 55,914
3) The entry date for the second prescription was the same as its prescription date but 
the entry date for the first prescription was earlier than its prescription date. These 
were thought likely to be data transfer or recording errors.
A d j u s t m e n t  o f  c e n s o r  d a t e s
Jick et al. found periods of missing data in nominally UTS records. To investigate 
whether such anomalies existed in GPRD2009, the numbers of clinical and prescription 
records each week in up-to-standard practices were counted, ignoring records for 
computer administration and in weeks 1,52 and 53 (the Christmas/New Year period). 
The weekly medians for a practice, ignoring weeks 1,52 and 53, were 1,223 clinical 
records and 1,588 prescriptions.
It was noticed that, even in clearly anomalous periods, the numbers of clinical and 
prescription records did not always fall synchronously, and often were not simply zero:
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there would still be a small number of entries. There was, therefore, a need to define a 
cut-off level below which a practice would be deemed to be "missing" data, and this was 
taken (somewhat arbitrarily) to be 25 records in a week.
All practices were searched for weeks with 25 or fewer clinical OR prescription records. 
Altogether 82 practices (17.2%) were found to have at least 1 week of missing data 
during their UTS period, other than during calendar weeks 1 or 52/53. However, as a 
practice may legitimately have closed for a short period, a decision was made to define a 
"missing data period" as at least 3 consecutive weeks of missing clinical or prescription 
data. By this criterion 21 practices had gaps in their UTS data.
It was felt inappropriate to use data spanning such periods due to the risk of missing 
important exposures or events. Accordingly, for truncated practices, when a patient’s 
UTS time spanned the truncation date, their left-censor date was reset to the start of the 
week following the missing data period. Figure 3.1 shows an example of a practice with 
missing prescription data and its truncation method.
Following truncation, patients were excluded if they no longer met the requirements for 
at least one year of UTS data with at least one insulin prescription during that time.
In 260 patients in the base study population the practice truncation date was after their 
right-censor date, and so these patients were removed. A further 1,076 patients were 
truncated with a loss of 3,633 patient-years of UTS data, an average of 3.4 years per 
affected person. While this loss is regrettable, it was felt to be acceptable given the 
greater confidence in the quality of the remaining data.
This produced a base study population of 55,914 insulin-using patients, 12,048 with 
Type 1 diabetes and 43,866 with Type 2 diabetes, from which sub-groups were drawn for 
analysis.
S u b - g r o u p s  f o r  a n a l y s is
The two major sub-groups of the base study population were used in the quantitative 
analyses: Table 3.2 gives the numbers of patients in the base study population and its 
sub-groups.
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Excluded dal
Truncation point
o 2000
R etained da ta
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Weeks since start of UTS period
Figure 3.1: E x a m p l e  o f  a  p r a c t i c e  with  m i s s i n g  data: p r e s c r i p t i o n  data 
FROM GRPD2009 PRACTICE 41, WITH METHOD OF TRUNCATION
1) Patients newly-starting insulin therapy during the study period. These "new" 
insulin users were defined as patients with at least 1 year of UTS time before their 
first insulin prescription.
2) Insulin users who "switched" insulins during the study period. "Switching" patients 
were defined as those who changed from one insulin exposure to another in 1999 or 
later, where the post-switch exposure contained at least one insulin not present in 
the pre-switch exposure, where the pre-switch exposure was at least 6 months long 
and where the post-switch exposure was at least 3 days long. The identification 
process is described in section 3.6.
3.4 Assignment of type of diabetes
Assignment of the type of diabetes was based primarily on the age at first insulin 
prescription, with the assumption that a first prescription at aged 35 or younger was 
indicative of Type 1 diabetes. The difficulty with this approach was that GPRD data is 
(generally) left-censored, so, if a patient started on insulin before their left-censor date, 
this age cannot be accurately determined. This makes it difficult to distinguish between
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Table 3.2: N u m b e r s  a n d  c h a r a c t e r i s t i c s  o f  pa tients  in t h e  b a s e  s t u d y
POPULATION AND ITS SUB-GROUPS, BY TYPE OF DIABETES
Base study population
Number of patients 
Number female (%)
Number male (%)
Median age at first insulin, years 
Median contributed UTS time years (IQR)
Median contributed UTS time after first insulin years (IQR) 
Number prevalent at left-censor date (%)
New insulin users
Number of patients 
Number female (%)
Number male (%)
Median age at first insulin, years 
Median contributed UTS time years (IQR)
Median contributed UTS time after first insulin years (IQR) 
Number prevalent at left-censor date (%)
insulin switchers
Number of patients 
Number female (%)
Number male (%)
Median age at first insulin, years 
Median contributed UTS time years (IQR)
Median contributed UTS time after first insulin years (IQR) 
Number prevalent at left-censor date (%)
Type 1 Type 2
1 2 ,0 4 8  
5 ,6 2 6  (4 6 .7 % )  
6 ,4 2 2  (5 3 .3 % )  
1 6 ( 2 5 ,3 0 )  
3 .2  (6 .9 ,1 1 .7 )  
2 .3  (4 .8 ,8 .9 )  
8 ,5 6 4  (2 8 .9 % )
3 ,2 8 0  
1 ,4 5 3  (4 4 .3 % )  
1 ,8 2 7  (5 5 .7 % )  
1 0 ( 1 5 ,2 6 )  
7 .5  (1 0 .8 ,1 5 .4 )  
2  (4 .5 ,7 .8 )  
1 3 3  (4 .1% )
5 ,5 7 7  
2 ,6 3 8  (4 7 .3 % )  
2 ,9 3 9  (5 2 .7 % )  
1 3 ( 2 4 ,3 0 )  
6 .5  (9 .9 ,1 5 .2 )  
5 ( 7 .9 ,1 1 .9 )  
3 ,8 4 4  (6 8 .9 % )
4 3 ,8 6 6  
1 9 ,8 4 1  (4 5 .2 % )  
2 4 ,0 2 5  (5 4 .8 % )  
51 (6 2 ,7 1 )  
4 .7  ( 8 .5 ,1 3 .2 )  
2  (4 .1 ,7 .3 )  
3 1 ,0 8 6  (7 0 .9 % )
2 3 ,6 3 1  
1 0 ,5 9 9  (4 4 .9 % )  
1 3 ,0 3 2  (5 5 .1 % )  
5 4  (6 4 ,7 3 )  
7 .9  (1 1 .6 ,1 6 .9 )  
1 .5  (3 .4 ,6 .1 )  
1 1 ,2 8 0  (4 7 .7 % )
12,200 
5 ,5 1 0  (4 5 .2 % )  
6 ,6 9 0  (5 4 .8 % )  
4 6  (5 6 ,6 6 )  
7.1  (1 0 .3 ,1 6 .2 )  
4 .7  (7 .2 ,9 .9 )  
9 ,3 0 1  (7 6 .2 % )
Type 1 patients who registered with the practice after age 35 and patients with Type 2 
diabetes who were receiving only insulin. Another group which can be difficult to 
identify are those who developed Type 2 diabetes as teenagers or young adults, and who 
may start on insulin before the age of 35.
While the GPRD has clinical codes specifically for "Type 1" and "Type 2" diabetes (as 
well as more general codes), these are not always used in accordance with the WHO 
guidelines. For example, 2,734 patients had specific codes for both types of diabetes. 
Review of a selection of these patients showed that, in some cases, patients with specific 
"Type 2" codes had later "Type 1" codes once they had started on insulin.'*’ Although 
such specific codes provided useful supporting evidence of diabetes type, they are 
insufficient to identify the type of diabetes.
In the 917 patients where this was found, the later "Type 1" code was ignored
78
3. Methods Assignment of type of diabetes
Accordingly, as well as the age at first UTS insulin prescription, the assignment method 
also took into account the patient’s pattern of oral hypoglycaemic drug use, records of 
ketoacidosis, GPRD records specifically for "Typel" or "Type 2" diabetes, and whether 
or not they were obese at the time of their first insulin prescription. The method is shown 
schematically in Figure 3.2.
Base study population (56,330) 
1
No 56 ,063Y es
2 67
Y es
No I 5 5 ,972
Y es
11,370
No 44 ,6 0 2
No Y es
6964 3 ,906
TYPE 1TYPE 2
A ge a t  1 s t  insu lin  < 35
A ge a t  1 s t  insulin  b e tw e e n  2 5  a n d  35  
AND 6 m o n th s  UTS tim e  fro m  1 s t  o ra l a n t i-d ia b e tic  
p re sc rip tio n  to  1 s t insu lin  p re sc rip tio n  
AND ora l a n t i-d ia b e tic  p rsc r ip tio n s  o v e r  a t  le a s t 
18 m o n th s  of UTS tim e
A ge a t  1 s t  insu lin  > =  35
AND NOT o b e s e  a t  1 s t insulin
AND sp ecific  co d e  fo r T ype  1
AND NO sp ecific  co d e  fo r T ype  2
AND no  o ra l a n t i-d ia b e tic  p re sc r ip tio n s  in UTS tim e
AND 1 s t insu lin  w ith in  91  d a y s  o f le f t- c e n s o r  d a te
A ge a t  1 s t  UTS insu lin  p re sc r ip tio n  b e tw e e n  13 a n d  3 5  
AND no  rec o rd  o f k e to a c id o s is  
AND sp ecific  c o d e  fo r T ype 2 
AND NO sp ec ific  c o d e  fo r T y p e  1
AND [ a t  le a s t  18 m o n th s  UTS tim e  fro m  1 s t  o ra l a n t i-d ia b e tic  p re sc r ip tio n  
to  1 s t insu lin  p re sc r ip tio n  
OR o b e s e  a t  1 s t  insulin  p re sc r ip tio n  a n d  a t  le a s t  6  m o n th s  UTS tim e  
from  1 s t  o ra l a n t i-d ia b e tic  p re sc rip tio n  to  1 s t  in su lin  p re sc rip tio n
44,264 12,066
Figure 3.2: A s s i g n m e n t  o f  t y p e  o f  d ia b e t e s
This resulted in 12,066 of the base study population (22%) being classified as having 
Type 1 diabetes, and 44,265 (78%) as having Type 2. The proportion of those with Type 
1 is higher than in the general diabetic population (5~10%), however, this study looks 
only at insulin-using patients, which not all Type 2 patients require.
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3.5 Mapping insulin exposure
C l a s s i f i c a t i o n  o f  i n s u l i n s
All insulins in the GPRD product dictionary were classified by type and by action. The 
insulin types were animal (any bovine or porcine insulin, or combination of these), 
human, analogue or unknown. The actions were fast/short, intermediate, long, mixed 
(meaning pre-mixed combined formulations) or, where the prescription information in 
the GPRD was insufficient to classify the insulin, unknown. A list of the human and 
analogue insulin codes and classifications is given in Appendix A, Table B .l.
For mapping and analysis, the insulin type and action were combined to produce a 
"combination code" for each GPRD insulin product, indicating for example 
"Human.Intermediate" or "Analogue.Long". The numbers of prescriptions issued to 
patients in the base study population in UTS time are given in Table 3.3.
Table 3.3: N u m b e r s  o f  UTS in s u l i n  p r e s c r i p t i o n s  i s s u e d  t o  t h e  b a s e  s t u d y
POPULATION BY COMBINATION CODE AND TYPE OF DIABETES
Combination
Code
Prescriptions 
Type 1 (%)^
Prescriptions 
Type 2
Animal 
Human.Short 
Human.Intermediate 
Human.Long 
Human.Pre-mixed 
Analogue. Fast 
Analogue.Long 
Analogue. Pre-mixed
25,014 (3.3%) 
119,285(15.7%) 
136,135 (17.9%) 
11,213(1.5%) 
135,895 (17.9%) 
176,379 (23.2%) 
112,105(14.8%) 
43,040 (5.7%)
84,849 (4.1%) 
163,961 (7.9%) 
316,837 (15.3%) 
15,475 (0.7%) 
675,161 (32.6%) 
257,149(12.4%) 
288,320 (13.9%) 
269,887 (13.0%)
Total 759,066 2,071,639
1 ) Percentage of prescriptions by type of diabetes 
I n s u l i n  p r e s c r i p t i o n  d u r a t i o n
Insulin-dependent patients will try to insure they always have insulin available, and 
hence are likely to obtain insulin in advance for use over a period. Although 
manufacturers recommend that, once opened, unused insulin should be discarded after 4 
weeks, sealed insulin, appropriately stored, could be kept for at least a year. There is, 
therefore, not always a direct relationship between the issue of a prescription and the 
exposure of the patient to that product. In addition, patients will vary their insulin dose 
as required, so there is no straightforward way to calculate the exposed time from the
8 0
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number of units prescribed. Insulin-dependent patients will try to insure they always 
have insulin available, and hence are likely to obtain insulin in advance for use over a 
period. Although manufacturers recommend that, once opened, unused insulin should be 
discarded after 4 weeks, sealed insulin, appropriately stored, could be kept for at least a 
year. There is, therefore, not always a direct relationship between the issue of a 
prescription and the exposure of the patient to that product. In addition, patients will 
vary their insulin dose as required, so there is no straightforward way to calculate the 
exposed time from the number of units prescribed.
To allow insulin exposures to be mapped from the prescriptions, three simplifying 
assumptions were made:
a) that patients used all the insulin prescribed for them (unless there was evidence of 
a switch in therapy)
b) that usage started on the day of prescription, and
c) that patients deemed to have Type 1 diabetes would, once started on insulin, 
continue to use insulin for the remainder of their UTS time.
An estimate of the "duration" of each insulin product was obtained by finding the time 
between repeat prescriptions of the same individual GPRD product code. All of the UTS 
insulin prescriptions in GPRD2009 were used for this, not just those for the study 
population. The "assumed duration" (in days) for each product was taken to be the 75^  ^
centile (upper quartile) repeat time, ignoring those of more than 400 days.
There were 302 distinct GPRD insulin product codes, and the distribution of their 75^  ^
centile times (grouped by combination code) is shown in Figure 3.3. While there was 
considerable variation between products, the upper quartile "times to next prescription" 
were generally between 50 and 100 days. Within insulin products of the same "action", 
the centile times were longest in animal insulins, and (generally) shorter in analogue 
insulins. This may reflect greater GP monitoring of patients on analogue rather than the 
more established animal or human insulins.
8 1
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II
An Hu Lg An Hu Lg
FastorShort Intermediate
An = animal. Hu = hum an. Lg = ana logue
An Hu Lg An Hu Lg 
Long Mixed
Figure 3.3: U p p e r  q u a r t il e  t im e  b e t w e e n  p r e s c r i p t i o n s  o f  t h e  s a m e
GPRD INSULIN PRODUCT CODE, BY TYPE AND ACTION
M a p p i n g  i n s u l i n  e x p o s u r e s
Using the "combination codes", each patient’s insulin exposure over their up-to-standard
time was found ("mapped") as follows (using a computer program written by the author):
1) All the UTS insulin prescriptions for a patient were located on a grid where each 
row was one of the insulin types and each column was a date.
2) The day of the prescription and the following days for the duration of the 
prescription were marked as "exposed" to that insulin.
3) When all prescriptions for the patient were plotted, each row of the grid was 
scanned looking for gaps of less than 91 days (or 181 days for fast-acting insulins). 
These gaps were assumed to be artefacts, and were filled as exposed days.
4) A "summary row" was then constructed using the information from all of the grid 
rows. For each day an integer field was used as a bit map: an exposure in the i*  ^
row of the grid was coded as a "1" in the i*  ^bit position of the summary integer. 
This generated a unique number for each possible combination of insulins on that 
day. An example is shown in Figure 3.4.
5) The summary row was scanned, searching for exposure patterns that were likely to 
be artefacts of the mapping process, and, where possible, these were removed.
82
3. Methods Mapping insulin exposure
Various adjustments were made:
a) Firstly, the summary row was scanned for exposure patterns of the form 
A+B —> A —> A+B where the first period was at least 3 times longer than the 
middle period, the middle period was at least as long as the th ird , and the 
middle included only drugs in the two outer periods. It was assumed that the 
middle period was an artefact: the patient was actually using the mixture of 
insulins, but not refilling some types as often as the others. In these cases, the 
first exposure was rolled over the middle period, and the summary row 
regenerated.^
b) Next, the summary row was scanned for exposures of the form
A —)■ A+B -+ B where the overlap was less than 91 days and there were no 
prescriptions for class "A" during the overlap. These were replaced by 
A ^  B, with the overlap period replaced by "B" alone, and the summary row 
regenerated. For example, in Figure 3.4 the period of overlap of the two 
prescriptions would be replaced by long-acting insulin alone from the date of 
the long insulin prescription.
insulin 
H um an.Inter 
Analogue.Long 
Summary
This p a t ie n t  h a d  a  p re s c r ip t io n  fo r  h u m a n  in te rm e d ia te -a c t in g  insulin  
s o m e  t im e  b e fo re  t h e  1 0 th  o f  M arch : its  "e x p o s e d "  t im e  ru n s  to  t h e  1 8 th  M arch . 
S h e  a lso  h a d  a  p re s c r ip t io n  fo r  lo n g -a c tin g  a n a lo g u e  in su lin  o n  th e  1 5 th  M arch , 
w h ich  e x te n d s  b e y o n g  th e  2 9 th . T h e re  is a n  o v e r la p  b e tw e e n  th e s e  p re s c r ip t io n s , 
so  th e  su m m a ry  ro w  s h o w s  3 v a lu e s : f irs tly  t h e  in te rm e d ia te  a c tin g  insulin  a lo n e  
(c o d e  1, b itm a p  0 0 0 1 ), th e n  b o th  in su lin s  (c o d e  3 , b itm a p  0 0 1 1 ), a n d  fina lly  th e  
lo n g -a c tin g  insu lin  a lo n e  (co d e  2, b itm a p  0 0 1 0 ).
Figure 3 .4 :  E x a m p l e  o f  a n  in s u l in  m a p p in g
c) Next, the summary row was scanned for unexposed periods of the form 
A —)■ none, where "A" was any insulin or combination of insulins, and the
For clarity, examples used in the mappings show only two insulins, however the methods applied to any 
insulin combination that met the criteria. For example, exposures A+B -+ A+B+C+D -+ B+C+D would 
be treated as an overlap provided the middle period was less than 91 days and had no "A" prescriptions, 
and converted to A+B -+ B+C+D.)
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unexposed period was less than 91 days. The unexposed periods were 
replaced by the preceding exposure, and the summary row regenerated.
d) The summary row was then scanned for exposures of the form A+B -+ A, 
where the second period was less than 91 days. The second exposure was 
overwritten by the first, and the summary row regenerated.
e) The summary row was then checked for a "ragged right" at the end of the 
patient’s exposed time. Exposures ending within 91 days of the patient’s last 
exposed day were assumed to be due to differences in the assumed durations, 
and hence spurious. They were removed by extending the preceding 
exposures to the last exposed day. An example is given in Figure 3.5. In this 
case the "1+2+3" exposure would be rolled forward to the last exposed day.
6) Finally, in patients deemed to have Type 1 diabetes, the summary row was scanned 
and all "unexposed" periods between two exposed periods were overwritten with 
the preceding exposure.
Last exposed date
< “assum id days'
rroauciA  ... — ' k fV
MAPPED EXPOSURE A + B + C B + C B
- is a prescription and its assumed exposure
Figure 3.5: E x a m p l e  o f  c o n s o l id a t io n  o f  t h e  "r a g g e d  r ig h t " e n d  o f
AN EXPOSURE RECORD
Once all adjustments had been made the summary was regenerated and the final 
exposure mapping produced. The output of the mapping process was a partition of each 
patient’s UTS time into contiguous exposure periods (which, for patients with Type 2 
diabetes, may have included periods unexposed to insulin): the 55,914 patients in the 
base study population were mapped into 219,271 exposures.
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3.6 Insulin switching
Patients whose insulin exposure changed during their UTS time were defined as 
"switchers". The assumptions in the mapping process mean that some of these mapped 
changes may have been artefacts. In particular, switches of the type A + B —> A 
{i.e. where the post-switch exposure was a sub-set of the insulins in the pre-switch 
exposure) may have resulted from incorrect assumptions about the prescription duration.
To give greater confidence that switches were genuine changes in exposure, restrictions
were applied to give a sub-set of switches for use in the analyses:
• Changes from "insulin-exposed" to "unexposed" (and vice-versa) were excluded, as 
the analyses were concerned with the effects of changes in insulin exposure, rather 
than with the initiation, resumption or cessation of insulin therapy.
• There must have been at least one insulin (by combination code) in the post-switch 
exposure that was not in the pre-switch exposure.
• There must have been a prescription on the switch date for each type of insulin (by 
combination code) not in the pre-switch exposure.
• There must have been at least 2 prescriptions in the pre-switch exposure for each 
type of insulin (by combination code) in that exposure.
Switches were limited to those in 1999 or later, and further restrictions were applied 
based on the exposure lengths. To ensure that the patient’s status pre-switch was due to 
the pre-switch exposure, a minimum duration needed to be set for the pre-switch period.
Too short a duration might mean the patient was still under the influence of earlier 
insulins, or that the change was not actually a "switch" but an artefact caused by a longer 
than usual period between prescription refills.
To evaluate what would be a reasonable amount of time the distribution of the length (in 
days) of the pre-switch period was examined (Figure 3.6).
There was a step-change in the distribution at 91 days, which reflects the 91 day 
"assumed usage" period used in the mapping, with the modal length being just over this.
As it seems possible that switches just longer then the assumed usage days were 
artefacts, it was decided to use twice the assumed usage period (182 days/6 months) as 
the minimum length of the pre-switch exposure.
The durations of the post-switch exposures were then examined (Figure 3.7). There was
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lO
c  CO
o
200 400
Length of pre-switch exposure (days)
600 800
W here exposure is less then 800 days
Figure 3.6: L e n g th  o f  p r e - s w i t c h  in s u l in  e x p o s u r e s
a modality around 3 months^, however 631 exposures lasted less than a week, and in 129 
the exposure lasted only 1 day. These short exposures may give valuable information: a 
patient may have tried a new insulin, had an adverse reaction, and then changed again. 
However, short exposures may also be an artefact due to some problem with the insulin 
prescription: perhaps the original insulin prescription was incorrect, or was lost by the 
patient, or the switch may have occurred shortly before the patient’s right censor date 
(meaning that any adverse effect would not be in the patient’s UTS record). Accordingly 
it was decided to remove switches where the post-switch exposure was less than 4 days 
or the patient did not have at least 3 months UTS time after the switch.
Only the first qualifying switch was used for each patient and, to ensure enough patients 
in each exposure class for robust analysis, switch pre- and post-switch exposure 
combinations (by combination code) with less than 5 patients were excluded. This gave 
17,777 "qualifying" switching patients: "established" insulin users with a change of 
exposure during their UTS time. Their observed pre- and post-switch insulin exposures, 
by combination code, are shown in Table 3.4.
As the post-switch exposures must have started on a prescription for at least one of its insulins, this 
suggests these exposures ended at the end of the assigned duration of those insulins
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Table 3.4: O b s e r v e d  in s u l in  e x p o s u r e s  ( b y  c o m b in a t io n  c o d e ) in "q u a l if y i n g "
SWITCHES BY PRE- AND POST- SWITCH EXPOSURE
PRE-SWITCH
POST-SWITCH < < I  I  X X I
£ i£
0 3
—I < X
X
_J _J (0 CO W
X X X X X X X
(/) cn CO 
X X X OJ 0 3  D )  TO 0 3  0 5
An
An; Hu.In 21
An; Hu.Mx 40
An; Lg.Fa 62
An; Lg.Fa; Lg.Lo 34
An; Lg.Lo 72
An; Lg.Mx 24
Hu.ln 18
Hu.ln; Hu.Mx 204
Hu.ln; Hu.Mx; Lg.Fa 7 24
Hu.ln; Hu.Mx; Lg.Fa; Lg.Lo 8
Hu.ln; Hu.Mx; Lg.Mx 10
Hu.ln; Lg.Fa 28 199 6
Hu.ln; Lg.Fa; Lg.Lo 15 128
Hu.ln; Lg.Fa; Lg.Lo; Lg.Mx !
Hu.ln; Lg.Fa; Lg.Mx 32
Hu.ln; Lg.Lo 68
Hu.ln; Lg.Mx 99 10
Hu.Lo; Lg.Fa 
Hu.Lo; Lg.Fa; Lg.Lo
Hu.Mx 82 514 7
Hu.Mx; Lg.Fa 12
Hu.Mx; Lg.Fa; Lg.Lo 
Hu.Mx; Lg.Fa; Lg.Mx 
Hu.Mx; Lg.Lo
Hu.Mx; Lg.Mx
Hu.Sh 31
Hu.Sh; An 45
Hu.Sh; An; Hu.ln 5
Hu.Sh; Hu.ln 11 297 6
Hu.Sh; Hu.ln; Hu.Lo
Hu.Sh; Hu.ln; Hu.Lo; Lg.Fa
Hu.Sh; Hu.ln; Hu.Mx 7 9
Hu.Sh; Hu.ln; Hu.Mx; Lg.Fa
Hu.Sh; Hu.ln; Hu.Mx; Lg.Fa; Lg.Lo
21
10
125 
168 
84 5
12
10 371 217 32823
13
24 28
78
27
42
10 37 66 79
368
124
5
102
407
70
236
82
13
56
9
6
670 9
18
7
154
11
5
57 13
16
9
18
9
Hu.Sh; Hu.ln; Lg.Fa 60 5 799 21 6
Hu.Sh; Hu.ln; Lg.Fa; Lg.Lo 94
Hu.Sh; Hu.ln; Lg.Lo 107
Hu.Sh; Hu.ln; Lg.Mx 66
Hu.Sh; Hu.Lo 21 56
Hu.Sh; Hu.Lo; Lg.Fa 49
Hu.Sh; Hu.Lo; Lg.Fa; Lg.Lo 8
Hu.Sh; Hu.Lo; Lg.Lo 12
Hu.Sh; Hu.Mx 576 28 216 9
Hu.Sh; Hu.Mx; Lg.Fa 13
Hu.Sh; Hu.Mx; Lg.Fa; Lg.Lo 5
Hu.Sh; Hu.Mx; Lg.Mx 7
Hu.Sh; Lg.Fa 6 25 60 6
Hu.Sh; Lg.Fa; Lg.Lo 16 371 26 12 40 16
Hu.Sh; Lg.Lo 28 32 194 42 5 22 5
Hu.Sh; Lg.Mx 7 125 7 39
Lg.Fa; Lg.Lo; Lg.Mx 6 33 7 93
Lg.Fa 25 36 150 11 37 34 71
Lg.Fa; Lg.Lo 12210 102 7765 5 19 91410 8 75 8 18 368 19 5676 567
Lg.Fa; Lg.Mx 21 31 8 21 16 223
Lg.Lo 24 304 23 7 337 7 11 120
Lg.Lo; Lg.Mx 6 87 72
Lg.Mx 81 341 9 1785 25 7 6 366
Insulin sou rces; An = animal, Hu = human, Lg = analogue
Insulin actions: Sh = short. Fa = fast. In = intermediate, Lo = long, Mx = pre-mixed
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0 100 200
Length o f post-switch exposure (days) 
W here exposure is less than 300 days
300
Figure 3.7: Le n g t h  o f  p o s t - s w it c h  i n s u l in  e x p o s u r e s
C l a s s i f i c a t i o n  o f  s w i t c h i n g  e x p o s u r e s  f o r  u s e  i n  a n a l y s is
Ideally, in those analyses that used switching patients, each different pre- and post-switch 
exposure combination would have been included as a category in the analysis. However 
the large number of observed insulin combinations, some of which were seen in 
relatively few patients, made this impractical. Accordingly, for analysis the exposures 
were grouped into the 14 categories shown in Table 3.5. This reduced the switching 
combinations to the 97 different pre-and post combinations listed in Table 3.6.
88
3. Methods Insulin switching
Table 3.5: O b s e r v e d  i n s u l in  e x p o s u r e s  in all  q u a l if y in g  s w i t c h e s , a n d  t h e ir
CLASSIFICATION FOR ANALYSIS
O bserved
Exposure Classification for analysis
Number
Pre­
switch
Number
Post­
switch
Total
Pre­
switch
Total
P ost­
switch
Hu.Sh+Hu.Mx (1) Short-acting human insulin, alone 101 829 98 5 9 30
Hu.Sh or with pre-mixed human insulin 8 84 101
Hu.Sh+Hu.ln (2) Intermediate or longer-acting human, 2609 1299 295 6 2 034
Hu.In+Hu.Mx insulin with short-acting or 50 372
Hu.Sh+Hu.In+Hu.Mx pre-mixed human insulin 16 270
Hu.Sh+Hu.Lo 281 77
Hu.Sh+Hu.In+Hu.Lo 16
Hu.ln (3) Intermediate or longer-acting human 2217 239 2 2 6 2 239
Hu.Lo insulin a lone 45
Hu.Mx (4) Pre-mixed human insulin alone 6024 800 6 0 2 4 8 00
Lg.Fa (5) Fast-acting analogue insulin, alone 753 364 779 6 8 4
Lg.Fa+Lg.Mx or with pre-mixed analogue insulin 26 320
Lg.Fa+Lg.Lo (6) Longer-acting analogue insulin with 115 3599 121 3903
Lg.Lo+Lg.Mx pre-mixedor fast-acting analogue 6 165
Lg.Fa+Lg.Lo+Lg.Mx insulin 139
Lg.Lo (7) Longer-acting analogue insulin alone 1187 833 1187 833
Lg.Mx (8) Pre-mixed analogue insulin alone 1500 262 0 1500 2 620
An (9) Animal insulin alone 694 21 6 9 4 21
Hu.Sh+An (10) Animal insulin with any human 15 72 15 161
An+Hu.Mx insulin 50
An+Hu.ln 21
Hu.Sh+An+Hu.ln 18
An+Lg.Lo (11) Animal insulin with any analogue 72 10 197
An+Lg.Fa insulin 10 67
An+Lg.Fa+Lg.Lo 34
An+Lg.Mx 24
Hu.In+Lg.Fa (12) Fast-acting analogue insulin and 1104 1274 1114 2 646
Hu.Sh+Hu.In+Lg.Fa intermediate human insulin, in 891
Hu.In+Lg.Fa+Lg.Lo any combination with other human 156
Hu.In+Hu.Mx+Lg.Fa and analogue insulins 120
Hu.Sh+Hu.In+Lg.Fa+Lg.Lo 94
Hu.In+Lg.Fa+Lg.Mx 10 64
Hu.Sh+Hu.In+Hu.Mx+Lg.Fa 20
Hu.Sh+Hu.In+Hu.Lo+Lg.Fa 9
Hu.In+Hu.Mx+Lg.Fa+Lg.Lo 8
Hu. In+Lg. Fa+Lg. Lo+Lg. Mx 5
Hu.Sh+Hu.In+Hu.Mx+Lg.Fa+Lg.Lo 5
Hu.Sh+Lg.Fa+Lg.Lo (13) Fast-acting analogue insulin with 481 57 1196
Hu.Mx+Lg.Fa human insulin other than intermediate. 23 39 2
Hu.Mx+Lg.Fa+Lg.Lo or other analogue insulins 132
Hu.Sh+Lg.Fa 97
Hu.Sh+Hu.Lo+Lg.Fa 49
Hu.Sh+Hu.Mx+Lg.Fa 13
Hu.Lo+Lg.Fa 34 9
Hu.Sh+Hu.Lo+Lg.Fa+Lg.Lo 8
Hu.Sh+Hu.Mx+Lg.Fa+Lg.Lo 5
Hu.Lo+Lg.Fa+Lg.Lo 5
Hu.Mx+Lg.Fa+Lg.Mx 5
Hu.Mx+Lg.Mx (14) Other com binations of human and 46 3 73 1513
Hu.Sh+Lg.Lo analogue insulins not otherwise 58 328
Hu.Sh+Lg.Mx classified 178
Hu.In+Lg.Mx 15 151
Hu.Mx+Lg.Lo 115
Hu.Sh+Hu.In+Lg.Lo 107
Hu.In+Lg.Lo 76
Hu.Sh+Hu.In+Lg.Mx 66
Hu.Sh+Hu.Lo+Lg.Lo 12
Hu.In+Hu.Mx+Lg.Mx 10
Hu.Sh+Hu.Mx+Lg.Mx 7
Insulin sources: Hu = human, Lg = analogue
Insulin actions: Sh  = short, Fa = fast. In = intermediate, Lo = long, Mx = pre-mixed
89
3. Methods Insulin switching
CD
Ü  CO
CO
_0)
.to
I
N . 
CO CO 
T - LO
I
l i
1 1
in  00  CD 
1 - m  CM CO 
CM -M- CO
:: ^  
CO CO
CM CO T j- O ) 
O  CM 05 CO 
1 -  C35 CO
CO ■M- i n  CO
I "
I f3 (005 C35
il
m g
Hi
ii
g> o
c l
c
2 5
CD CO
ÎI
1 1
II
If  
i f
0 ) X3
i ii f
to 5
= III
0) CO)II
CO tos g
ÛI SNin  CO CM 
CO N  T -
T f Tj- i n
CO 05 CM 
CM
1
3SI
L= 3  C 3
o
CD
CCO
C o
3 to
CO c
c
3
CD CO
3 c
O )
o CD CD
CO 3C3)
C
o
■ i
to
O)
c
■•0 TO
i
;
to CD
X
(D c l o
0 5 1 E
O
!»
to r -
(0
%
O  3
= s lÇ I  „
f f  S'i l s
P I10 C to
III
CÜsÏ
I
3
If
2 SCO
90
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3.7 Hypoglycaemic episodes
The GPRD cannot provide information on a patient’s day-to-day glycaemic control: it 
records only those events made known to the GP, either during a consultation or other 
contact, or when the GP is informed of a hospital event or test result. As patients are 
unlikely to report minor, symptomatic events to their GP, only the more serious events 
are likely to be recorded. Accordingly, the events identified in the GPRD records are 
referred to as "serious" hypoglycaemic events.
GRD2009 clinical codes for hypoglycaemia and also had records of blood glucose test 
results. However, hypoglycaemic episodes may not necessarily be recorded using the 
specific codes, and blood glucose levels may not always be measured, so the use of other 
clinical information in the GPRD to identify events was explored.
In preliminary studies, clinical records for the symptoms of hypoglycaemia were 
extracted, and the full GPRD medical records of samples of patients were reviewed to 
see if the events could reasonably be associated with hypoglycaemia. The symptoms 
included loss of conciousness, convulsions, confusion, sweating, pallor, dizziness, 
fatigue, hunger, blurred vision or weakness. Headache and nausea were excluded, as 
although they are symptoms of hypoglycaemia they are both very common and 
non-specific.
As well as the clinical codes themselves, additional information, including the record’s 
"entity type" was used. The VISION software used by the GPs has some data structuring 
which can be used to associate clinical events with a pre-defined set of conditions or 
processes. A number of these "entities" are for diabetes: they are listed in 
Appendix B Table B.2. However, use of these categories is optional, and events are often 
recorded under non-specific entities: 97% of the explicit hypoglycaemia records were 
recorded under the entity "Medical History".
On the assumption that an episode might trigger a non-routine contact with a health care 
provider (such as an ambulance calls, emergency hospital admission, or out of hours 
telephone calls), these were also reviewed. Only 7.5% of explicit hypoglycaemic records 
(including low blood glucose test results) had a non-routine contact on the same day.
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Given this low association, and that there could be many other reasons for a non-routine 
contact, it was decided that they could not be used to provide supporting evidence for 
hypoglycaemia events.
Prescriptions for glucagon were also reviewed, on the assumption that a request might be 
prompted by an episode. However, comparing prescriptions to explicit records of 
hypoglycaemia did not show an association: only 3% were followed by a glucagon 
prescription within 7 days.
To understand the extent to which the underlying cause of a particular symptom could be 
determined from the patient’s GPRD record, the medical histories of samples of patients 
were reviewed. A randomly-selected sample of 330 patients from the base study 
population who had at least one record of a symptom of hypoglycaemia were extracted 
and their full medical records examined.^ An (edited) sample of a patient record is 
shown in Table 3.7.
Table 3.7: S a m pl e  o f  a  m ed ica l  r e c o r d  in c l u d in g  a ( po t e n t ia l ) sy m p t o m  o f
HYPOGLYCAEMIA
Date Clinical record
11/08/1993 MSU = abnormal (12199) [73]
23/08/1993 Scabies (2430) [73]
26/08/1993 Follow-up consultation (345) [73]
31/08/1993 D]Collapse (1812) [73]
31/08/1993 Referral » Collapse / Source: Self / Patlype: In Patient (1812) [73]
07/09/1993 Seen In psychiiatry clinic (2764) [73]
09/09/1993 Atrial fibrillation (1664) [73]
24/09/1993 Medical report received from fiospital (2763) [73]
04/10/1993 Day fiospital care (2280) [73]
08/02/1994 Diabetes mellitus (711) [74]
08/02/1994 Diabetes mellitus screen » Program type Practice Cfieck Up Type Annual (5234) [74]
08/02/1994 0/E - peripfieral pulses L.leg » Left Dorsalis Pedis Diminisfied Left Posterior Tibia (13333) [74]
08/02/1994 Diabetes monitoring admin. (9897) [74]
This patient had a collapse, a potential symptom of hypoglycaemia, on the 31st August 
1993, associated with a self-referral to hospital, where the patient was admitted as as 
in-patient. There were no clinical records on the date of the collapse associating it with 
diabetes, but on the 9th September there was a record of atrial fibrillation. It seems likely
 ^ Medical histories were reviewed using "Browser" software, written by the author, which displays all the 
patient’s GPRD information in chronological order.
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that the collapse was associated with a heart condition, rather than hypoglycaemia.
Following the record review, it was decided that the symptom codes were not, on their 
own, specific enough to identify hypoglycaemia. Accordingly, a restricted set of 
symptoms was used (indications of coma or unconsciousness, confusion, disorientation 
and convulsions/seizures) and only accepted as indicating hypoglycaemia if there was 
supporting evidence that the events were associated with diabetes or insulin use. A list of 
the selected symptom codes is given in Appendix B Table B.4. The process used to 
identify hypoglycaemic episodes was:
1 For each patient in the base study population the following GPRD records were
extracted. Only codes in the patient’s up-to-standard time and after the patient’s 
first insulin prescription were included.
a) Specific clinical records for hypoglycaemia (see Appendix A Table B.3).
b) Blood glucose test results with a valid "units" indicator and a value of 
<3.9mmol/l or <70mg/dL.)
c) Clinical records for a sub-set of the symptoms of hypoglycaemia. Records were 
excluded if their entity type was for asthma, epilepsy or hypertension.
d) All clinical records on the the same day as a symptom event (and not already 
extracted), omitting administrative events and routine clinic attendances.
2 Symptom events were deleted if a clinical record on the same day indicated a 
non-hypoglycaemic reason for the event. Alternative causes included ketoacidosis, 
raised blood glucose level, infarction, thrombosis, any heart condition, renal 
problems, acute pain, stroke or other cerebrovascular conditions, epilepsy, asthma 
or other respiratory conditions, pneumonia, burns, falls, fractures or dislocations, 
road traffic accidents, wounds or traumatic injury, poisoning, influenza, thrombosis, 
gastroenteritis, infection, pregnancy, bites or stings, depression, suicide attempts, 
excessive alcohol intake, diarrhoea, abdominal pain, or any indication of cancer.
Symptom days were also deleted if the patient had a record of heart failure or 
myocardial infarction within 7 days, or if they died within 7 days.
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3 Symptom events were deleted unless their entity type was 91 (diabetic concern) or 
97 (insulin dosage), or there was "supporting" evidence from other clinical codes 
on the same day. Records were taken as "supporting" if they referred to an adverse 
effect of medication, a diabetic emergency, diabetic instability, initiation or change 
in insulin therapy, or the failure of the patient to manage medication.
4 The specific hypoglycaemia and remaining symptom records were collated by 
patient and date, producing an "event day" table. Days where there was a test result 
indicating low blood glucose within 3 days were marked. Any low blood glucose 
test results not within 3 days of an existing hypoglycaemic event day were added as 
additional events.
3.8 Covariates
Information on smoking status, ethnicity, UK geographic region (of the GP practice), 
alcohol usage, body mass index, socio-economic status and HbAic measurements were 
extracted from the GPRD for use as covariates in the analyses.V ariables which could 
change over time (alcohol usage, BMI, smoking status and HbAic values) were mapped 
to allow a patient’s status at a given date to be found.
Other covariates included an estimation of the duration of diabetes, the presence (or 
absence) of various diabetic complications, and the number of clinical contacts over a 
given period (expressed as an annualised contact rate).
Marital status was also investigated as a potential covariate, however preliminary 
investigation showed that only about 20% of the study population had a usable record, so 
the data was inadequate for use in analysis.
Details of the covariate identification and classification are given below. In some 
analyses, there were too few patients in the covariate categories for stable analysis, so
" Data on smoking, alcohol usage and BMI were provided by Julia Snowball, Research Fellow and Oracle 
database manager for the University’s pharmacoepidemiology section at the time the study data was 
extracted.
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categories were merged. Where this was done, details are given in the Results section for 
the analysis.
UK GEOGRAPHICAL REGION
The GPRD codes each GP practice as being in one of the following UK geographical 
regions: North East, North West, Yorkshire and Humber, East Midlands, West Midlands,
East of England, South West, South East South Central, London, South East, Northern 
Ireland, Scotland or Wales. As it was associated with a GP practice, this was available 
for every patient.
S m o k i n g  s t a t u s
Patients were classified as smokers or non-smokers based on their GPRD records of 
smoking status or prescriptions for smoking-cessation aids. Smoking status records were 
taken as valid until superseded. Patients without such records were classified as 
unknown. Patients aged 13 or under at the date of interest were assumed to be 
non-smokers unless there was an explicit record indicating otherwise.
A l c o h o l  u s a g e
Patients were classified as non-drinkers, drinkers or heavy drinkers based on their GPRD 
records of alcohol intake or records indicating binge drinking, alcoholism or related 
conditions. Patients without such records were classified as unknown. Patients were 
assigned as heavy drinkers where their weekly consumption exceeded 42 units for men 
or 31 units for women or they had clinical records indicating alcoholism. Status records 
were taken as valid until superseded. Patients aged 13 or under at the date of interest were 
assumed to be non-drinkers unless there was an explicit record indicating otherwise.
B o d y  m a s s  in d e x  (B M I)
Patients were classified as obese, overweight, normal or underweight** based on GPRD 
records indicating height and/or weight or giving a calculated BMI. BMI was not 
calculated for children less than 2 years of age or under 0.9m in height, and the
BMI ranges were underweight = <18.5, normal = >18.5 <25, overweight = >25  <30, obese = > 30
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classifications in children were not adjusted using BMI-to-age percentile curves.
Records were taken as valid for 2 years, so patients without a valid record within 2 years 
of a given date were classified as unknown, as were patients without GPRD records.
S o c i o -e c o n o m ic  s t a t u s
The GPRD provides an individual Townsend score and an individual index of multiple 
deprivation (HMD) score for some patients in English practices. In patients with both 
scores, the observed correlation was r=0.736. Practice-level IMD scores were also 
available, however these were poorly correlated with the individual patient scores (r=0.33 
with the Townsend score and r=0.17 with the IMD). Given this, the socio-economic 
status (SES) was based only on individual scores, where present, and patients without 
individual scores were classified as unknown. Only one value of socio-economic status 
was available per patient, so this covariate was not time-dependent.
For analysis the quintile of the Townsend score was used where available, otherwise the 
quintile of the individual IMD score was used. The centile points were calculated from 
all of the Townsend or IMD scores available in the GPRD, not just those for the study 
population. The quintiles were labelled 0 to 4, where 0 was the most deprived, and 4 the 
least deprived.
E t h n i c it y
GPRD codes for ethnicity were extracted and grouped (using the terms defined in GPRD 
records) as: Caucasian (including Mediterranean, Arab and Middle Eastern); Black 
(including Afro-Caribbean); Asian (Indian, Pakistani, Sri Lankan, Bangladeshi or "other 
Asian"); Oriental (Chinese and "other oriental"); or Mixed race. 82% of the base study 
population did not have an ethnicity code, and these were classified as unknown.
In 2002, the Office for National Statistics estimated that ~91%  of the population were 
Caucasian, 4% were Asian, 2% black and 1% of mixed race. Where ethnicity was 
recorded in the GPRD, the proportions in the study population were 62% Caucasian, 9%
Asian, 6% Black, and 22% mixed race. There is clearly differential recording of 
ethnicity by GPs, with over-recording in minority ethnic groups, particularly those of 
mixed race, and under-recording in the majority, Caucasian, population. BAS,
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N u m b e r  o f  c l i n i c a l  c a r e  c o n t a c t s
The "clinical care contact rate" over a given time period was calculated as the number of 
days on which there were GPRD clinical records indicative of contacts with care 
providers, divided by the number of days in the period, converted to an annualised rate. 
Multiple records on the same day were treated as a single contact. GPRD records of 
personal contact with either the GP or another care provider (such as the practice nurse, 
or a clinic attendance) were included; records indicating administrative activities, letters 
or referral requests were excluded, although phone calls to or from the patient were 
retained.
R e g i o n a l  d i f f e r e n c e s  b e t w e e n  p a t i e n t s  a n d  i n  e t h n i c i t y  r e c o r d i n g
The Office for National Statistics (ONS) has published data (from the 2011 census) on 
the regional distribution of ethnic groups in England and Wales. Table 3.8 compares 
the ONS estimates to the ethnicity recorded in the GPRD. The ONS regional divisions 
are similar, but not identical to, those used by the GPRD: the ONS does not have a 
"South Central" region, so the Southern English regions may not be directly comparable.
There were marked differences in the GPRD recording of patient ethnicity across the 
regions: half of the patients from the London area had their ethnicity explicitly recorded, 
compared to just under 3% of patients from Northern Ireland. The proportion of ethnic 
minorities varies across the UK, with London (according the the ONS) being the most 
ethnically diverse region, however the proportions derived from the GPRD ethnic 
codings do not correspond to the ONS estimates. Overall, while ethnicity is a valuable 
covariate for the analyses (there are known to be diabetes-related differences between 
ethnic groups) the GPRD ethnicity data is of poor quality.
Patient ethnicity may also have affected the level of recording of other covariates. A 
study by Gray et a l  looking at the impact of ethnicity on the quality of diabetes care 
in primary care in Wandsworth, London, found that Black patients were more likely to be 
asked about their smoking status and have their BMI measured than were White patients.
They also noted, however, that there were no ethnic differences in HbAic recording.
Table 3.8 also compares the levels of socio-economic deprivation (where recorded) and
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the pre-insulin contact rate in the geographic regions. There were small (but statistically 
significant) differences between the regions in the patient’s health care contact rate in the 
period leading up to their first insulin prescription (%  ^p-value<0.001). There were also 
substantial differences between the regions in the proportion of those in the most 
deprived socio-economic group, from 25% of patients in London to 5% of those in the 
South East.
Table 3.8: D if f e r e n c e s  b e t w e e n  UK r e g io n s
UK
R egion
R eg ion
Ethnicity
recorded % B iack
GPRDb; ONSc
% A sian
GPRDb; ONSd
M ost
d ep rived
%«
P re-insu iin
co n ta cts /y ea r '
m edian (IQR)
North East 14.9% 0.23%; 0.5% 2.3%; 2.9% 16.7% 14.7  (9.3,24.1)
North W est 16.2% 0.30%; 1.4% 0.8%; 6.2% 23.8% 1 4 (8 .7 ,2 2 .0 )
Yorkshire and Humber 17.7% 0.25% ; 1.5% 0.4%; 7.3% 12.6% 13.8  (8,21.3)
East Midlands 10.9% 0.24%; 1.8% 1.3%; 6.5% 16.3% 12.7  (8,20.6)
W est Midlands 20.2% 0.74% ; 3.3% 3.0%; 10.8% 19.0% 14.5  (9.0,23.0)
East of England 11.4% 0.31%; 2.0% 0.5%; 4.8% 13.1% 12.7  (8,20.6)
South W est 11.7% 0.34% ; 0.9% 0.2%; 2.0% 13.7% 15.3 (9.3,24.0)
South Central 18.9% 0.33%; NA 0.8%; NA 6.1% 1 4 (8 ,2 2 .4 )
London 50.1% 8.26% ; 13.3% 8.2%; 18.5% 25.0% 12.2  (7.3,18.7)
South East 8.5% 0.07% ; 1.6% 0.2%; 5.2% 5.3% 12.1 (7 .3 ,19 .0)
Northern Ireland 2.8% 0 0 NA 14.0 (8,23.0)
Scotland 13.4% 0 0.3%; NA 13.3  (7.9 ,22 .1)
W ales 10.7% 0;0.6% 0.41% ;2.3% NA 1 4 (8 .7 ,2 1 .0 )
NA = not available
a) Percentage of patients in region with an explict ethnic coding
b) Percentage of patients in region coded as ethnically Black
c) Percentage of patients classified by the ONS as Black/African/Caribbean/Black British
d) Percentage of patients classified by the ONS as Asian/Asian British
e) Percentage of patients in region in most deprived SES quintile 
r) Annualized rate of contact with health care providers
D u r a t i o n  o f  d i a b e t e s
A number of studies have indicated an association between the risk of hypoglycaemia 
and the duration of diabetes, hence this is a valuable covariate for the analyses. To 
estimate the duration of diabetes we need to know when the patient was diagnosed as 
diabetic (their diabetes index date). This was estimated as the earliest of: the first GPRD 
clinical code explicitly for diabetes or for an HbAic measurement; the first insulin 
prescription; or the first prescription for an oral hypoglycaemic drug. For all of these, 
records on the 1st January or in the year of birth were ignored,^'*’ as were uncollected 
prescriptions, but events before the patient’s left-censor date were included.
GP’s sometimes enter clinical notes by adding records in the patient’s year of birth.
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For patients who were already diabetic when they registered with the GP {prevalent 
patients), there may be an "historic" index date in the GPRD record. However, as GP’s 
often record historical information under "dummy" dates such as Jan 1st 1900, or the 
patient’s year of birth, dates outside UTS time were not felt to be reliable enough for use 
in analysis. Even when the patient’s index date falls in UTS time, it may not be accurate.
Figure 3.8 shows the difference (in weeks) between the patient’s index and left-censor 
dates: there is a clear "spike" in the index dates around the left-censor date. For patients 
transferring into a practice, their left-censor date is generally either their first 
consultation (which may be a "new patient screening") or the date on which their records 
were transferred, hence the spike represents medical histories being taken, rather than 
diabetes diagnoses.
Accordingly, the approach taken in this study was to use two variables:
a) A binary variable was set to 1 if the patient’s diabetes index date was earlier than 6 
months after their left-censor date (indicating a patient who was probably 
prevalent at the start of their UTS time), otherwise it was set to 0.
b) A categorical variable was used to indicate the patient’s UTS time with diabetes.
The time from  the latest of the patients left censor date or diabetes index date to the 
date of interest (for example their first insulin prescription) was classified as: 1 year 
or less; between 2 and 5 years; between 6 and 10 years; and more than 10 years.
Both the categorical and binary variables were included as covariates in the analyses.
O r a l  h y p o g l y c a e m ic  d r u g  p r e s c r i b i n g
UTS prescriptions for oral hypoglycaemic drugs were collated over a time period (as 
relevant for the analysis, often the year before the patient’s first insulin prescription). The 
prescribing history was included in the analyes as a binary variable, indicating whether 
or not the patients had (at least one) prescription for metformin, sulphonylureas, 
thiazolidinediones or "other" oral hypoglycamic drugs in the time inteval.
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G l y c o s y l a t e d  h a e m o g l o b in
Measurement of the glycosylated haemoglobin (HbAic) level is recognised as among the 
most reliable indicators of medium-term glycaemic control. The GPRD includes 
HbAic test results (although in 2.3% the numeric values were not correctly recorded), 
and also has clinical codes which do not include a numeric value but which indicate 
"good" (<7%), "borderline" (>7 - <10%) or "poor" control (>10%). Test results 
recorded before 1995 may not have been standardised to the Diabetes Control and 
Complications Trial (DCCT) guidelines.
To check the quality of the HbAic data available in the GPRD, and hence its suitability 
for use as a covariate in the analyses, HbAic records in the base study population in UTS 
time were collated. Overall there were 571,209 HbAic records, 99% of which were test 
results with usable numeric values.
Recording rates changed over the study period, increasing ~9-fold from 1992 to 2004, 
after which it stabilised. Figure 3.9 shows the rates in women with Type 2 diabetes; 
similar changes were seen in males and in Type 1 diabetes. In the late 1990s 
HbAic recording was included in the Government’s targets for primary care, and it is 
likely that this, together with the increasing automation of test result downloads, was 
responsible for the increase.
Overall, recording rates were generally higher in Type 2 rather than Type 1 diabetes, and 
(sightly) higher in females rather than in males, as illustrated in Figure 3.10.
Furthermore, patients with Type 2 diabetes with poor glycaemic control (as evidenced by 
higher HbAic values) were more likely to have subsequent HbAic records than were 
patients with better control, although no such pattern was seen in patients with Type 1 
diabetes.
It is clear that during the study period HbAic values were not systematically recorded for 
all diabetic patients, however, as an objective indicator of glycaemic control, it remains a 
valuable covariate. HbAic status was included in analyses as a categorical variable, 
using the 3 levels defined in the clinical GPRD records. HbAic readings were taken as 
valid for 4 months: for the assignment of status at a given date, patients without a record 
within 4 months of that date were classified as unknown.
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Figure 3.9: HbAic RECORDING RATES IN THE BASE STUDY POPULATION: FEMALES 
WITH T y p e  2  d i a b e t e s  b y  a g e  (a s  1 0 - y e a r  a g e  b a n d ) in c a l e n d a r
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Figure 3.10: C o m p a r i s o n  o f  H b A ic  r e c o r d i n g  r a t e s  in f e m a l e s  a n d  m a l e s  
AND in T y p e  1 a n d  T y p e  2  d ia b e t e s  b y  s e l e c t e d  a g e  b a n d  in
CALENDAR YEAR
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C o m p l ic a t io n s  o f  d i a b e t e s
Patients often present with pre-existing diabetic complications, particularly in Type 2 
diabetes, and the presence (or absence) of these may influence their treatment.
Accordingly the presence of comorbidities was included in the analyses.
Evidence for longer-term complications in the study population was found using GPRD 
clinical codes and, where appropriate, related prescribing. Clinical and prescription 
codes dated 1st January, in the patient’s year of birth, or outside the patient’s 
up-to-standard period were excluded. The algorithms used to extract comorbidities were 
based on those developed by Dr Henrietta Mulnier, adapted by the author for the 
GPRD2009 database.
For use as covariates in the analyses these were grouped into 3 classes, although it is 
recognised that the divisions may not be strictly clinically accurate:
"Macro-vascular" Acute myocardial infarction, heart failure, ischaemic heart disease, 
carotid artery surgery, coronary artery bypass surgery, stroke, 
peripheral vascular disease or lower-limb amputations
"Micro-vascular" Diabetic retinopathy, blindness or diabetic neuropathy
"Renal" Diabetic nephropathy, renal failure, renal dialysis or kidney
transplantation
The method of identification for each complication is summarised below.
Acute myocardial infarction (AMI) A patient was deemed to have had an AMI if:
a) they had a clinical record indicating an infarction AND any of:
i) a record of an BCG
ii) a record giving the location of the infarction
iii) death within 1 month
iv) a record of coronary bypass surgery or angioplasty within 1 year
v) a record of abnormal cardiac enzymes within 1 month
vi) specific drug therapy (eg. statins or low dose aspirin) started within 2
months
vii) thrombolytic therapy started within 2 months
b) OR they had a clinical record of chest pain not associated with pulmonary 
embolism, chest surgery or angina AND they died within 1 month.
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Stroke A patient was deemed to have had a stroke if  they had a clinical code for a 
stroke event AND they did not have a diagnosis of cancer or multiple sclerosis AND
a) death occurred within 1 month of event
b) OR the patient had stroke-specific surgery within 1 year of event
c) OR the patient had at least one of:
i) a prescription for a drug used in the treatment of stroke within 2 months of 
the event
ii) evidence of residual damage; at least 1 clinical record for paresis; 
numbness; speech, vision or swallowing problems; rehabilitation or 
physiotherapy within 4 months of the stoke event
iii) confirmation of the stroke by CT, NMR or other method within 6 weeks of 
the event
Blindness or retinopathy A patient was deemed to be blind or to have diabetic 
retinopathy if they had an indicative clinical code.
Renal disease A patient was deemed to have had dialysis or a kidney transplant if they 
had an indicative clinical code; and as having renal failure or diabetic nephropathy where 
they had an indicative clinical code OR an abnormal creatinine test result.
Lower limb amputation A patient was deemed to have a lower limb amputation if 
they had an indicative clinical code.
Neuropathy A patient was deemed to have diabetic neuropathy if they had an 
indicative clinical code, including codes for nerve palsy and abnormal nerve reflexes.
Heart failure A patient was deemed to have heart failure if they had an indicative 
clinical code AND either a prescription for digoxin, an ACE inhibitor or a diuretic 
between 14 days before and 91 days after the event OR they had a clinical code for an 
echocardiogram within 1 year of the event.
Angina A patient was deemed to have angina if they had an indicative clinical code 
AND a prescription for nitrates between 14 days before and 91 days after the event.
Ischaemic heart disease (IHD) A patient was deemed to have ischaemic heart disease 
if the patient had an indicative clinical code AND
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a) the patient had any of
i) a prescription for an anti-arrthymia drug
ii) a record of angioplasty
iii) a record of coronary bypass
iv) a first prescription for aspirin in the range 14 days before to 64 days after
the IHD code
v) a record of ECG
vi) a history of AML
b) OR the patient had more than one code for IHD at least 5 days apart
c) OR the patient had an IHD code and one (or more) "IHD-related" codes (including
generic heart disease codes)
Carotid surgery A patient was deemed to have had carotid artery surgery if they had a
clinical code for carotid artery surgery AND;
a) a code for any cardiovascular condition/heart disease at any time before the event
b) OR at least 2 prescriptions for drugs used in the management of cardiac conditions 
between 1 year before to 1 year after the event
c) OR death occurred within 14 days of the event.
Coronary bypass surgery A patient was deemed to have had coronary artery bypass
surgery if they had an indicative clinical code AND:
a) a code for any cardiovascular condition/heart disease at any time before the event
b) OR at least 2 prescriptions for drugs used in the management of cardiac conditions 
between 1 year before the event and 1 year after the event
c) OR death occurred within 14 days of the event.
Peripheral vascular disease A patient was deemed to have had peripheral vascular
disease if they had an indicative clinical code AND:
a) a clinical code for claudication, gangrene of the foot or toe, peripheral arterial 
disease or ischaemic limb disease
b) OR two or more clinical codes for gangrene of the hand or finger, resting pain, 
gangrene in diabetes (location not specified), amputation of foot or toe.
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c) OR a clinical code for thromboembolytic disease or ulceration or abscess of the 
feet not associated with Charcot’s disease AND a clinical code for any of 
retinopathy, AMI, angina, stroke, ischaemic heart disease, coronary bypass 
surgery, or nephropathy from two years before any of these codes to two years after.
P r a c t ic e  a n a l o g u e  p r e s c r i b i n g  s t a r t  d a t e
The date on which a practice started prescribing analogue insulin was estimated as the 
date of the first GPRD record of an analogue insulin prescription for that practice, 
ignoring prescriptions issued on the January or marked as uncollected. All insulin 
prescriptions were included, not just those for the base study population, as were 
prescriptions before the practice’s UTS date.
The base study population patients were from 412 different GP practices. Their first 
analogue prescription dates ranged from 9th July 1996 to the 11th October 2006. To 
allow this date to be treated as a continuous variable, it was decimalised (to two decimal 
places); for example the 1st January 1998 was 1998.00, and the 1st July 2000 was 
2000.50.
To include the relative speed of the practice in the uptake of analogue insulin in the 
analyses practices were sorted by their start date and assigned an ordinal sequence 
enumber, with 1 for the earliest practice. Ties on the decimalised start date were allowed, 
so the last practice to begin prescribing was numbered 293.
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CHAPTER
Insulin prescribing over the study period
It was hypothesised (A) that
Insulin prescribing in the UK would change following the introduction of analogue 
insulins, and that GPRD prescription records could be used to track those changes.
To investigate this all GPRD2009 insulin prescriptions from 1992 for patients in the base 
study population and in patients newly-starting insulin therapy were collated, and the 
secular trends examined, in particular, tracking the uptake of analogue insulins. In 
addition, the insulin prescription mapping was used to identify changes in insulin 
exposure over the study period. Changes in exposure in the base study population were 
summarized, and the secular trends of changes in exposure in "switching" patients were 
identified.
4.1 Insulin prescribing patterns over the study period
The first analogue insulin (the fast-acting lispro) first appeared in the GPRD prescribing 
record in 1996, followed by pre-mixed analogues in 1998 and longer-acting products in 
2002. Their rapid uptake can be seen in Figure 4.1, which shows the secular trend in the 
prescribing of animal, human and analogue insulin in the base study population over the 
study period.
In 1992 84% of prescriptions were for human insulins, with the remaining 16% for . 
animal insulins. The proportion of animal insulin prescriptions fell steadily over the 
study period, (accounting for less than 1 % of prescriptions in 2008), however, the most 
marked trend was the decline in the proportion of human prescriptions after 1996 and the 
concomitant rise in analogue insulin prescriptions. By 2008 almost 80% of prescriptions
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F i g u r e  4 . 1 :  P r e s c r i p t i o n s  f o r  a n i m a l , h u m a n  a n d  a n a l o g u e  i n s u l i n  b y
CALENDAR YEAR OVER THE STUDY PERIOD, AS THE PROPORTION OF 
ALL INSULIN PRESCRIPTIONS ISSUED TO THE BASE STUDY POPULATION 
IN THE CALENDAR YEAR
were for analogue insulin.
Figure 4.2 tracks the insulins initially prescribed to patients newly-starting insulin 
therapy during the study period, and shows the same pattern of change. In 1992 85% of 
patients newly-starting on insulin were prescribed only human insulin products, 13% 
started on animal insulin, with the remainder on a combination of animal and human. 
Over the study period the proportion of patients starting on animal insulin steadily 
declined with, between 1992 and 1997, a proportionate rise in those starting on human 
insulin. However, after 1997 the proportion of patients starting on analogue insulin 
rapidly increased, at the expense of human products. By 2008 analogue insulin (alone) 
was the first insulin of choice for over 80% of new insulin users. Despite its steady 
decline across the study period, animal insulin had not fallen completely out of use: a 
few patients (<1% ) still started on animal insulin, either alone or in combination human 
or analogue products.
109
4. Results Insulin prescribing patterns over the study period
I
I
I
£
0.8 -
Analogue only 
Animal only 
Animal-Analogue: 
Animal.Human 
Human only 
H um an A nalogue
0.6 -
0.4 -
0.2 -o
.5
- o -I o —  o0.0 -CL
s 88 g s s g g
Calendar year
F i g u r e  4 . 2 :  FIRST INSULINS BY TYPE IN PATIENTS NEWLY-STARTING INSULIN 
THERAPY, AS THE PROPORTION OF PATIENTS STARTING INSULIN 
THERAPY IN THE CALENDAR YEAR
Figures 4.3 and 4.4 give a more detailed breakdown of insulin prescribing over the study 
period, showing the secular trend for each insulin "combination code" {i.e. by the 
combination of insulin type and insulin action) in Type 1 and Type 2 diabetes 
respectively.
While the general trends of a decline in human insulins and an increase in analogue 
insulins are clear in both Type 1 and Type 2 diabetes, there were variations among the 
different insulin products.
In both Type 1 and Type 2 diabetes the proportion of prescriptions for longer-acting 
human insulins and short-acting human insulins fell steadily over the study period, a 
decline that had started before the introduction of analogue insulins. In contrast, the 
proportion of prescriptions for pre-mixed human insulin increased between 1992 and 
1999 (2000 in Type 2 diabetes): at which point it accounted for nearly half of the insulin 
prescriptions issued to patients with Type 2 diabetes. Thereafter its use declined, 
although by 2008 it still accounted for ^15%  of prescriptions in Type 2 diabetes and
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~7%  in Type 1,
Between 1992 and 2002, in both Type 1 and Type 2 diabetes, around 20 to 30% of 
prescriptions were for intermediate-acting human insulin, although its use declined 
slightly over that time. However, after the introduction of longer-acting analogue insulins 
in 2002 this trend was interrupted, falling more sharply, although it remained in use, 
accounting for ~5%  of prescriptions in 2008.
Although the general trends were similar, there were some differences between Type 1 
and Type 2 diabetes, presumably reflecting the different management regimes. In Type 1 
diabetes the most common analogue insulin in 2008 was fast-acting (44% of all 
prescriptions), while less than 1% of prescriptions were for pre-mixed analogue. In 
contrast, in Type 2 diabetes in 2008 pre-mixed analogue and fast-acting analogue both 
accounted for just under a quarter of the prescriptions.
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4.2 Changes in exposure in the base study population
Of the 55,914 patients in the base study population, 34,768 (62%) changed insulin 
exposure at least once during their UTS time. The number of exposures per patient was 
strongly skewed (Figure 4.5), with a small number of patients (less than 1%) mapped to 
more than 20 exposures (although it is possible that some of these were artefacts of the 
mapping process).
Seventy-six percent of patients with Type 1 diabetes had a change in exposure compared 
to 58% of those with Type 2 diabetes. Females were more likely to switch than males, 
and also tended to have more switches (Table 4.1). Unsurprisingly, the longer a patient’s 
UTS time the more likely they were to have exposure changes.
The likelihood of a change also depended on the type of insulin: 71% of those with a first 
exposure of animal insulin subsequently changed exposure, but only 48% of those with a 
first exposure of analogue insulin did so, and only 19% of those who started on analogue 
insulin changed to an exposure containing human or animal insulins. (Table 4.2).
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Figure 4.5: UTS i n s u l i n  e x p o s u r e  f r e q u e n c y  b y  s e x  a n d  t y p e  o f  
D IA B E T E S
Table 4.1 :  C h a n g e s  o f  i n s u l i n  e x p o s u r e  i n  t h e  b a s e  s t u d y  p o p u l a t i o n ,  c o m p a r i s o n  
O F  p a t i e n t s
Type 1 Type 2
Median UTS time, years(IQR) No changes 
Changes
3.4(1.9,7.5) 
7.9 (4.0, 12.8)
7.7 (3.5,12.6) 
9.0 (5.4, 13.9)
% changers by sex (%) F 80%; M 74%
p=<0.001^
F 59%; M 58%
p=0.002^
fVledian number of exposures (IQR) Females F 4 (2,7); MS (1,6) 
p=<0.00f
F 2 (1,3); M2 (1,3) 
p=<0.00f
F = female, M = male
1) test for differences in proportion with changes in exposure between sexes
2) test for differences in median number of exposures between sexes
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Overall, just 3.5% of the observed changes in insulin exposure were to an exposure 
including animal insulin, which is consistent with the decline in the use of animal 
products noted above. 57% of the changes were to an exposure with analogue insulin, 
either alone or in combination with human or animal insulin, while less than 1% were 
changes completely away from analogues. Again, this is consistent with the observed 
increase in analogue insulin prescribing.
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S e c u l a r  t r e n d s  i n  q u a l i f y i n g  s w i t c h  p a t ie n t s
The changes in insulin exposures over the study period were tracked in the 17,777 
"qualifying switching" patients, defined as described in the Methods section 3.6, pg. 85).
Their pre- and post-switch insulin exposures, by insulin type, are summarized in 
Table 4.3.
Table 4.3: N u m b e r s  o f  o b s e r v e d  p r e -  a n d  p o s t - s w i t c h  i n s u l i n  e x p o s u r e s  in
SWITCHING PATIENTS, BY INSULIN TYPE
Pre-switch
e x p o s u r e
P ost -sw itch  e x p o s u r e
Animal
only
Animal + 
Human
Animal + 
analogue
Human
only
Human + 
analogue
Analogue
only Total
Animal only 111 192 111 28 252 694
Animal + human 6 9 15
Animal + analogue 10 10
Human only 21 4 4 3 ,666 4,306 4 ,190 12,227
Human + analogue 13 337 894 1,244
Analogue only 5 204 6 84 2 ,694 2,587
Total 21 161 197 4 ,003 5,355 8 ,040 17,777
The most common pre-switch exposure, seen in 69% of switching patients, was for 
human insulins only. 36% of these patients then changed to a different combination of 
human insulins, with the remainder about evenly split between analogue insulin alone 
and combinations of analogue and human insulin. Twenty-one patients switched from 
human to animal insulin, against the general trend away from the use of animal insulins.
The most common change in exposure, seen in 4,306 patients (24.2%) of patients, was 
from only human insulin to a combination of human and analogue insulin, although 
almost as many patients (4,190, 23.6%) changed from only human insulin to only 
analogue insulin. Overall 8,040 (45%) of the switches were to analogue insulin alone, of 
which 2,694 were patients switching between different analogue products. When 
patients who received a mixture of insulin types were included, 76% of the switching 
patients moved onto analogue insulin, either alone or in combination with other insulin.
The secular trends in switching over the study period in Type 1 and Type 2 diabetes are 
shown in Figures 4.6 and 4.7 respectively. These schematics show each type of switch 
(for example from animal to human) as an arrow starting on the pre-switch insulin 
exposure and ending on the post-switch insulin exposure, with the weight of the arrow 
(approximately) proportional to the number of patients: the exact number is given at the
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top of each column.
In 1998 human insulin accounted for over 80% of all insulin prescriptions, with 
relatively few patients still using animal products, hence the low numbers of switches 
involving animal insulins. In both Type 1 and Type 2 diabetes, and in every year of the 
study period, the largest number of switches involved a change from human insulin alone 
to either analogue insulin alone or a combination of human and analogue insulins. The 
volume of these switches peaks around 2004/2005, which was also when analogue 
insulin overtook human insulin in the UK (Figure 4.1). While the number of such 
switches fell after 2005, this may be because by that time fewer patients were using 
human insulin.
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4.3 Differences between GP practices
D a t e  o f  f i r s t  a n a l o g u e  i n s u l i n  p r e s c r i p t i o n
The base study subjects were from 412 different GP practices. There was considerable 
variation in when practices began prescribing analogue insulin (Figure 4.8), with the 
earliest starting on the 9* July 1996, and the latest on the 13^  ^December 2004.
20-
5 -
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Date of first analogue insulin prescription
Figure 4 . 8 :  D a t e s  o f  f i r s t  a n a l o g u e  i n s u l i n  p r e s c r i p t i o n  b y  a  p r a c t i c e ,
DERIVED FROM ALL VALID GPRD2009 INSULIN PRESCRIPTIONS, 
FOR PRACTICES WITH PATIENTS IN THE BASE STUDY POPULATION
While some practices were "early adopters" of analogue insulin, they tended to be fairly 
cautious in their use. Figure 4.9 shows the proportion of the practice’s insulin 
prescriptions in the year following its first analogue prescription that were for analogue 
products, plotted against the practice’s ordinal position for analogue insulin prescribing.* 
While one practice (in South-Central England) seems to have made an almost immediate 
transition to using only analogue insulins, in most practices, particularly the early 
adopters (those with lower ordinal numbers), the proportion of analogue prescriptions in 
the first year was rarely above 15% of the total, and was usually under 10%. While later 
adopters, particularly those in the last quartile of practices to adopt analogues, tended to 
have a higher proportion of analogue prescriptions, in the majority of those practices
An integer giving the ordinal position of practices sorted by the date of their first analogue (of any type) 
insulin prescription. Tied values were allowed, so practices starting on the same decimal date had the 
same number. Separate ordinal numbers were also derived for the first prescription for rapid-acting, 
intermediate or long acting and pre-mixed analogue insulins.
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analogues still accounted for 20% or less of their total insulin prescriptions.
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Figure 4.9: A n a l o g u e  i n s u l i n  p r e s c r i p t i o n s  a s  a  p r o p o r t i o n  o f  a l l
INSULIN PR E SC R IPTIO N S ISSU E D  BY THE GP PRACTICE IN 1 S T  YEAR  
AFTER THE START OF ANALOGUE PRESCRIBING
Analogue insulins of different absorption profiles became available in the UK at different 
times, starting with rapid-acting analogues in 1996. Figure 4.11 breaks down the 
practice 1st insulin prescription dates by the insulin action, and Table 4.4 gives a 5-figure 
summary for the date of the first analogue prescription by insulin action. Although all of 
the 214 practices prescribed some form of analogue insulin during the study period, 2 
did not prescribe fast-acting analogues, 14 did not prescribe intermediate or 
longer-acting analogues, and 8 did not prescribe pre-mixed analogues.
Table 4.4: 5 - F i g u r e  s u m m a r y  o f  d a t e  o f  f i r s t  a n a l o g u e  i n s u l i n
PRESCRIPTION BY INSULIN ACTION, BASED ON P R E SC R IPT IO N S IN THE 
BASE STUDY POPULATION
Insulin action
Date of 1st analogue prescription
minimum median (IQR) maximum
Rapid-acting
Pre-mixed
Intermediate or longer acting
1996.52
1998.79
2002.69
1998.44(1997.36,1999.50) 
2000.45 (1999.90,2001.315) 
2003.00 (2002.88,2003.14)
2004.99 
2004.94
2004.99
The spread of rapid-acting analogue insulins across practices was gradual. Although 
there were early adopters (Figure 4.1 la), it was nearly 2 years before the median practice 
started prescribing rapid-acting analogues, and 3 years before the upper quartile practice 
was reached. Rapid-acting analogues were the first analogue products, and their slower
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spread was consistent with a newly-introduced product gradually becoming accepted. 
Prescribing of pre-mixed analogue formulations spread more quickly (Figure 4.1 lb), 
again with a small number of early adopter practices: the median practice was reached 
just 6 months after the first, although it took over 17 months to reach the upper quartile 
practice. By the time longer-acting products became available most GPs were already 
prescribing other analogue insulins, so reducing barriers to their uptake. The use of 
long-acting analogues spread rapidly (Figure 4.11c): the median practice was reached 
after only 4 months, and the upper quartile in less than 6 months.
Regardless of the type of insulin, a small number of practices lagged behind, not starting 
to prescribe analogue insulins until the end of 2004, 8 years after their initial 
introduction.
There was some, albeit weak, evidence that practices that were slow to start using 
faster-acting analogue insulins were also slow to start using pre-mixed analogues: the 
correlation between the practice’s ordinal numbers for their first fast-acting analogue 
prescription and their first pre-mixed analogue prescription was r=0.39 (r^=0.15). There 
was, however, considerable inter-practice variation, as can be seen in Figure 4.10.
2 00 5-
2004-
=  2003
2002
m m #
^ 2001 -
2000 -
1999-
1998 1999 2000
Date of 1st rapid-acting analogue insuiin
20011996 1997 2002 20042003 2005
F i g u r e  4 . 1 0 :  RELATIONSHIP BETWEEN PRACTICE FIRST PRESCRIPTION DATES FOR 
RAPID-ACTING AND PRE-MIXED ANALOGUE INSULINS
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(a ) R a p i d -a c t in g  a n a l o g u e  i n s u l i n
1 4 -
12-
E 6
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Date of first rapid-acting analogue insulin prescription
( b ) I n t e r m e d ia t e  o r  l o n g e r -a c t in g  a n a l o g u e  i n s u l i n
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Date of first pre-mixed analogue insulin prescription
(c) P r e - m ix e d  a n a l o g u e  i n s u l i n
30
2 5 -
.e 20
1996 1997 1998 1999 2000 2001 2002 2003 2004
Date of first intermed/long-acting analogue insulin prescription
2006
Figure 4.11: D a t e s  o f  GP p r a c t i c e ’s  f i r s t  p r e s c r i p t i o n  f o r  a n a l o g u e
INSULIN BY INSULIN ACTION (BASED ON PRESCRIPTIONS FOR PATIENTS 
IN THE BASE STUDY POPULATION)
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N u m b e r  o f  p a t i e n t s  p e r  p r a c t i c e
The number of base study population patients per practice varied from 13 to 395, with a 
median of 126 patients (IQR[84.5,179.5]).
Figure 4.12 plots the number of patients in the practice against the practice’s ordinal 
number of their first prescription for rapid-acting analogue insulin. There was some 
(weak) evidence that practices with fewer patients tended to be slower to adopt analogue 
insulins: the correlation between the number of (base study population) patients and the 
date ordinal was r=-0.35. However, this was probably driven by the largest practices who 
tended to be relatively early adopters. Over most of the practices there was no clear 
association between practice size and when they started prescribing rapid-acting 
analogue insulin.
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F i g u r e  4 . 1 2 :  R e l a t i o n s h i p  b e t w e e n  p r a c t i c e  f i r s t  p r e s c r i p t i o n  d a t e s  f o r
RAPID-ACTING ANALOGUE INSULINS AND NUMBER OF STUDY PATIENTS 
CONTRIBUTED BY THE PRACTICE
The relationship between the number of patients a practice contributed to the base study 
population and the proportion of their insulin prescriptions that were for analogue insulin 
in the year after they started prescribing analogues is shown in Figure 4.13. As noted 
above, in the majority of practices analogue insulin use began cautiously, accounting for 
less than 15% of the insulin prescriptions in the practices’s first year of analogue use. 
There was some (relatively weak) evidence that practices with smaller numbers of 
patients made a greater early commitment to analogue insulins (correlation r=-0.30).
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however it is likely that this was driven by the relatively small number of larger practices, 
all of whom had 10% or less analogue prescriptions in their first year. Overall, there was 
little association between the size of a practice and their pace of introduction of analogue 
insulins.
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Figure 4.13: R e l a t i o n s h i p  b e t w e e n  t h e  p r o p o r t i o n  o f  a n a l o g u e  i n s u l i n
PRESCRIPTIONS IN THE FIRST YEAR OF ANALOGUE PRESCRIBING AND 
THE NUMBER OF STUDY PATIENTS CONTRIBUTED BY THE PRACTICE 
PRACTICE
V a r i a t i o n s  b y  UK r e g i o n
The number of practices, subjects per practice and the date of first rapid-acting analogue 
insulin prescription in the UK regions and countries are summarized in Table 4.5, and 
the date quartiles by UK geographic region are shown in Figure 4.14.
Figure 4.14 suggests differences in the pace of analogue insulin uptake in different UK 
regions. For example, the inter-quartile range was relatively short in the South Central 
and East Midland regions, but longer in the North East, suggesting it took longer for 
analogue insulin use to penetrate some regions than others. However, overall, the 
difference in the median date at which English practices started prescribing rapid-acting 
analogue insulin was not statistically significant (non-parametric K-sample test on the 
equality of medians, p=0.069). There was, however, some (weak) evidence of statistically 
significant differences between the UK countries. The median first prescription date in 
England was at least 9 months earlier than in the other countries (K-sample test
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p-value=0.046) and Scotland had the latest median date of all UK region (Table 4.5).
2 0 0 5 -
2 0 0 3 -
2002 -
i2000 -
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1 9 9 7 -
1 9 9 6 -
Figure 4.14: Box p l o t  o f  d a t e  o f  f i r s t  r a p i d - a c t i n g  a n a l o g u e  i n s u l i n
PRESCRIPTION ISSUED BY A PRACTICE, BY UK REGION
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4. Results Summary
4.4 Summary
By the start of the study period animal insulins had already been substantially (but not 
completely) superseded by human insulins, and over the study period human insulins 
were, in turn, increasingly displaced by analogue products. By 2004, analogue insulins 
were both the first choice for patients newly-starting insulin therapy, and over the study 
period they were increasingly the "destination" insulin for established insulin users.
Individual practices differed in how quickly they began prescribing analogue insulins, 
particularly the rapid-acting analogues: a few practices did not start prescribing 
analogues until 8 years after their introduction. There were also some differences in the 
speed of analogue insulin uptake between UK regions. Although there was considerable 
inter-region variation, and all regions had some early adopters, penetration tended to be 
slightly earlier and faster in the south and east of England, and later and slower in 
northern England and the other UK countries.
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CHAPTER
Factors affecting the initial choice between human and 
analogue insulin in patients newly-starting insulin
therapy
5.1 Hypothesis and analysis approach
The secular trends described in Chapter 4 showed analogue insulin was increasingly the 
first choice for patients newly starting insulin therapy. Hypothesis B postulated that:
GPs would be selective in their use of analogue insulins, choosing between human 
or analogue products based on the patient’s characteristics, and hence that the 
GPRD data could be used to predict the chosen insulin.
This hypothesis was tested in patients newly-starting insulin therapy who met the 
inclusion criteria defined in the Methods section 3.2. Logistic regression was used to 
estimate the effect of the patient’s characteristics and other covariates on their likelihood 
of being prescribed analogue rather than human insulin.
Patients with Type 1 and Type 2 diabetes were analysed separately, with a "complete 
case" analysis* for patients with Type 2 diabetes. Only 115 Type 1 patients had known 
values for all of the relevant covariates. Furthermore, of these patients, 6 who started in 
1999 all started on human products. Excluding these would have left only 109 "complete 
case" patients: too few for meaningful analysis.
"Complete cases" were patients with values, at first insulin prescription, for the covariates for socio- 
econonomic status, smoking and alcohol usage, BMI and glycaemic control status (H bAic).
5 1
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5.2 Patient numbers and characteristics
The 21,314 new insulin users who met the analysis inclusion criterial are summarized in 
Table 5.1 by sex and type of diabetes.
Table 5.1 : N u m b e r s  o f  s t u d y  s u b j e c t s  f o r  t h e  a n a l y s i s  o f  f a c t o r s
AFFECTING THE INITIAL CHOICE OF INSULIN
All patients Type 1 Type 2
Number of patients All patients 2,226 19,088
Number female (%) 966 (43.4%) 8,379 (43.9%)
Number male (%) 1,260 (56.6%) 10,709 (56.1%)
Median age at first insulin (IQR) Female 14(9,25) 65 (55,74)
Male 15(10,26) 63 (54,72)
Initial insulin in females (%) Human 513 (53.1%) 3,918 (46.8%)
Analogue 453 (46.9%) 4,461 (53.2%)
Initial insulin in males (%) Human 645 (51.2%) 4,588 (42.8%)
Analogue 615 (48.8%) 6,121 (57.2%)
Complete case patients Type 1 Type 2
Number of patients Complete cases 115 5,357
Number female (%) 54 (47%) 2,319 (43.3%)
Number male (%) 61 (53%) 3,038 (56.7%)
Median age at first insulin (IQR) Female 27 (21,32) 65 (55,73)
Male 28 (20,31) 63 (55,71)
Initial insulin in females (%) Human 19 (35.2%) 869 (37.5%)
Analogue 35 (64.8%) 1,450 (62.5%)
Initial insulin in males (%) Human 16 (26.2%) 1,041 (34.3%)
Analogue 45 (73.8%) 1,997 (65.7%)
5.3 Logistic regression on initiai choice of analogue or human insuiin in 
patients with Type 2 diabetes newly-starting insuiin therapy
The results of the logistic regression in patients with Type 2 diabetes are given in Table 
5.2, and the analysis of complete cases is in Table 5.3.
The all-patients analysis included a statistically significant interaction between a history 
of sulphonylurea use and a history of metformin use (the only statistically significant 
interaction between covariates that was found in the data).
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The largest effect sizes were associated with the calendar year of first insulin: a patient 
starting insulin therapy in 2 008  was 4 5  times more likely to start on analogue insulin 
(O R adj48.2 CIgspS.S, 59.9]) compared to a patient starting in 2000 . This was also the 
best single predictor of the use of analogue insulin: a logistic model with only the 
calendar year correctly predicted the first choice of insulin in 77.7%  of the patients, while 
adding all the other available covariates only improved the prediction rate to 78.2% .
The analysis found no statistically significant associations between the initial choice of 
insulin and a patient’s socio-economic status, smoking status or alcohol usage. There 
was also no association with whether or not the patient had a "macro-vascular" or renal 
comorbidity at the time of their first insulin prescription.
A pre-existing "micro-vascular" condition was associated with statistically significant 
lower likelihood of being given analogue insulin in the all-patient analysis (ORadjO-87 
Cl95[0.69,0.95]); although this association was not seen in the complete-case analysis.
In both the complete-case and all-patient analyses, patients with good glycaemic control 
(H b A ic  < 7 .5 )  at first insulin prescription were less likely to start on analogue insulin ( 
ORadjO.77 CI95[0.65,0.92] and ORadjO.64 Cl95[0.49,0.84] respectively).
There were also regional differences. In both Northern Ireland (ORadj L 73  
0195 (1 .3 5 ,2 .2 2 ])  and Wales (ORadj L 43  0 1 9 5 (1 .1 9 ,1 .7 2 ]) patients were more likely to 
start on analogue insulins than were patients in the (English) reference area. Scottish 
patients were less likely to be prescribed analogue insulin, but the difference was not 
statistically significant. Northern Ireland, Scotland and Wales have some degree of 
independent control of the NHS, so the differences between them and the English 
regions may reflect different national prescribing practices, or differences in their 
populations. However, there were also statistically significant differences between some 
English regions. Oompared to the reference group of patients in the West Midlands, 
patients in the North East of England were 76%  less likely to start on analogue insulin 
(ORadj0 .24  0 1 9 5 (0 .1 7 ,0 .3 2 ]) , while those in the North West were 39%  more likely to 
start on an analogue (ORadj 1 3 9  0 1 9 5 (1 .2 0 ,1 .6 1 ]) . Again, this may reflect differences in 
either the regional populations or in local prescribing preferences.
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There was a statistically significant, although very small, association with the patient’s 
age at first insulin: older patients were less likely to be prescribed analogue insulin 
(ORadjO-98 C l95[0 .9 S, 0.99]), an eflfect seen in both the all-patient and complete-case 
analyses. There was also an association with sex, with males more likely to start on 
analogue insulin than females (ORadj 1-1 0 1 9 5 (1 .0 2 ,1.19]), and with the practice’s 1st 
analogue prescription ordinal number (an indication of how quickly after their 
introduction the practice started prescribing analogue insulins. Patients in practices that 
were slower to start prescribing analogue insulins were (slightly) less likely to be 
prescribed analogue insulin (ORadj0.997 0 1 9 5 (0 .9 9 7 ,0.998]). This is consistent with the 
finding in Chapter 4 that practices tend, initially, to be cautious in their use of analogue 
insulins.
Compared with ethnic "Caucasians", both the all-patient and the complete-case analysis 
found that ethnically Black patients were less likely to be given analogue insulin 
(ORadj0.53 0 1 9 5 (0 .3 8 ,0.73] and ORadj0.39 0 X95(0 ,21,0.74] respectively).
The insulin regimes appropriate for patients with Type 2 diabetes include twice-daily 
injections of biphasic insulins, basal-bolus (with overnight intermediate or long-acting 
"basal" insulin and additional "bolus" insulin before meals), and once daily injections of 
basal insulin. The G PR D  does not provide information on a patient’s injection schedule, 
and so their regimen cannot be accurately identified, however the insulin action (fast, 
intermediate, long, or pre-mixed) was known. Fifty-two percent of patients were 
prescribed only pre-mixed insulins, suggesting a twice-daily injection regimen, while 
41%  were prescribed only intermediate or longer-acting insulins, suggesting a 
"basal-only" regime. In the all-case analysis, for patients prescribed only intermediate or 
long-acting insulins there was no statistically significant difference in their likelihood of 
receiving analogue or human products (compared with the pre-mixed only reference 
group); however, in the complete case analysis there was a slight preference for human 
insulins (ORadjO.84 0 X95(0 .7 2 ,0.99)]), although, with a p-value of 0.032, this might be 
considered marginal.
Six percent of patients were prescribed only short- or fast-acting insulins, but it is 
unlikely that Type 2 patients were genuinely only using short/fast acting products: the
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current NICE guidelines'^ recommend initiation on NPH insulin (or glargine or biphasic 
human insulin in some groups of patients), with pre-mixed analogues where pre-prandial 
injection is required. Although this analysis looks at the patient’s first GP prescriptions, 
it is possible that patients had previously received insulin from elsewhere, such as a 
hospital or specialist clinic, and their first GP prescriptions were replenishing their 
supply rather than indicating the start of insulin therapy. Regardless of the reasons, in the 
all-patient analysis, those needing a short/fast acting insulin tended to be given analogue 
products (O R adjl-49  Cl95[1.26,1.76]), although the complete-case analysis (which only 
included English patients) did not find a statistically significant difference.
The relative effect of a particular covariate on the preference for analogue insulin is 
easier to see by looking at the adjusted model’s predicted outcome as a function of the 
covariate: Figure 5.2 shows this for the calendar year and age at first insulin prescription, 
for both the "all patient" and "complete-case analyses". All the graphs are plotted with 
the same vertical scale for easier comparison, and show the results as log-odds rather 
than odds ratio.^
The steady reduction in the likelihood of receiving analogue insulin with increasing age 
is clear (Figure 5.2b). The association with calendar year (Figure 5.2 a) shows a step 
change in 2002, corresponding to the introduction of longer-acting analogue insulins 
part-way through the study period. That longer-acting analogue products were not 
available at the start of the study period may also explain why patients prescribed 
longer-acting analogue insulins were (slightly) less likely to receive analogue insulin.
Looking at the combined effect of age and year (Figure 5.2c), the age effect was 
consistent over the study period: in any given year older patients were less likely to 
receive analogue insulin than were younger patients (there was no statistically significant 
interaction between age and calendar year).
The only statistically significant interaction between the covariates was between 
sulphonylurea and metformin use in the all-patient analysis. A history of prescribing for
Odds ratio = exp(log odds); log(odds ratio) = log odds
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either drug increased the likelihood of the patient starting on analogue insulin 
(O R adjl-43  Cl95[1.2,1.7] for metformin, O R adjl-65 Clgsfl.d, 1.9] for sulphonylureas), 
however having both further increased the likelihood slightly. The predictive margins 
(Figure 5.1) gave adjusted odds ratios of ORadj 1-61 for patients with neither drug, 1.71 
for those with metformin alone, 1.76 with sulphonylureas alone and 1.77 with both, all 
statistically significant with p<0.001.
Interaction effect of tiistory of metformin or suiphoniyurea use
.6 -
.55-
,45-
Metformin history
sulphbefore=0 -  sulphbefore=1
F i g u r e  5 .1 :  C o m b i n e d  e f f e c t  o f  a  h i s t o r y  o f  m e t f o r m i n  o r  s u l p h o n y l u r e a  u s e  o n  t h e
LIKELIHOOD OF A PATIENT WITH TYPE 2  DIABETES STARTING ON ANALOGUE RATHER 
THAN HUMAN INSULIN (FROM THE "ALL PATIENT" ADJUSTED LOGISTIC REGRESSION  
MODEL)
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T y p e  2: a l l  p a t i e n t s T y p e  2 : C o m p l e t e  c a s e s
( a )  E f f e c t  o f  c a l e n d a r  y e a r
Effect o f calendar year
I
I
t
C a le n d ar  y e a r  o f first insulin  p rescrip tion
Effect o f calendar year
C a le n d ar  y e a r  o f  first insulin prescrip tion
( b )  E f f e c t  o f  a g e  a t  f i r s t  i n s u l i n  p r e s c r i p t i o n
Effect o f age
I
I
I
A ge  a t f irst insulin  prescrip tion
t
I
E
I
A ge  a t  first insulin  p rescrip tion
(c) C o m b i n e d  e f f e c t  o f  a g e  a n d  c a l e n d a r  y e a r
Combined effect o f age and calendar year
I
f
C a le n d ar  y e a r  o f first insulin  prescrip tion
Combined effect o f  age and calendar year
/ / /
C a le n d a r  y e a r  o f first insulin  p rescrip tion
—#—  ageins=20 — agerns=40 
ageins=60 ■ A ageins=l
— #—  ageins=20 — —  ageins=40
—fit— ageins=60 " ■ A"— ageins=80
Figure 5.2: E f f e c t  o f  c a l e n d a r  y e a r  a n d  a g e  ( b o t h  a t  f i r s t  i n s u l i n  p r e s c r i p t i o n ) ,  a n d
THEIR COMBINED EFFECT, ON THE LIKELIHOOD OF A PATIENT WITH TYPE 2  DIABETES 
STARTING ON ANALOGUE RATHER THAN HUMAN INSULIN (FROM THE ADJUSTED 
LOGISTIC REGRESSION MODELS)
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5.4 Logistic regression on choice of analogue or human insulin in patients 
with Type 1 diabetes newiy-starting insulin therapy
C o v a r ia t e  r e c o d in g
In patients with Type 1 diabetes some of the covariate categories had few patients for 
stable analysis, so were merged.
• Only 2 patients were classified as of Oriental ethnicity, so these were added to the 
Asian patients.
• 10 patients were prescribed thiazolidinediones before the start of insulin therapy, 
these were added to the "other oral-antidiabetics" category.
• 12 patients had clinical records indicating a "macro-vascular" complication before 
their first insulin prescription, 22 had a record of a "micro-vascular" complication 
and 17 of a renal complication. These 3 comorbidity covariates were combined into 
a single covariate.
• Only 11 patients had more than 1 year of UTS diabetic time before their first insulin 
prescription. In addition there was a strong correlation (r^=0.76) between the two 
covariates used for duration of diabetes^, so only the binary "prevalence" field was 
included in the analysis.
L o g is t ic  r e g r e s s io n  r e s u l t s
The results of the logistic regression in patients with Type 1 diabetes are given in 
Table 5 .4 .
As in Type 2 diabetes, the largest effect sizes were associated with the calendar year of 
first insulin: a patient starting insulin therapy in 2008 was over 230 times more likely to 
be given analogue insulin than a patient starting in 2000. A logistic model with only the 
calendar year correctly predicted the first choice of insulin in 76.7% of the patients.
Adding the age at first insulin increased this to 80.05%; adding all the other available 
covariates only slightly improved the prediction rate to 82.17%.
 ^ A binary field for patients with diabetes before their left-censor date (prevalent patients), and a categori­
cal variable indicating the duration of diabetic UTS time.
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5. Results Logistic regression on initial choice of analogue or human insulin in Type 1 diabetes
Age at first insulin prescription was also statistically significant; the likelihood of 
receiving analogue insulin increased slightly with age (ORadj 1-06 01%[1.04,1.08]).
This differed from Type 2 diabetes, where increasing age was associated with a reduced 
likelihood of being prescribed analogue insulin, however, the age ranges were different, 
with a median age at first insulin of ~14  years in Type 1 patients compared to ~65 in 
Type 2.
The effects of age and calendar year are shown in Figure 5.3. The effect by calendar year 
did not show the "step change" in 2002 seen in Type 2 diabetes. In Type 1 diabetes a 
higher proportion of the insulin prescriptions were for fast-acting analogue products, 
which were available throughout the period covered in this analysis (shown in Figure 4.3, 
page 111), rather than for longer-acting analogues which were only available from 2002.
( a )  E f f e c t  o f  c a l e n d a r  y e a r
E ffe c t o f  c a le n d a r  y e a r
9 .è'
I
I
t
C a le n d a r  y e a r  o f  first insulin  prescrip tion
( b )  E f f e c t  o f  a g e
E ffe c t o f  a g e
I
o .
f
A ge  a t  first insulin  prescrip tion
F i g u r e  5 .3 :  E f f e c t  o f  c a l e n d a r  y e a r  at  f i r s t  i n s u l i n  a n d  a g e  at f i r s t  i n s u l i n  o n  t h e  
LIKELIHOOD OF A PATIENT WITH TYPE 1 DIABETES STARTING ON ANALOGUE RATHER 
THAN HUMAN INSULIN(FROM THE ADJUSTED LOGISTIC REGRESSION MODEL)
No statistically significant associations were found with sex, ethnicity, UK geographical 
region, smoking status or BMI at first insulin prescription, although, unlike in Type 2 
diabetes, there was an association with alcohol usage. Patients who were "moderate" 
drinkers were twice a likely to receive analogue insulin as were non-drinkers (O Radj2.1 
Cl95[1.43,2.99]).
The effects of glycaemic control status over the analysis period are shown in Figure 5.4, 
which clearly shows that "well controlled" patients were consistently less likely to start
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on analogue insulin than were patients in the other glycaemic control categories 
(ORadjO.28 C I95 [0 .1 4 ,0 .6 0 ]).
Two hundred and fifty-four of the patients classified as Type 1 diabetics had at least one 
prescription for an oral hypoglycaemic drug in the year before their first insulin 
prescription. Although this suggests that they may have been misclassified (and were 
really Type 2 patients), a review of their prescribing does not support this. All of these 
patients started on insulin at age 34 or younger (35 is a generally accepted cut-off point 
for Type 1 diabetes), and 27 of them were aged 20 or less at their first insulin prescription.
In all but 18 of the patients the oral prescriptions were in the 3 months before their first 
insulin prescription, and 161 patients had an oral prescription in the month before: this 
may suggest they were patients with some residual beta-cell function. However, while 
half of the patients (129) were prescribed sulphonylureas (which require some residual 
beta-cell function), the remainder received other oral drugs. While apparently 
anomalous, mis-prescribing by GPs is possible. Although misclassification of their type 
of diabetes cannot be ruled out (particularly in those not prescribed sulphonylureas), it is 
also possible that these were atypical, or atypically treated. Type 1 diabetics.
Although a history of metformin or sulphonylurea use was not found to be significant in 
the multivariate analysis, patients with a history of "other" oral-antidiabetic drug use 
(thiazolidinediones, exenatide or repaglinide) were more than 5 times more likely to be 
given analogue insulin than were patients with no such drug use (ORadj 5.77 
Cl95[1.17,28.3]. However, only 15 patients received these drugs, and, given the wide 
confidence interval, this result should be treated with caution.
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Effect of glycaemic control status at first insulin prescription
By ca len dar  y ea r
.6 -
.5 -
.4 -
.3 -
.2-
2000 2002 2003 2004 2005
C alen d a r  y ea r  of first Insulin prescription
G ly caem ic  control (HbA1c) 
• - # —  Borderline — B - - -  Poor Unknown
Figure 5 . 4 :  E f f e c t  o f  g l y c a e m i c  c o n t r o l  a t  f i r s t  i n s u l i n  p r e s c r i p t i o n  l i k e l i h o o d  o f
T H E  P A T IE N T  W IT H  T Y P E  1 D I A B E T E S  S T A R T I N G  O N  A N A L O G U E  R A T H E R  T H A N  
H U M A N  IN S U L I N  ( F R O M  T H E  A D J U S T E D  L O G I S T I C  R E G R E S S I O N  M O D E L )
While BMI was not a significant contributor in the multivariate analysis, and was not 
included in the final models, a comparison of the proportion of patients in the BMI 
categories who were prescribed detemir did find a statistically significant difference. A 
higher proportion of the patients who were obese at their first insulin prescription were 
prescribed detemir than were those in the other BMI categories p-value <0.001). 
Given the beneficial effects on weight gain associated with determir, this suggests some 
targeting of products within the analogue insulins.
5.5 Regional and ethnic differences between patients
The analysis found differences between the UK geographic regions in the likelihood of a 
patient starting on analogue insulin, which may have been due to underlying differences 
in their populations. There were regional differences in the recording of ethnicity, levels 
of socio-economic deprivation, and some (small) differences in clinical contact rates 
between the regions, as shown in Table 3.8 (Methods pg. 98). While ethnicity and 
contact rate were included in the multivariate model (and hence adjusted for), the SES 
was not found to be a significant contributor and was omitted. While there may be other 
differences between the regional populations, it is possible that the regional differences
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were partly a reflection of differences in socio-economic status.
The analyses also found differences between ethnic groups, in particular that Black 
patients were less likely to receive analogue insulin, which may also have been due to 
differences between the group. Where ethnicity was recorded there were statistically 
significant differences between the ethnic groups in the median age at first insulin.
Caucasian and Asian patients tended to be a few years older at their first insulin 
prescription (56 years [IQR 39,67] and 56 [44,65] respectively) compared to Oriental or 
Black patients (53 years [IQR 46,64] and 53 [41,66] respectively). However, these 
differences were small, and age was included in the multivariate model, and so. adjusted 
for. There was, however, a strong association between ethnic group and socio-economic 
status (SES). Where both ethnicity and SES were known, univariate logistic regression 
was used to evaluate the likelihood of a patient being in a particular socio-economic 
group given their ethnicity; results are shown in Table 5.5:
Table 5.5: P r e d i c t i o n  o f  s o c i o - e c o n o m i c  s t a t u s  q u i n t i l e  f r o m  e t h n i c i t y
S o c io - e c o n o m ic  
s ta t u s  quintile
Black
OR [CI95] (p-value)
C a u cas ian
OR [CI95] (p-value)
Asian
OR [CI95] (p-value)
0 - least deprived
1
2 - reference
3
4  - m ost deprived
0 .50 [0.27,0.93] (0.033)  
0.79 [0.46,1.36] (0.393)
2.53 [1.69,3.80] (<0.001 ) 
3.32 [2.21,4.97] (<0.001 )
0 .97  [0.82,1.17] (0.778) 
0 .99 [0.83,1.19] (0.936)
0 .89  [0.75,1.05] (0.169)  
0 .94  [0.79,1.12] (0.497)
0 .30  [0.21,0.51] (<0.001 ) 
0 .46  [0.31,0.67] (<0.001 )
1.51 [1.15,1.97] (0.003)  
1.35 [1.02,1.81] (0.039)
In the Caucasian patients there was no association between ethnicity and SES: given that 
the SES levels were based on dividing the population into quintiles and the majority of 
the population is Caucasian, this simply reflects the even partition of the population. 
However, Black patients were over 3 times more likely, and Asian patients were 35% 
more likely, to be in the most deprived group than they were to be in the middle of the 
socio-economic range. Asian and Black patients were also less likely to be in the least 
deprived group.
There were also statistically significant differences (%  ^p=0.003) between ethnic groups 
in the clinical care annualised contact rate in the period leading up to their first insulin 
prescription, which was not included in the analyses. In Caucasian patients the median 
contact rate was 14.0 contacts/year (IQR 8.6,21.0), while Asian patients had the highest
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contact rate (15.4 IQR 10.0,23.3). Black patients had the lowest contact rate at 12.6 
contacts/year (IQR 8.6,18.2). While these differences were small, and the wide IQRs 
indicate a lack of precision, it is possible that the observed differences in the ethnic 
groups at least partly due to differences in clinical contact rates: patients who visit their 
GP more often have more opportunity to review their medication.
Overall it is possible that the differences between geographic regions and ethnic groups 
were, at least partly, due to differences in socio-economic status.
5.6 Summary
To some extent the initial choice between human and analogue insulin was influenced by 
a patient’s characteristics. Patients with Type 2 diabetes were more likely to start on 
analogue rather than human insulin if they were male, had a history of oral 
hypoglycaemic drug use or were of mixed race. They were more likely to start on human 
insulin if they were ethnically Black, had good glycaemic control or were older at the 
time of first insulin use. In patients with Type 1 diabetes there was some preference for 
analogue insulin in older patients (which, in patients with Type 1 diabetes, means those 
older than ~15 years). In both Type 1 and Type 2 diabetes patients for whom a 
short/fast-acting insulin was deemed appropriate were more likely to be given analogue 
products.
However, the effects of these factors was dwarfed by the effect of the calendar year of 
first insulin use. In both Type 1 and Type 2 diabetes, the major determinant of the choice 
between analogue and human insulins was the calendar year in which therapy started, 
which, on its own correctly predicted the initial choice of insulin in ~77%  of patients.
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CHAPTER
Factors influencing a change in insulin exposure in
established insulin users
6 1
6.1 Hypothesis and analysis approach
Hypothesis C, that
GP’s would change a patient’s insulin regime depending on their medical history 
and characteristics, that GPRD data could be used to predict such changes
was tested using case-control analyses to compare patients in the period before a change 
in insulin therapy.
These analyses used eligible "switching" patients (defined in the Methods section 3.6, 
pg. 85) as the "cases", matched to control patients from the base study population as 
described in the Methods section, pg. 67. The analyses compared the cases and controls 
over a "contributed time" period that ended on the case’s switch date, and began between 
6 and 18 months before that, depending on the case’s pre-switch exposure time.
There were 17,777 eligible "switching" cases, however 532 of them could not be 
matched and were excluded from the analysis, leaving 17,245 cases; 5,284 with Type 1 
diabetes and 11,961 with Type 2 diabetes.
C o m p a r i s o n  o f  m a t c h e d  a n d  u n m a t c h e d  c a s e s
The matched and unmatched patients are compared in Table 6.1. Overall, 95% of the 
Type 1 cases and 98% of the Type 2 cases were matched, with a mean of 3.9 controls per 
case in Type 1 patients and 4.0 for Type 2. In both Type 1 and Type 2 diabetes there was 
a statistically significant difference in the median ages of matched and unmatched cases, 
with younger patients less likely to be matched. The effect can be seen in Figure 6.1, 
which shows the median ages of matched and unmatched cases across the study period.
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In Type 2 diabetes (but not in Type 1) females were marginally less likely to be matched 
than males. Despite these differences, the author considers that the high proportion of 
cases that were matched mean that the exclusion of the unmatched cases did not unduly 
bias the results.
Type 1 Type 2
CM ■
Calendar year of end of exposure
Unmatched cases Matched cases
Figure 6.1: Median-band plot of age at end of exposure by calendar year
OF SWITCH IN MATCHED AND UNMATCHED CASES
6.2 Patient numbers and characteristics
The numbers and characteristics of the case and control subjects used in the analysis are 
given in Table 6.2, which also includes their observed insulin exposures.
152
6. Results Patient numbers and characteristics
o
CO
cc
g
so
Ü
(£>
Û)
sa.<0
CM "O
ij
c
ZD
CM XJ
II
II
II
E
c
3
T- TJ
II
il
q  rv. CO 
0>CO CD CO CM CM T-
1— ^
CO 00 O) CO lO
CM CM q  
CM in Tj-
in CO
CO CO CM 
in (35 CD ' - ' r t  in 
CO '  (35 CO M CM T)- Tf
in rs: CM"4" mII
II»
1 1 1
e  E E 
z z z
- yOcoo ' tT-mincooocor^coo  Zw co'-'T-'-'i^.Ttr^in—'co'-'co'-^ 
CO '- 'C M  '- " C O  ' - " ' - " ' - " ' - " T -  — '  C5 '-"■M-CO 1— in comm-»-
CM T -
COCOCMC55COi-COC35i-'~"CMC35'^CO N  CM (35 1— in M Nin CO m  CM -M" ■M-
CMt-'M -C O C330-i-COCM COOCO-i-  
-M-' CD in o ' CD CD o ' CD cd o ’ CD
to 05 '—' Tf (35 "I— CM '—' CO 051- TJ-COC33 1— CO CM COin CO in CM
?q in 05 q q q N.CD 0 0 q . CDin.
00 m m in ■M-
0 in (35 in q q CO CO(35 C35 C35 cd cd 0 05 cd 0500_ U3_S . CO 05, in. 05, CO, 05,
CO CM 05 CO in CO■M- CM •M- in CO 00CO 0
1— O  O  CO o  o
T- ' m  N  CO Tf M 00 
j r  T- N  CO CO Tf O  CO
o '
CM 0 05 CM CD
s i q CO, 0
0 CO cdCM C35 CO CMq 05
cd
o'-COOCMOOOCOOC35r^<'CMinOCO'M-OOOMC35 . i^ncDcdcdcMcdcDCDT-^CDT^ x- i^nT-lcDCMcdT-^
^ ' - ' O t- C O '- " C O O C 3 5 t1 - '— —'C O - r - T - T t
T-'-^'M-i--»-in'-"oin r c^Mcoi-'M-'M-cMin^  T— -r- ^  T— T—
O) CO <35 0
N  CD s l(M,q,
8
in CO
CO
58 58 5 8 ° 58 58 58 58 58 58 58 58 58 ° 58
M: CM q q q 0 q CO CO q in 0 N CO 0 q q q CM 0Tj- r-g CM : CO cd CO s i c d 05 CO cd in cd cd cd 00 in 0 CM cd cd05 , 2 ; , 05 , 00 , J2 , 05 , U5, 05 in. CO, CM, S2-CD, CO, 00 , in. CO, CD N S3,
Tf CM CM CO C35 in in 0 0 CO N N CO CM N - CO <35
CO (35 (35 : CO CO (35 (35 CM 0 in (35 CO 0
CM •«+ r% : CM ■M- q CO CM ■M-in CM CM : T -
C M O O C O t- i- i-CMCM
ooT-cocoinco'f-T-cM 
C O  T— o  *f—  T— 
T - CO If)
OCOm->-COCM-»-T-CMCOC35COCM
rfCDCDCDCDCDCMT-^CDcdCDCDT^
'—'Nin '^-"T-M'M-CMC3500C0N CO 1— CO CMi—t—COt— CO(35 CO CO CO00 T-
.CO
I
Z <
I  
+
+ 5 5
C35
tZ g
3
+ + + +
S Ç c . 3 . 3
3 3 3 3 3
.CO
CD)
I
+
c  c
C3)<  I  I  X  I  J j  
■!■ + + + + + + 
^ ^ ^ ^ S Z S I X Z S Z^cococnwcococn_ 3 3 3 =3 :3 3 : 3 3< x x x x x x x x x x x x x x x x
5 :
+
.CO .CO .
+
o  .
(35 0 5  (35 C35 C3) 0 5
Kgs
s s S
° g §  
S.E 5
i l
CO O)i^g
OJ O) CO
^  cd
5  (35
'T N
g?<3
zz. C3f
00CVJ I (35
CM cd
gg
i
• i  s  £III
III05 g a 
o % £ 
c  <  m
II
C  05 c
=6 ■§ =5 
§ Z §
o
■o
!l|
S ' S ' s
05 05
05 05
w
£  
o
g s  s
III_1 >
«
! ‘I fill
.c  CO CO CO to 05 05 05 05I ii§|
^  o  0
05 C 
« O
'co °  °05 CD 05
M F FO c  c
±= T - CM CO TT
153
6. Results Patient numbers and characteristics
c
8
CM
. 1
O
CM
. 1
«
2
c
8
I
I
P' ?o O CD LO LO ■M" CO
IT5 LO - , CM q CO CM q O
*£ .: id
■M- M  ! CO CO CD CO
CO h -  : CM CM CD
CO in : U5 N LO
LO CO . CO
s g
s ' à
g
CD
i t -
III
IIIz  z  z
o^i-'+COCMt^T-mcor^OO-t-r^COOOT-OCDCOCMCDCOCM
' ~ ' C O O I ^ C M C J ) O O O O C D O O O O C O O C M - ' - C O O O L n O C O
^TtoinCDTfCjCDCDCDTfcjcÔCDCMCDi-^CDcJcMCDCDoj
O t-  '  T f  T f  T f  CM CO ^  '— ' C D i — C O '~ " '^ C M C O C O C M '+ C O C O  
i n C M ' + O C D  CM CM CO CO - M - i - O  N  N  LO T|- CO - r-  CO 
CD CO 1 -  CO O ) CO 05  I f )  r C O C M  "M"
CM ^  CM ' t  ^  ^  r f
N  CO U5
Tf 05s °O  05
O  CO 
CM CM 
CO
CO 05 -r- "^CM  05 T t " "  
^  N
• • - O O C 0 0 0 0 5 0 C 3 5
CO CM T- 05 CO •
"M" CM ^  IC5 CO 
T - CO
^ 5 8 5 8  ^ q  P ' q
LO q  q  1- ;  q 0
o CC) 1-^ CD CD CD
s i CD q  CO C Ô— 'C M  N  CO 05 ' ' ' — '
CO CD 10  T - C D  CO C5
CO CO - I - T+ "M- q
o ^  CO 0
?  K -
58 58 58 58 58 58 g 58 58 ^ 5 8 58 q 58 CD
00 Tf lO CM CM CD LO 10 h - CO CM N CM ■M" CM CD CM CO q q q CD
CO 0 ■M- CD CD q q CD q q CD ■M- CD CO S cd c d
s i s i CD 0 (Ô s i 0 CD s i 05, CD CO, sCO CM
CO CO ■M- ■M" CD CO CM CO 05 CM LO CO CD LO CM CO N CO S CO qCM CO CM CD CO 05 CM CD CD CM CO CD '+ N CO CD CO CM CO CO05 CM CO CM 10 10 LO CD
q
'4-
05 N c d
C? g g g ?
? CD
CM CO 00 CD N CM CM CO N CD CM CO LO 00 CO CM LO CO CD N cd q C3
rvl CM Z
CD CO CD CD N CD q CD CO 05 CM CD 10 06 0 Tj- CD
3 , LO, si si Ô_ LO 0 , CO, si 0 SI CO &CO CM LO SiCM CM 00 CD 10 LO CD CO CO CM CO CO CD 00 LO
CD CD CO CO CD CD CM N CD LO CD ■«+ •M- CD OÛ N
■M" N CM ■M" CD CO CM T t CO 0
CM CM q LO 00 CM
+
CO
2  C3) CD C3) CD
CD
X  
+
S  Ç
C  3  3  3  3 CD
X  _J 
+ + + +
i s i i
+ ±z iz ^  i=.
X  X
<  X  X  X  X  J j  
+  +  4" +  4- 4- 4-
i i m m r a m m M m i î
î s s m i s ê s i i É â
+
o  o
X
CD
3^
CD CD
0 q
CO CO CO LO CD CD 0
cd 2 , 0 cd CM
0 , 0 g .
&CD Tj" CD cdT f 00 CM
q0 CO CM CM
LO
5
CM CM
CO
Ri
0
<D CD
CD
Eè EV-*
0 TD
' e CD TD
s 3 Bç o j Q 3
C5 *k. X»
Z - C
0 1
1
ü
g 8
J Z ç
CD i
3 c c
0 CD CD
• 3 > >
CD CD CD
CO 0
CD 3
il
3  c
i!
CD O 
CM CO
t ï l
III
IF  C  CD
m < m
I
ifi
c  o  c  
• • 6  E  %
CD 3  CD
S ° 
«■§
il05 milli
II!
O
B CDll
3o  m
tl•05-g 
sz >
II
CD £
I
o  c
il
o  >  -o ffi
CD "O
il*— <4— W— ^O O O g
(D CD (D E
™ ™ ™ o  
c  c  c  -o
g g g 8
f  X X X 
Î- 'cm' cÔ '^
CM
CÔ
0
1
154
6. Results Factors affecting a switch in insulin therapy in patients with Type 2 diabetes
6.3 Factors affecting a switch in insulin therapy in patients with Type 2 
diabetes
C o v a r ia t e  r e c o d i n g
Only 11 patients with Type 2 diabetes were classified as ethnically Oriental; they were 
combined with the Asian patients for analysis.
C a s e - c o n t r o l  a n a l y s is  r e s u l t s
The results of the case-control analysis in patients with Type 2 diabetes are given in 
Table 6.3. The overall goodness-of-fit estimate of the multivariate model (its pseudo-i?^ 
value) was 65%: for observational data this is a reasonably good model.
The largest effect size was the association with total insulin-exposed time: patients with 
less than a year of insulin exposure at the switch date were more than 26 times more 
likely to switch insulin than were patients with between 9 and 15 years of exposure 
(ORadj26.5 0 1 9 5 (2 2 .9 ,3 0 .6 ]) . While the likelihood of switching generally increased 
with increasing insulin exposure, this effect size was an order of magnitude larger than 
those of the other exposure categories. It seems likely that in the early months of insulin 
therapy a patient’s insulin regime is still being adjusted to their needs, with a 
corresponding increased likelihood of changes.
There was an association between the frequency of a patient’s contacts with care 
providers and their risk of switching insulins. Patients who had little or no contact over 
their contributed time were roughly half as likely to switch insulin as those whose 
contact rate was 9 -1 5  times/year (ORadjO.54 CIgsfO.Sé, 0.86], while those with the 
highest contact rate were 44%  more likely to switch (ORadj 1.44 CIg5[1.34,1.56]).
Given that later analyses look at the risk of serious hypoglycaemic events, one of the 
reasons for this analysis was to see if such events predicted a change in insulin exposure. 
In fact the analyses suggests the opposite is true: patients who had a hypoglycaemic 
episode in their contributed time were over 70%  less likely to switch insulin (ORadjO.27 
0195 (0 .0 .2 3 ,0 .3 2 ]) . The likelihood was even lower in those with two or more events, 
O R adj0.09 in patients with 2 events and ORadj0 .03  in those with 3 or more.
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The patient’s glycaemic control status at the end of the exposure period was also 
significant. Patients with good control (H b A ic  < 7 .5 )  or moderate control 
(H b A ic  > 7 < 1 0 )  were less likely to switch (ORaUj0.34 C I95[0 .3 1 ,0 .3 7 ] and ORadjO.56 
0 1 9 5 (0 .5 5 ,0 .6 2 ]  respectively) than were patients with poor control (H b A ic  > 1 0 ) . In 
clinical terms it seems reasonable that there is no reason to change a patient’s insulin 
exposure if they are doing well on their current regime.
There was no evidence that the patient’s socio-economic status or ethnicity affected the 
likelihood of a switch, and neither did their smoking status or alcohol usage status at the 
switch date, or the date on which the practice first started prescribing analogue insulins.
There were however, some statistically significant geographical regional differences, 
with, for example, patients from Northern Ireland being 20%  more likely to switch than 
those from North West England (ORadj R 24  0 1 9 5 (1 .0 7 ,1 .4 3 ]). As with the similar 
differences seen in Analyses 1 and 2, these may reflect regional differences in clinical 
practice or in the regional populations (including socio-economic status).
The patient’s BMI at the switch date was statistically significantly associated with the 
likelihood of switching. Obese or overweight patients were less likely to switch 
(ORadj0 .8 0  0 1 9 5 (0 .7 4 ,0 .8 6 ]  and ORadj0 .9 0  0195 (0 .8 4 ,0 .9 6 ] respectively) than those of 
normal BMI. Underweight patients were more likely to switch, but this was not 
statistically significant.
Patients prescribed metformin during their contributed time were less likely to switch 
than those who were not (ORadjO.76 0 1 9 5 (0 .7 2 ,0 .8 ] )  but the multivariate analysis found 
no statistically significant associations with prescribing of any other oral hypoglycaemic 
drugs.
While there was no evidence of an association between the risk of switching and a 
patient’s history of "micro-vascular" or renal comorbidity, there was an association with 
"macro-vascular" conditions. Patients were more likely to switch if they had a first 
clinical record of a "macro-vascular" comorbidity during their contributed time 
( O R a d j  1 . 1 6  0 1 9 5 ( 1 . 0 4 , 1 . 3 0 ] ) .  Conversely, they were less likely to switch if they had 
been diagnosed with such a condition before the start of their contributing time
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(ORadjO-92 CIgsfO.ST, 0 .97]). It is possible that the diagnosis of the comorbidity 
triggers a review of the patient’s insulin therapy, while patients diagnosed earlier had 
already had such a review.
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6.4 Factors affecting a switch in insulin therapy in patients with Type 1
diabetes
The results of the case-control analysis in patients with Type 1 diabetes are given in
Table 6.4. The pseudo-i?^ value of the multivariate model was 39%.
As in patients with Type 2 diabetes, the largest effect size was seen in total 
insulin-exposed time. Patients with one year or less of insulin exposure at the switch date 
were 28  times more likely to switch (O R adj28.0 C l95[2 2 .4 , 35.1]) than those in the 
reference group (with 2~5 years insulin exposure), and this effect was an order of 
magnitude larger than in those with longer exposed times.
The associations with other covariates were also essentially the same as those in patients 
with Type 2 diabetes.
Patients with a single serious hypoglycaemic event during their contributed time were 
significantly less likely to switch than those with no events (ORadj0.38 
0 X95(0 .3 0 ,0 .4 8 ]) ,  and the likelihood was even lower in those with 2 events (ORadj0 .07  
0 195 (0 .0 3 ,0 .1 6 ])  or with 3 or more events (OR&dj0.04 0195 (0 .0 2 ,0 .0 .1 2 ]) . Patients were 
less likely to switch insulins if they had good or moderate glycaemic control at the end of 
their contributed time (ORadjO.56 0 1 9 5 (0 .4 9 , 0.64] and ORadj0.81 0 X95(0 .7 2 , 0.91] 
respectively) compared to those with poor control. Patients with more frequent clinical 
contacts were more likely to switch than those with fewer, and the adjusted O R  of 
switching increased with increasing contact rate: from 0 .5 9  OI95 [0 .54 ,0 .64 ] in those 
with little or no contact in their contributed time to 1.5 C l95[1.3 ,1.8] in those with a rate 
of more than 25  contact/year during that time.
There was no evidence of an association between the likelihood of switching and the 
patient’s ethnicity or socio-economic status, or with the patient’s smoking status or 
alcohol usage status at the switch date. However, unlike in patients with Type 2 diabetes, 
no statistically significant association was found with the patient’s BMI at the switch 
date.
Six percent of the cases, and 9% of the controls, had prescriptions for oral 
hypoglycaemic drugs during their contributed time, which, as in the logistic regression
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patients in the previous analysis, may suggest a mis-classification of patients with Type 2 
diabetes as Type 1. However, also as in the earlier analysis, there was some evidence to 
suggest that this was not the case. All of the patients prescribed oral agents, both cases 
and controls, were aged 34 or younger at their first insulin prescription, and 100 of them 
were aged 15 or younger. The median time from the patient’s first UTS insulin 
prescription to their first oral drug prescription was 3.1 years, and in all but 137 patients 
their first oral prescription was at least 6 months after their first insulin prescription.
Many of these patients clearly had a substantial period of only insulin use before oral 
agents were added, for whatever reason, to their therapy. As before, while the possibility 
of mis-classification cannot be ruled out, it seems possible that they were Type 1 patients 
with atypical patterns of treatment.
Patients prescribed metformin during their contributed time were less likely to switch 
(ORadjO.54 C l9 5 [0 .4 6 ,0 .64]), but no statistically significant association was seen 
between switching and prescriptions for the other oral hypoglycaemic drugs.
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6. Results Summary
6.5 Summary
These case-control analyses investigated factors that influenced switches in insulin 
therapy in "established" insulin users. The matched case-control study adjusted for the 
effects of the patient’s age, year of birth, sex and insulin exposure, and also, by matching 
exposure dates in cases and controls, for the effect of calendar date.
In both Type 1 and Type 2 diabetes, the analyses suggest that switching is more common 
in patients who were relatively new users of insulin, presumably as their treatment was 
adjusted to their needs, and in patients who were in more frequent contact with their care 
providers. Serious hypoglycaemic events were not found to be a trigger for changes in 
insulin therapy: in fact having an event reduced the likelihood of a switch. However, 
hypoglycaemic events were rare: overall 95% of patients did not have an event during 
their contributed time.
Overall, the analyses showed that a patient’s characteristics and medical history could, to 
some extent, be used to predict a switch in insulin exposure, particularly in patients with 
Type 2 diabetes. However, the most influential criterion was a total insulin-exposed time 
of less than a year, reflecting treatment adjustments in relatively new insulin users.
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CHAPTER
Comparative risk of serious hypoglycaemic events 
under different insulin exposures in patients 
newly-starting insulin therapy
7 1
7.1 Hypothesis and analysis approach
Hypothesis D postulated that:
GPRD records could be used to determine differences in the "real-life " risk of 
hypoglycaemic events between patients using analogue and human insulins.
The risk was compared in patients newly-starting insulin therapy using recurrent events 
survival analysis, as described in the Methods section (page 67). Patients with Type 1 
and Type 2 diabetes were analysed separately, with a "complete-case" analysis for 
patients with Type 2 diabetes. In Type 1 diabetes there were too few complete cases for 
meaningful analysis. Patient records were censored (to meet the proportional hazard 
assumption) at 60 months in patients with Type 2 diabetes and 48 months in those with 
Type 1 diabetes.
H y p o g l y c a e m ic  e v e n t s
Hypoglycaemic events were identified as described in the Methods section (page 91). In 
the base study population a total 24,222 hypoglycaemic episodes were found: 12,427 
patients (22% of the base study population) had one or more events during their UTS 
time. On average there were 7.1 serious hypoglycaemic events per 100 patients years in 
patients with Type 1 diabetes and 5.8/100 patient-years in patients with Type 2 diabetes; 
broadly in line with the median rate of ~5/100 patient-years found by Egger et a l
In the subjects for this analysis, 1,412 patients with Type 2 diabetes (7.3%) and 138 
patients with Type 1 diabetes (6.1%) had one or more hypoglycaemic episodes in the
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time they contributed to the analysis.
COVARIATE RECODING
In patients with Type 1 diabetes some of the covariate categories had few patients for 
stable analysis, so covariate levels were merged.
a) Ten patients were prescribed thiazolidinediones before, and 6 after the start of, 
insulin therapy. These were combined with the "other anti-diabetic drug" category.
b) Twelve patients had clinical records indicating a "macro-vascular" complication 
before their first insulin prescription, 21 had a record of a "micro-vascular" 
complication and 19 of a renal complication. These 3 comorbidity covariates were 
combined into a single covariate.
c) Only 11 patients had more than 5 years of UTS diabetic time before their first 
insulin prescription. They were merged with those with more than 1 year.
d) Patients from the North East of England were combined with those in the North 
West.
e) Patients with recorded ethnicities other than Caucasian were combined into a 
single "non-Caucasian" group.
f) Only 7 patients had prescriptions for thiazolidinediones or "other" oral 
hypoglycaemic drugs after the start of insulin therapy. Even when combined, their 
inclusion made the Cox model unstable, and so they were excluded.
In addition to these changes, in patients with Type 1 diabetes the covariate for 
pre-existing renal comorbidity at first insulin prescription was unstable when included in 
the Cox model, and so was not included in the analysis.
In the "complete case" analysis in Type 2 diabetes, too few patients started on 
short-acting human insulin or fast-acting analogue insulin for a stable analysis. As 
merging these insulin groups with others would have obscured the effect of the insulin 
exposure, it was decided to drop patients receiving these insulin groups from that 
analysis.
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I n s u l i n  e x p o s u r e s
Although the analysis subjects were limited to those starting on only human or only 
analogue insulins, there were still 16 different combination of insulin products across the 
group. These were grouped for analysis as described in the Methods section. Table 3.6 
(pg. 88); the numbers of subjects in each exposure class are shown in Table 7.1. All of 
the analyses used pre-mixed human insulin (category 4) as the reference group.
Table 7.1 : N u m b e r  o f  p a t i e n t s  b y  c l a s s i f i e d  i n s u l i n  e x p o s u r e
Observed Insulin 
exposure
Number patients
T1 T2 Classification for analysis
Hu.Sh 54 152 (1) Short-acting human Insulin, alone or with
Hu.Sh + Hu.Mx 107 20 pre-mixed human insulin
Hu.In + Hu.Mx 4 18 (2) Intermediate or longer-acting human insulin,
Hu.Sh + Hu.in 131 307 with short-acting or pre-mixed
Hu.Sh + Hu.Lo - 2 human insulin
Hu.Sh + Hu.In + Hu.Mx 21 2
Hu.In 157 2,906 (3) Intermediate or longer-acting human insulin.
Hu.Lo - 22 alone
Hu.Mx 714 5,338 (4) Pre-mixed human insulin alone
Lg.Fa 132 294 (5) Fast-actiing analogue insulin, alone or with
Lg.Fa + Lg.Mx 87 14 pre-mixed analogue insulin
Lg.Fa + Lg.Lo 346 428 (6) Longer-acting analogue insulin
Lg.Fa + Lg.Lo + Lg.Mx 9 1 with pre-mixed or fast-acting analogue
Lg.Lo + Lg.Mx 87 14 insulin
Lg.Lo 55 5,000 (7) Longer-acting analogue insulin alone
Lg.Mx 423 4,808 (8) Pre-mixed analogue insulin alone
Insulin s o u r c e s :  Hu = h u m an , Lg = a n a lo g u e
Insulin a c tio n s: S h  = sh ort, Fa = fast. In = in term ediate , Lo = lon g , Mx = pre-m ixed
7.2 Patient num bers and characteristics
19,323 patients with Type 2 diabetes and 2,240 patients with Type 1 diabetes met the 
inclusion criteria: Tables 7.3 and 7.4 give their characteristics by insulin exposure. The 
tables also show the completeness of the covariate recording, including the numbers of 
patients who had HbAic measurements both before and after the start of their insulin 
therapy.
Covariate recording levels varied: Table 7.2 summarizes the recording levels according 
to whether the patient was prescribed analogue or human insulin. While a high 
proportion of patients had records of smoking status and alcohol usage, recorded values
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of these covariates were taken as valid until explicitly superseded: hence it is likely that 
many of the records were historical values. With the exception of ethnicity in patients 
with Type 2 diabetes, covariates were more likely to be recorded in patients who received 
analogue insulins, and these differences were statistically significant.
Table 7.2: C o v a r i a t e  r e c o r d i n g  l e v e l s  in  p a t i e n t s  p r e s c r i b e d  a n a l o g u e
OR HUMAN INSULIN, BY TYPE OF DIABETES
Covariate record at Type 1: Percentage with record Type 2: Percentage with record
1st insulin prescription Human Analogue test^ Human Analogue X  ^test^
Body-mass index 78.1% 91.0% p=<0.001 29.3% 43.1% p=<0.001
Glycaemic control (H bAic) 52.5% 72.3% p=<0.001 12.5% 23.4% p=<0.001
Smoking status 98.6% 99.8% p=<0.001 94.8% 92.6 p=0.032
Alcohol usage 92.9% 94.5% p=<0.001 85.2% 73.0% p=<0.001
Ethnicity 17.3% 21.5% p=<0.001 12.2% 12.5% p=0.806
Socio-economic status 46.9% 48.5% p=0.025 42.8% 47.1% p=0.041
1) Pearson test for differences between patients prescribed analogue or human insulin
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7,3 Survival to  ser io u s  h ypoglycaem ic ev e n ts  in patients with Type 2 d iab etes, 
ail patients
Table 7.5 gives the results of the Cox proportional hazards analysis for (recurrent event) 
survival to serious hypoglycaemic events in patients with Type 2 diabetes.
The analysis found some statistically significant differences between the insulin 
exposures in the risk of hypoglycaemia in the first 60 months of insulin use. Compared 
to patients using pre-mixed human insulin, those starting on only long-acting analogue 
insulin were 23% less likely to have an event (HRadjO.77 CIgsp.OG, 0.90]). A 
statistically significant lower likelihood was also seen in patients who started on 
intermediate or longer-acting human insulins (HRadjO.72 CIgsp.Ol, 0.85]). Although 
patients starting on rapid-acting analogue insulins wer the least likely to have an event 
(HRadjO.47 C Igsp.lS , 1.23]: p=0.132), this was not statistically significant, and neither 
were the effects under any of the other insulin exposures.
The relative risks under the various insulin exposures as estimated by the multivariate 
model are shown in Figure 7.1. Although statistically significant effects were seen, the 
confidence intervals were relatively wide, indicating a lack of precision in the results.
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Risk of hypoglycaemia by insulin exposure
20-
15-
CD
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I
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Type of insulin
Figure 7 .1 :  T y p e  2  d i a b e t e s : R e l a t i v e  r i s k  o f  h y p o g l y c a e m i c  e v e n t s  
BY i n s u l i n  e x p o s u r e
The analysis did not show any association between the risk of hypoglycaemic events and 
the patient’s sex, socio-economic status, the calendar date (included in the model as the 
number of days to the first insulin prescription from January 1997), the use of (any) 
oral antidiabetic drug in the year before the start of insulin therapy, or whether or not the 
patient was "prevalent" at the start of their UTS time, or whether or not the patient had a 
pre-existing diabetic comorbidity. The only significant regional variation was in patients 
from Wales, who were 38% less likely to have a serious hypoglycaemic event 
(HRadjO.62 Cl95[0.49,0 .7 9 ,3 .0 7 ])  than were patients in the North West of England.
The largest effect was seen in ethnically Black patients, whose risk of a serious 
hypoglycaemic event was double that of the reference Caucasian group (H R adj2.0  
Clgsfl.SO, 3.07]): the relative risk in all ethnic groups is shown in Figure 7 .2 . The risk 
was lower in patients of mixed-race (HRadjO.72 CIg5[0.52,1 .00]), although, with a 
p-value of 0 .0 4 8 , this was not a strong association. Figure 7 .2  suggests that the 
likelihood was broadly similar in all ethnic groups other than the ethnically Black.
Patients co-prescribed sulphonylureas during the time they contributed to the survival 
analysis were more likely to have a serious hypoglycaemic event (HRadj 1.3
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Effect of ethnicity across insulin exposures
40-
-10-
Type of insulin
Ethnicity
— # —  Caucasian — —  Black " - - - - - Asian
— —  Orientai — X— - Mixed.Race -----1---- Unknown
Figure 7.2: T y p e  2  d ia b e t e s : E f f e c t  o f  eth n ic ity  o n  t h e  r isk  o f
HYPOGLYCAEMIC EVENTS BY INSULIN EXPOSURE
CI95f l . l l ,  1.46]). These drugs are known to have hypoglycaemic effects, however 
patients co-prescribed thiazolidinediones showed a similarly increased likelihood 
(HRadj 1.4 C lgsfl.l, 1.88]), while those co-prescribed metformin co-prescribing were 
less likely to have an event (HRadj0.83 CIgsfO.Tb, 0.92]).
The likelihood of an event increased with increasing age at first insulin, consistent across 
all insulin exposures, as shown in Figure 7.3.
More frequent contact with health care providers, both before and after the start of 
insulin therapy, was associated with an increased likelihood of hypoglycaemia: their 
combined effect is shown in Figure 7.4.
Various "lifestyle" factors also showed significant associations with risk: smokers were 
more likely than non-smokers to have an event (HRadj 1.3 CIg5[1.2,1.5]), and with an 
alcohol problem at first insulin were ~40%  more likely to have an event than were 
"moderate" drinkers (HRadj 14  (Jlgsfl.l, 1.8]). People deemed to be "non-drinkers" at 
first insulin were also more likely to have an event (HRadj 1.2 C lgsfl.l, 1.3]), however, as 
well as genuine teetotallers, this group included patients with a history of alcohol abuse
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a ) E f f e c t  o f  a g e
Effect of ag e  at firs t insu lin  on risk o f hypoglycaem ia
1
I
A ge a t  first Insulin
b )  E f f e c t  o f  a g e  a c r o s s  i n s u l in  e x p o s u r e s
Effect o f ag e  a t first insulin  a c ro s s  Insulin  ex p o su re s
^ 20-
T y p e  o f  Insulin
A ge a t f irst Insulin p rescrip tion  
ageins=20 —$—  agejns=30 -R-—• agelns=40 —A ■■ ageins'SO
ageins=60 agelns=70 ...0   ageins=80
Figure 7.3: T y p e  2 d ia b e t e s : E f f e c t  o f  a g e  at f ir st  in su l in  on  t h e  r isk  o f  
HYPOGLYCAEMIC EVENTS
C o m b in e d  e f f e c t  o f  p r e - a n d  p o s t - in s u l in  m o n ito r in g  r a te
15-
m
IQ-
10 20 30 40
A n n u a lised  p o st-in su lin  c o n ta c t  rate  (c o n ta c ts /y e a r )
- D/year
- 20 /year
- 4 0 /year
— 0 —  10/year 
— A—  30 /year 
 1------- 50 /year
Pre-switch 
contact rate
Figure 7.4: T y p e  2 d ia b e t e s : C o m b in e d  e f f e c t  o f  p r e - a n d  p o s t - in su l in  
m o n it o r in g  r a t e s  o n  th e  r isk  o f  h y po g l y c a e m ic  e v e n t s
but who were currently non-drinkers.
There was an association with BMI at first insulin: in general terms the risk of a serious 
hypoglycaemic event fell with increasing BMI. Compared to patients of normal BMI, 
obese patients were 48%  less likely to have an events (HRadjO.53 C Ig 5 [0 .4 6 ,0 .6 1 ]), 
while underweight patients had 45%  more likely to have one (HRadj 1.45
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Cl95[1.18,1.77]).
Only 35% of patients (8.5% Type 1, 38% Type 2) had usable HbAic measurements in 
the 4  months before their first insulin prescription and 1 to 5 months after (Tables 7.3 
and res:pattl), too few to use attained HbAic in the analyses.
In patients who had both HbAic records females had a greater reduction in HbAic than 
males (%^  p=0.035 Type 1; p=0.026 Type 2). In both Type 1 and Type 2 diabetes the 
greatest difference in attained HbAic was seen in patients prescribed combinations of 
intermediate and longer-acting analogue insulins. The differences in attained HbAic in 
males with Type 1 diabetes across the insulin exposure categories were not statistically 
significant, but those between females were, as were those in patients with Type 2 
diabetes.
Patients who started on insulin within a year of their diabetic index date were 48%  more 
likely to have a hypoglycaemic event (HRadj 1-48 Cl95[1.28,1.80]) than patients in the 
reference group of those with 1 ~ 5  years. These patients are either newly-diagnosed with 
diabetes, and so learning how to manage their condition, or have recently changed their 
GP, and so, perhaps, are dealing with different support arrangements.
7.4 Survival to ser io u s  hypogiyoaem ic ev en ts  in patients with Type 2 d ia b etes , 
com p iete  c a s e s
Table 7.6 gives the results of a Cox proportional hazards analysis for (recurrent event) 
survival to hypoglycaemic events in Type 2 diabetes in "complete case" patients. Due to 
low patient numbers in the short/fast-acting insulin categories, patients with these 
exposures were not included.
The statistically significant lower risk in patients using intermediate or long-acting 
human insulin seen in the all-patient analysis was also seen in the complete cases, with a 
larger effect size; complete case patients were 42% less likely to have an event 
(compared to 28% in the all-patient analysis). The effect sizes seen in patients prescribed 
combinations of human intermediate and long insulins, or pre-mixed analogue insulins
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were similar in both analyses, although none of the differences were statistically 
significant
Unlike the all-patient analysis, the complete case analysis found a statistically significant 
increase in the likelihood of serious hypoglycaemic events in patients prescribed 
longer-acting analogue insulin in combination with other analogue products (HRadj2.2  
Cl95[1.23,3.3]). The all-patient analysis also showed an increased likelihood in these 
patients (HRadj 1.02), but this was not statistically significant(p=0.929). The lower 
likelihood of an event in patients prescribed longer-acting analogue insulins alone was 
also seen in the complete case analysis, but was not statistically significant (HRadj 0.80 
CI95 [0.62,1.04]).
In the complete case analysis the risks associated with the patient’s ethnicity and age at 
first insulin exposure were comparable to those seen in the all-patient analysis, with the 
likelihood of an event increasing with age at first insulin, and higher in ethnically Black 
patients than the other ethnic groups (HRadj2.32 Cl95[1.06,5.06]). The increased 
likelihood in patients with less than a year of UTS diabetic time was also seen in the 
complete cases (HRadj 1.68 Cl95[1.23,2.30]). As in the all-patient analysis, no 
statistically significant associations were found with the patient’s sex, socio-economic 
status, the calendar year of first insulin use, or whether or not the patient was prevalent at 
their left-censor date. Unlike the all-patient analysis, there was no association with 
smoking status at first insulin prescription. Patients with "good" glycaemic control 
(HbAic <7.5) when they started on insulin were more likely to have a serious 
hypoglycaemic episode than were patients with HbAic in the range 7.5-10).
While all-patient analysis showed that Welsh patients had a statistically significant lower 
likelihood of a hypoglycaemic event, the complete case analysis, which was restricted to 
English patients, showed a statistically significant greater likelihood of an event in 
patients from the East Midlands (HRadj 1.4 C l95[1 .0 , 2.0]), although with a p-value of 
0 .43 , this was not a strong effect, and in patients from the South East (HRadj 1.5 
0 195 (1 .0 2 ,2 .1 ]) . Also patients from London were 46%  less likely to have an event 
(HRadjO.54 0 195 (0 .3 4 ,0 .8 5 ]).
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7.5 s
Survival to serious hypoglycaemic events in patients with Type 1 diabetes
Table 7.7 gives the results of a Cox proportional hazards analysis for (recurrent event) 
survival to hypoglycaemic events over the first 48 months of insulin therapy in patients 
with in Type 1 diabetes.
As the objective of the analysis was to compare the risk in different insulin exposures, 
this was retained as a covariate in the multivariate analysis even though no statistically 
significant associations were found.
Overall, most of the covariates included in the analysis were not significantly associated 
with the risk of hypoglycaemia in the first 48 months after the start of insulin therapy.
The only ones retained in the multivariate model were the geographic region, BMI at 
first insulin prescription, and the pre-insulin and post-insulin monitoring rates.
The relative risk by BMI category is shown in Figure 7.5. Patients who were either obese 
or overweight at their first insulin prescription were less likely to have a serious 
hypoglycaemic event compared with patients of normal BMI: HRadjO.28 
0 195 (0 .1 1 ,0.71] and HRadjO.26 C I95(.15,0.77] respectively. However, this data lacks 
precision, as suggested by the wide (and overlapping) confidence intervals.
Increasing rates clinical of care contact rates, both before and after the start of insulin 
therapy, were associated with an increased risk of hypoglycaemic events: their combined 
effect is show in Figure 7.6.
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Effect of body-mass index
go
BMI category
Figure 7.5: E ff e c t  o f  body- m a s s  in d ex  at fir st  in su l in  o n  su r v iv a l  to
HYPOGLYCAEMIC EVENTS IN PATIENTS WITH TYPE 1 DIABETES
Combined effect of pre- and post-insuiin monitoring rate
3 0 -
S
Ü  2 0 -
I
Annualised post-insulin contact rate
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Figure 7.6: C o m b in e d  e f f e c t  o r  p r e - a n d  p o s t - f ir st  in su l in  m o n it o r in g
RATES ON SURVIVAL TO SERIOUS HYPOGLYCAEMIC EVENTS IN PATIENTS 
WITH T y p e  1 d ia b e t e s
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7. Results Summary
7.6 Sum m ary
These recurrent event survival models investigated the association between insulin 
exposure and the risk of serious hypoglycaemic event in patients newly-starting insulin 
therapy in the study period, over the first 60 months of insulin use in patients with Type 2 
diabetes and in the first 48 months in patients with Type 1 diabetes.
There were no statistically significant differences in risk between insulin exposures in 
patients with Type 1 diabetes. Some statistically significant differences between 
exposures were found in patients with Type 2 diabetes: patients using long-acting 
analogue insulin were 23% less likely to have a serious hypoglycaemic event than were 
those using pre-mixed human insulin (after adjustment for the other covariates included 
the multivariate analysis); however a similar reduced likelihood was seen in patients 
using only intermediate/long-acting human insulin.
The patient’s BMI, glycaemic control and post-insulin rate of contact with care providers 
were all significant predictors of a patient’s risk of serious hypoglycaemic episodes in 
both Type 1 and Type 2 diabetes. The largest effect in Type 2 patients was with the 
patient’s ethnicity, with the likelihood of a hypoglycaemic event doubling in Black 
patients compared to Caucasians.
In both Type 1 and Type 2 diabetes patients with more frequent contacts with their care 
providers after the start of their insulin therapy were more likely to have serious 
hypoglycaemic events, and in Type 2 diabetes the same effect was seen with the 
pre-insulin contact rate. It is possible that patients experiencing hypoglycaemia contact 
their GP more often, however, as the GPRD only records events known to the GP, it is 
also possible that the more often the patient sees their GP (for whatever reason), the 
more opportunities they have to inform them of events.
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CHAPTER
Comparison of the risk of a serious hypoglycaemic 
event under different post-switch insulin exposures after
a switch from human insulin
8 1
8.1 H ypoth esis and an a lysis  approach
The second analysis testing Hypothesis D, that
GPRD records could be used to determine differences in the "real-life" risk of 
hypoglycaemic events between patients using analogue and human insulins
was a comparison of the risk of a serious hypoglycaemic event following a change in 
insulin exposure.
The analysis subjects were drawn from the qualifying "insulin switching" patients with a 
pre-switch exposure to only human insulins, and excluded patients who switched to 
animal insulin or who had a post-switch exposure of only fast-acting analogue insulin 
(see the Methods section, page 88).
12,162 patients met the inclusion criteria, 3,929 with Type 1 diabetes and 8,233 with 
Type 2 diabetes.
Survival analysis to the first serious hypoglycaemic event using Cox proportional 
hazards models was used to compare the risk under different post-switch insulin 
exposures. A separate analysis was carried out for all the patients and in the 3,606 
"complete cases": those with explicit covariate values for glycaemic control status 
(HbAic), alcohol usage, smoking status, BMI and socio-economic status at their switch 
date. The proportional hazard assumption did not hold for the post-switch contact rate, 
so the analysis was stratified by that variable.
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8. Results Hypothesis and analysis approach
Both the pre-switch and post-switch insulin exposures were included as covariates in the 
analysis. The observed pre- and post-switch insulin exposures were grouped for analysis 
as described in the Methods section. Table 3.5, and are given in Table 8.1.
612 of the analysis patients patients had hypoglycaemic events in the 6 months before 
their switch date, and all of these patients also had events in the post-switch time they 
contributed to the survival analysis. Hence pre-switch hypoglycaemia was a "perfect 
predictor" of post-switch events, and was rejected in the statistical models because of 
collinearity. It was not included as a covariate in the results presented here.
C o v a r ia t e  r e c o d in g
In both the all-patient and the complete case analyses, patients of Asian and Oriental 
ethnicity were combined.
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8.2 Survival to  first se r io u s  hypoglycaem ic even t after sw itch ing from human 
insulin
S u r v iv a l  a n a l y s i s  r e s u l t s , a l l  p a t ie n t s
The results of the survival analysis to the first serious hypoglycaemic event after 
switching from human insulin are given in Table 8.2.
The analysis found no association between the patient’s post-switch insulin exposure and 
the risk of a serious hypoglycaemic event. Of the covariates included in the analysis, the 
only statistically significant differences in the likelihood of an event were with the type 
of diabetes, the patient’s age at the switch, alcohol usage, concomitant metformin use, 
and the frequency of pre-switch contacts with health care providers. As the objective of 
the analysis was to compare risks across different post-switch insulin exposures, the 
post-switch exposure was retained in the multivariate analysis, even though no 
statistically significant effects were seen.
As noted in the Introduction, rates of hypoglycaemia are generally higher in patients with 
Type 1 diabetes, and this was observed in the analysis: patients with Type 1 diabetes 
were 46% more likely to have a hypoglycaemic event in the first 60 months post-switch 
than were patients with Type 2 diabetes (HRadjl.46 Glgsfl.lG, 1.96]).
To avoid breaching the proportional hazard assumption, the Cox model was stratified by 
the patient’s post-switch contact rate (the annualised rate of the patient’s personal 
contacts with health case providers), although the pre-switch contract rate was included 
in the analysis as a categorical covariate. The effect of the pre-switch contact rate is 
shown, by type of diabetes, in Figure 8.1. In both Type 1 and Type 2 diabetes the 
likelihood of a hypoglycaemic event decreased as the patient’s contract rate increased. 
Patients with 25 or more contacts/year with health care providers were 37% less likely to 
have a hypoglycaemic episode than were patients in the reference group with 10-15 
contacts per year (HRadjO.64 Clgsp.SO, 0.82]). Although the effect was only statistically 
significant in the higher contact rate bands there was a trend across the contact rate 
categories.
There was a statistically significant association between the patient’s age at the switch
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Combined effect of diabetes type and pre-switch contact rate
2  4 -  
O
I
I
< 0.01 0.01<=5
A nnualised  pre-sw itch con tac t ra te  b and  (con tac ts/year)
10<=15
diab_type= 1 — ^ —  d iab_ type= 2
Figure 8.1: C o m b in e d  e f f e c t  o f  t y p e  o f  d i a b e t e s  a n d  t h e  p r e - s w i t c h  c o n t a c t  r a t e  o n
THE RISK OF A SERIOUS HYPOGLYCAEMIC EVENT )
date and the risk of an event, although the effect was very small: HRadj 1.01 
Cl95[1.00, 1,01]. Alcohol usage at the switch date also showed a significant association: 
non-drinkers were more likely to have an hypoglycaemic episode (HRadj 1.19 
CI95 [1.01,1.41]) compared to the reference group of alcohol drinkers. The combined 
effects of age and alcohol use status are shown in FigureS.2.
Combined effect of age and aicohoi usage
P atien ts  with T ype 2 d ia b e te s
4 -
I "
I,.
A ge a t switch d a te
— E -- - -  P roblem  drinker
— —  D rinker 
— A —  U nknow n
Figure 8.2: C o m b in e d  e f f e c t  o f  t h e  p a t i e n t ’s  a g e  a t  t h e  s w i t c h  d a t e  a n d  t h e i r
ALCOHOL USAGE ON THE RISK OF A SERIOUS HYPOGLYCAEMIC EVENT
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Patients who were concomitant metformin users were 53% less likely to have an event 
compared to the patients with no concomitant use (HRadj0.43 ClgsfO.SO, 0.53]).
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S u r v iv a l  a n a l y s is  r e s u l t s , c o m p l e t e  c a s e s
The results of the survival analysis in the 3,606 "complete case" patients are given in 
Table 8.3.
In complete case patients, while the increase in the likelihood of an event in patients with 
Type 1 diabetes compared to those with Type 2 was similar to that in the all-patient 
analysis, it was no longer statistically significant (HRadj 1.32 p=0.117), and neither was 
the patient’s age at the switch date. However, the pre-switch contact rate was significant, 
although not at all levels, with the same general trend of a lower likelihood of a serious 
hypoglycaemic event with increasing contact with care providers. The effect is shown, 
by type of diabetes, in Figure 8.3, which also illustrates the lack of a significant 
difference between Type 1 and Type 2 diabetes in these patients.
Patients prescribed metformin during the time they contributed to the survival analysis 
were 57% less likely to have a serious hypoglycaemic event (HRadj0.43 
ClgsfC.Sb, 0.51], as was seen in the all-patient analysis.
There were no statistically significant associations between the risk of a hypoglycaemic 
event and the patient’s post-switch insulin exposure.
Combined effect of diabetes type and pre-switch contact rate
In com plete  c a s e  patien ts
1 0 -
£
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Figure 8.3: E f f e c t  o f  p r e - s w i t c h  c o n t a c t  r a t e  o n  t h e  r i s k  o f  a  s e r i o u s
H Y P O G L Y C A E M rC  E V E N T  IN C O M P L E T E  C A S E  P A T IE N T S , BY T Y P E  O F  D IA B E T E S
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8.3 Summary
This analysis looked at the risk of serious hypoglycaemic events in the first 60 months 
following a switch from only human insulins, under different post-switch insulin 
exposures.
Its main objective was to compare the risk of serious hypoglycaemic events under 
different insulin exposures: however no statistically significant associations between the 
risk of hypoglycaemia and the patient’s pre-switch or post-switch insulin exposures were 
found. There was, however, a "perfect predictor" of the risk: all of the (potential) 
analysis patients who had a hypoglycaemic event in the 6 months before their switch date 
subsequently also had an event post-switch.
Patients with Type 1 diabetes are generally more likely to have hypoglycaemic events, 
and this analysis did show an increase in risk in these patients.
The increased likelihood of an event seen in alcohol non-drinkers compared to alcohol 
drinkers was interesting, given that alcohol is known to induce hypoglycaemia, and 
that known drinkers also had a raised hazard ratio, although this was not statistically 
significant (HRadj 1-4 p=0.23).
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CHAPTER
Discussion
9 1
Chapters 4 to 8 presented the results of analyses using GPRD data to test the hypotheses 
formulated in the Introduction (pg. 21).
This chapter will review the hypotheses in the context of the analysis results, discuss 
methodological issues, and draw overall conclusions.
9.1 Changes in insulin prescribing over the study period
The introduction of analogue insulins increased the choices available to clinicians, and it 
was hypothesised that:
GP s insulin prescribing practices would change following the introduction of 
analogue insulins, and that GPRD prescription records could be used to track those 
changes
GPs use the GPRD software to manage and record prescribing, so the prescription data 
is generally of good quality. Given this, and its representative coverage of the UK, the 
GPRD is, therefore, a good source of information on prescribing. Accordingly, the 
secular trends described in Chapter 4 reflect genuine changes in insulin prescribing over 
the study period.
There was a rapid update of analogue insulins after their introduction into the UK. By 
1992 animal insulins had already been substantially replaced by human-sequence 
insulins (84% of insulin prescriptions in 1992 were for human insulins), and in 2001 
human insulins still accounted for ^^80% of prescriptions. However, by 2008 more than 
80% of prescriptions were for analogues. Over the study period, analogues became the 
insulins of first choice for patients newly-starting insulin therapy: in 2008 more than
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80% of new users started on analogue insulin alone. There was a also substantial 
migration of users of human insulin onto analogue products, either alone or in 
combination with human insulins.
The NICE guidelines (during the study period) on the management of patients with 
diabetes recommended starting patients on human insulin, so many GPs chose not to 
follow this advice.
The purported advantages of analogues include "quality-of-life" improvements (more 
flexibility in injection times and increased patient satisfaction with their treatment) and a 
reduced risk of nocturnal hypoglycaemia. In addition, insulin therapy can lead to weight 
gain in both Type 1 and Type 2 diabetes, in turn associated with increased 
cardiovascular risk, and detemir has been associated with reduced weight gain.
While some reduction in nocturnal hypoglycaemia was observed in clinical trials (as 
discussed in the Literature Review), less information was available concerning 
quality-of-life measures. The Cochrane review in Type 2 diabetes by Horvath 
included only 1 trial that reported on patient satisfaction, finding it higher in patients 
using glargine than in those using NPH insulin (but noting that the quality of reporting 
was poor). Thirteen of the trials included in Siebenhofer’s Cochrane review in Type 1 
diabetes reported on quality of life, but she noted that the different study designs and 
data collection methods made comparisons difficult, although those studies that used the 
Diabetic Treatment Satisfaction Questionnaire (DTSQ) showed greater satisfaction in 
patients treated with analogue insulins.
Analogue insulins are more expensive than human insulins, and this change in 
prescribing practice incurred substantial costs for the NHS. Holden et a l estimated 
that between 2000 and 2009 the NHS spent £2,732 million on insulins (adjusted for 
inflation and in 2010 values), and that if the patients prescribed analogue insulins could 
have been give human insulins instead, £625 million could have been saved. However, 
the need to treat patients for diabetic comorbidities also incurs substantial costs.
Minshall et a l estimated that, in the USA, if currently glycaemically-uncontrolled 
patients could be maintained at an HbAic of 7.0%, then, over 10 years, the accumulated
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cost savings would be between 35 and 50 billion US dollars, equivalent to ~4% of total 
US health care costs.
It is possible, therefore, that improvements in glycaemic control, which could delay the 
development of long-term diabetic complications, would offset the addition cost of 
analogue insulins. It was noted in the literature review that, although many trials of 
analogue insulins have HbAic levels as a primary outcome, they are often of short 
duration (sometimes just 4 weeks); they cannot, therefore, provide evidence for the 
impact of analogue insulins on long-term glycaemic control. However, the 10-year 
follow-up study of the UKPDS patients found significant reductions in the risk of both 
micro vascular and cardiovascular complications, as well as in all-cause mortality, in 
patients with early glucose control.
Sibenhofer-Kroitzsch et al. summarizing the effect of analogue insulins on 
glycaemic control in an editorial in the Canadian Medical Association Journal, stated 
that "compared with regular insulin, insulin analogues produce only minor additional 
reductions in HbAic". She also noted that, while the higher levels of patient satisfaction 
with analogue insulins were most likely due to the greater flexibility of injection times, 
the importance of injection times in intensive insulin therapy has not been demonstrated 
in clinical trials.
This present study cannot provide information on why GPs preferred analogue insulins, 
but greater patient satisfaction (and hence, perhaps, greater adherence to glycaemic 
targets), reduced hypoglycaemia and lower weight gain are worthwhile clinical 
objectives. However the clinical evidence, including the two Cochrane reviews, 
suggested that analogue insulins offered only minor clinical benefits compared to human 
insulins. While the long-term benefits of tighter glycaemic control have been 
demonstrated,^^ there is little evidence that patient outcomes, in the long term and in 
"real-life", would be better on analogue insulin than they would on human insulins.
Andrea Sibenhofer and Andrea Siebenhof-Kroitzsch are the same person
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9.2 Factors influencing the choice of human or analogue insulin in new insulin 
users
Over the study period clinicians had a choice between established human insulins and 
the newer analogue products. It was hypothesised (B) that:
GPs would be selective in their use of analogue insulins, choosing between human 
or analogue products based on the patient’s characteristics, and hence that the 
GPRD data could he used to predict the chosen insulin.
The logistic regressions presented in Chapter 5 tested this in patients newly-starting 
insulin therapy.
The analysis confirmed that GPRD data could be used to predict a patient’s initial 
assignment to analogue or human insulin: however the most important determining 
factor was not the patient’s characteristics, but the calendar year in which they started 
insulin therapy, as illustrated in Figure 9.1. Calendar year alone correctly predicted the 
initial choice of insulin in 77% of patients with Type 1 diabetes and 78% of those with 
Type 2 diabetes.
250
"4— Type 2 diabetes (com plete cases) 
Type 2 diabetes 
Type 1 diabetes
200
150 -
100  - •
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Calendar year of first insulin prescription
Figure 9.1: A d j u s t e d  h a z a r d  r a t i o s  f o r  t h e  e f f e c t  o f  c a l e n d a r  y e a r  o f
FIRST INSULIN PRESCRIPTION ON THE INITIAL CHOICE OF ANALOGUE 
RATHER THAN HUMAN INSULIN IN PATIENTS NEWLY-STARTING INSULIN 
THERAPY (DATA FROM TABLES 5 .2 ,  5 .3  AND 5 .4 )
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Although their effects sizes were small compared with that of the calendar year, some 
patient characteristics were found to have a statistically significant influence on the initial 
choice of insulin. In both the all-patient (ap) and complete-case (cc) analyses of patients 
with Type 2 diabetes statistically significant associations were seen with the patient’s 
age, HbAic status and duration of diabetes at their first insulin prescription. Older 
patients were less likely to be given analogue insulin (ORadjO.98 p<0.001 ap and cc), as 
were patients with good glycaemic control (an HbAic <7.5) (ORacijO.77 p=0.004 ap, 
ORadjO.64 p=0.001 cc). Patients with an estimated duration of diabetes or 10 years or 
longer were more likely to be prescribed analogue insulin (ORadjl l p<0.001 ap, 1.7 
p<0.001 cc).
In patients with Type 2 diabetes, but not in those with Type 1, ethnicity also influenced 
the initial insulin choice. Ethnically Black patients were less likely to be prescribed 
analogue insulins (ORadjO.52 p=0.003 ap, 0.38 p=0.003 cc). Black ethnicity was also 
found to be a statistically significant risk factor for hypoglycaemia after starting insulin 
therapy. Ethnicity is discussed below in section 9.6.
In all analyses, statistically significant differences were seen in the UK geographical 
regions. While these may be random fluctuations, they may also reflect differences in the 
regional populations or in regional prescribing practices. Regional differences in 
socio-economic status were noted in the Methods section (pg. 97), and Scotland, Wales 
and Northern Ireland have some degree of independence in the management of the NHS 
in their regions.
The analyses suggested that patients’ characteristics and clinical needs did influence the 
initial choice of insulin to some extent, for example with the preference for analogue 
products in patients needed faster-acting insulins, and the reluctance to prescribe 
analogues to ethnically Black patients with Type 2 diabetes. However, when a patient 
started on insulin was far more influential.
It is possible that the clinician’s initial choice of insulin was influenced by factors that 
were not available for inclusion in the analyses, however, given the association with 
calendar year, the analysis suggests that clinician (or patient) preferences were a major
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determining factor in initial insulin choice.
9.3 Factors influencing a change in insuiin exposure
Hypothesis (C) postulated that:
GP’s would change a patient’s insulin regime depending on their characteristics 
and medical history, and that GPRD data could be used to predict such changes.
This was tested by a case-control study comparing "switching" patients to controls 
drawn from the base study population. The results are presented in Chapter 6.
Cases and controls were matched on sex, type of diabetes, insulin exposure, year of birth, 
and the calendar time of the case’s exposed period (to compensate for the effect of 
calendar year found in the analysis of new insulin users).
Overall, the factors found to influence a switch in insulin exposure seemed consistent 
with clinical management. Patients with less than a year of (overall) insulin exposure 
were 26 times (Type 2) or 28 times (Type 1) more likely to switch than were patients 
with longer exposures, and these were the largest effect sizes seen in the analyses. This 
presumably reflects the patient’s insulin therapy being adjusted to their needs. Patients 
who had achieved "good" or "moderate" glycaemic control on their current regime were 
less likely to change, as were patients who had been on their current insulin regime for 
more than 5 years. Clearly, there is no less need to change therapy in patients who are 
stable on their current treatment.
Patients with Type 2 diabetes who were diagnosed with a "macro-vascular" morbidity 
during the time they contributed to the analysis were ~16% more likely to switch than 
those without such a morbidity, while those who were diagnosed before the start of the 
time they contributed to the analysis were ~9% less likely to switch. It is possible that 
diagnosis of a "macro-vascular" comorbidity during an exposure triggered a review of 
the patient’s treatment, leading to a change, while the regimes of patients with 
longer-standing comorbidity would have already been reviewed.
The analyses found that serious hypoglycaemic events reduced the likelihood of a change 
in insulin exposure. It might be hypothesised that serious hypoglycaemic events would
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prompt a review of the patient’s treatment: if so, then the outcomes did not seem to 
include a change of insulin therapy, at least in patients that meet the definition of 
"switchers" used in this study. However, few patients had serious hypoglycaemic events 
during the time they contributed to the analysis (1.8% of Type 1 patients and 1.4% of 
Type 2).
Unlike the analysis of initial choice of insulin, this analysis found no association between . 
a patient’s ethnicity and their likelihood of switching, although there were some 
statistically significant variations between UK geographic regions. In developing the 
multivariate models, the patient’s socio-economic status was not found to be a significant 
contributor, was it was omitted from both the Type 1 and Type 2 adjusted models.
However, there were regional variations in SES (noted in the Methods section 3.8, 
pg. 94), and it is possible that observed regional differences reflect these.
There was an association with the patient’s rate of contact with health care providers: the 
likelihood of switching increased as the contact rate increased, as shown in Figure 9.2.
In both Type 1 and Type 2 diabetes the difference were statistically significant at all 
covariate levels. Adjusted for other covariates, patients who were in contact with their 
care providers 25 or more times a year were ~40% more likely to switch insulins than 
those with a contact rates of 10-15 times a year. It may have been that patients who were 
unhappy with their insulin regime (for whatever reason) would contact their health care 
provider more often. However, in over 70% of the qualifying switching patients (who 
provided the cases for these analyses), the patient switched to analogue insulin. It is 
possible that clinicians have more opportunity to "modernise" a patient’s insulin therapy 
in those patients they saw more often.
The goodness-of-fit values of the multivariate case control models (the analyses’ 
pseudo-77^ values) were 0.39 in Type 1 diabetes and 0.65 in Type 2. While this 
"percentage of variance" estimate is not exact in logistic regression, for patients with 
Type 2 the covariates included in the multivariate analysis were reasonably good 
predictors of a patient’s likelihood of switching, explaining ~65% of the observed 
variation. Prediction was less accurate in patients with Type 1 diabetes, at around 35% 
of the variation. The research hypothesis, that a patients characteristics could be used to
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Figure 9 .2 :  A d j u s t e d  h a z a r d  r a t i o s  f o r  e f f e c t  c l i n i c a l  c o n t a c t  r a t e  o n
FIRST INSULIN PRESCRIPTION ON THE INITIAL CHOICE OF ANALOGUE 
RATHER THAN HUMAN INSULIN IN PATIENTS NEWLY-STARTING INSULIN 
THERAPY (DATA FROM TABLES 5 .2 ,  5 .3  AND 5 .4 ) )
predict changes in insulin exposure, was therefore, to some extent, confirmed.
9.4 Comparative risk of serious hypoglycaemic events under different insulin 
exposures in new insulin users
The fear of hypoglycaemia is a barrier to the achievement of tight glycaemic control, and 
a reduction in hypoglycaemic episodes is clinically desirable. There is reasonably 
consistent evidence for a reduction in nocturnal hypoglycaemia with analogue insulins, 
as discussed in the Literature Review, however, this was mostly obtained from clinical 
trials. Trial conditions, with controlled circumstances, high monitoring levels, selected 
patient sets, and (often) short durations means that they are not necessarily indicative of 
the effects in "real-life" clinical practice. It was, therefore, hypothesised (D) that:
GPRD records could be used to determine differences in the "real-life” risk of 
hypoglycaemic events between patients using analogue and human insulins.
This was examined in two survival analyses using, respectively, patients newly-starting 
insulin therapy and patients who switched/ram an exposure of only human insulin.
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R i s k  o f  s e r i o u s  h y p o g l y c a e m ic  e v e n t s  i n  p a t ie n t s  n e w l y -s t a r t in g  i n s u l i n
THERAPY
Chapter 7 presented the results of recurrent event survival analyses to hypoglycaemic 
events in new insulin users who were initially prescribed only human or only analogue 
insulins, during the first 60 months of insulin use in patients with Type 2 diabetes, and 
the first 48 months in patients with Type 1 diabetes.
For convenience, the hazard ratios from the analyses for the various insulin exposures are 
repeated in Table 9.1.
Table 9.1: A d j u s t e d  h a z a r d  r a t i o s  f o r  i n s u l i n  e x p o s u r e s  f r o m  t h e  r e c u r r e n t
EVENT SURVIVAL ANALYSES IN PATIENTS NEWLY-STARTING INSULIN THERAPY
A d ju sted  Hazard R atio (CIgs) [p-value]
Insulin
e x p o su r e
T ype 2  
a ll-p a tien ts
T ype 2  
c o m p le te -c a s e s T ype 1
(1 ) Human short-acting
(2) Human intermediate/long com b.
(3) Human intermediate/long alone
(4) Human pre-mixed alone
(5) Analogue rapid-acting
(6) A nalogue long-acting com b.
(7) A nalogue long-acting alone
(8) A nalogue pre-mixed alone
1.29 [0.60,2.72] (0 .526) (excluded) 
0 .73 [0 .45,1.190] (0 .210) 0 .76  [0.30,1.91] (0.561) 
0 .72  [0.61,0.85] (<0.001 ) 0 .42  [0.29,0.59] (<0.001 ) 
R eference R eference  
0 .47  [0.16,1.26] (0 .132) (excluded) 
1 .02 [0.70,1.49] (0 .929) 2 .02  [1.23,3.31] (0.005) 
0 .77  [0.66,0.90] (0 .001) 0 .80  [0.62,1.04] (0.090) 
0.99  [0.88,1.11] (0 .821) 0 .90  [0.72,1.12] (0 .349)
0 .47  [0.15 .1 .51] (0.202) 
1.04 [0 .53 ,2 .06] (0.908) 
0 .75  [0 .35 ,1 .60] (0.460) 
R eference  
0 .63  [0 .25 ,1 .59] (0.331) 
1.19 [0 .78 ,1 .82] (0.422) 
0 .56  [0 .13 ,2 .34] (0.423) 
0 .84  [0 .54 ,1 .30] (0 .431)
Source table 7.5, pg. 178 7.6  pg. 186 7.7 , pg .190
The all-patient multivariate analysis of patients with Type 2 diabetes found patients who 
started on only longer-acting analogue insulins were (a statistically significant) 23% less 
likely to have serious hypoglycaemic events compared with those starting on pre-mixed 
human insulin over the first 60 months of insulin use. The factors adjusted for included 
ethnicity, geographical regions, age at first insulin, BMI, monitoring rate, oral 
hypoglycaemic drug use, smoking status and alcohol usage, and the duration of diabetes. 
The Type 2 complete-case analysis found a similar reduction in the likelihood, but this 
was not statistically significant.
Where the studies included in the Literature Review found statistically significant 
differences in the risk of hypoglycaemic episodes in longer-acting analogue insulin 
compared with NPH insulin, the effect sizes varied, ranging from a 8-47% lower risk of 
nocturnal hypoglycaemia, 27-44% lower risk of of "severe" hypoglycaemia, and 2-57% 
lower risk of of overall hypoglycaemia. Many studies did not find statistically significant
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differences in the likelihood of severe or "all" hypoglycaemic episodes between 
long-acting analogue insulin and NPH insulin. The observed lower likelihood in the 
all-case patients was similar to the 21.7% lower likelihood with detemir compared with 
NPH insulin reported by Haukka et al. , an observational study of Finnish patients 
newly-starting insulin therapy, and closer in methodology to this study than were the 
RCTs from which most of the Literature Review estimates were derived.
Comparison of the analysis results to other studies was complicated by the different 
definitions of hypoglycaemia. Published studies generally classified hypoglycaemia as 
"severe", "nocturnal", or "symptomatic" (as described in the Literature Review, pg. 59), 
but equivalent classifications could not be applied to events identified in the GPRD.
Minor hypoglycaemic events were unlikely to be reported to the GP, so the GPRD events 
were termed "serious", however this did not necessarily mean that they met the definition 
of "severe" events -  commonly events that required 3^  ^party assistance. The GPRD 
events were probably closest to the "severe" event class, but were likely to also include 
nocturnal events. The GPRD2009 clinical dictionary did not (surprisingly) have a 
specific code for "nocturnal hypoglycaemia", and while it did have a code for "events 
requiring 3rd party assistance", only 63 records used it. While the GPs may have used 
the GPRD "free text" to provide more information on hypoglycaemic episodes, such as, 
for example, noting nocturnal events, the free text was not available to this study.
Comparison was further complicated by the different reference groups used. The 
survival analyses used the most commonly seen exposure, pre-mixed human insulin, as 
the reference group, while the RCTs used NPH insulin. While NPH (intermediate-acting 
human insulin) alone was not one of the exposure classifications used in the analysis, the 
closest in composition was group (3), which included patients exposed to only 
intermediate human insulin or only long-acting human insulin. In patients with Type 2 
diabetes, only 10 of the 2,928 patients in this group started on long-acting insulin, so it 
was very close to the RCT reference group.
The all-patient analysis found that, compared with patients using pre-mixed human 
insulin, patients using only intermediate or long-acting human insulin (exposure group 
3) of the also had a statistically significant 28% lower likelihood of hypoglycaemic
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events: similar to the effect in long-acting analogue insulin. This group also showed a 
(statistically significant) 53% lower likelihood in the complete-case analysis. The 
similarity of the effect sizes in the all-patient analysis suggest that, had group (3) been 
the reference group, the effect in long-acting analogue insulins may not have been 
statistically significant.
In patients with Type 1 diabetes, no statistically significant differences were found 
between the risk of hypoglycaemic events in patients using pre-mixed human insulin and 
any of the other insulin exposures. While there was a (non-significant) 45% lower 
likelihood of events in patients using long-acting analogue insulin compared to the 
reference group, there were only 55 patients in that category and the precision was poor 
(Cl95[0.1,2.3]).
There was also an association between pre- and post-switch clinical contact rates and a 
patient’s risk of having a hypoglycaemic episode; the more clinical contacts, the greater 
the risk. Given that the GPRD records include events reported at GP consultations, this 
may be a data bias, as patients making more frequent contact with their GP had more 
opportunity to record events. Alternatively, it may be a genuine effect, as patients with 
less stable diabetes or other health problems that place them at greater risk of 
hypoglycaemia may visit their GPs more often. This could be be resolved by a detailed 
analysis of individual patient records, looking at a patient’s overall health, combined 
with a more reliable source of data on hypoglycaemia, such as patient diaries.
Covariate recording and the complete-case analysis
While the patient characteristics available in the GPRD included BMI, HbAic, alcohol 
usage status and smoking status (the "life-style" covariates) as well as ethnicity and 
socio-economic status, not all patients had values for these covariates. In at least some 
cases, the covariates were not missing at random. For example, in a preliminary review 
of the HbAic records, it was found that the likelihood of a patient having a 
HbAic record depended on the value of the previous reading: patients with "better"
HbAic values were less likely to have subsequent GPRD records. Similarly a patient 
was less likely to have more than one record of their smoking status if their first record 
was as a "non-smoker". As these covariates were time-varying, this meant that the
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likelihood of a patient having a covariate value on an given date depended on their 
earlier values for that covariate. While the impact of this was reduced by taking a 
patient’s smoking or alcohol usage status as valid until superseded, this increased the 
risk that the covariate values were inaccurate.
For the analyses, missing values were coded as "unknown", and this was included as a 
covariate level in the analyses. However, the "unknown" categories were likely to contain 
a range of actual states, and thus risked biasing the results. Some of the "unknown" 
categories had statistically significant associations with the outcome, suggesting residual 
confounding in the data. To mitigate this, a complete case analysis was carried out in the 
27% of patients with Type 2 diabetes with values for all the life-style covariates, 
ethnicity and SES (which was only available for English patients). There were too few 
complete-case patients with Type 1 diabetes for meaningful analysis.
While the complete-case analysis removed the effects of including missing covariate 
values, it also reduced the power of the analysis (as patient numbers were substantially 
reduced, from 19,323 to 5,301), increasing the risk of failing to detect a real difference in 
the likelihood of hypoglycaemic events between exposures. It also changed the analysis 
population.
Levels of covariate recording were not equal across the different insulin exposures 
(Table 7.2, pg. 170). BMI, HbAic, alcohol usage and SES were more likely to be 
recorded in Type 2 patients using analogue insulin than in those using human insulin.
Thus the compete-case analysis included proportionally more analogue insulin users 
than human insulin users. Also, as socio-economic status was only available for English 
patients, patients from Wales, Northern Ireland and Scotland were excluded. It is also 
possible that GPs were more likely to record covariate values in patients who they felt to 
be in need of closer monitoring. The complete-case analysis may, therefore, have been 
biased towards patients who were, for whatever reason, less able than the general 
population to manage their diabetes.
The complete-case analysis did show a 20% lower likelihood of an hypoglycaemic event 
in patients using long-acting analogue insulins compared with those using pre-mixed
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human insulin, however it was not statistically significant. There was, however, a 
statistically significant 58% lower likelihood in users of intermediate or long-acting 
human insulin. Thus the complete-case analysis, despite its differences to the all-patient 
subjects, also suggested that intermediate (or long-acting) human insulin offered a 
greater "real-life" benefit than did longer-acting analogue insulin.
9.5 Comparative risk of a serious hypoglycaemic event in patients following a 
change in insulin exposure
The second analysis testing hypothesis (D) was a survival analysis to the first 
hypoglycaemic event following a change in insulin exposure in patients who switched 
from human insulin.The results were presented in Chapter 8.
The analysis also found that patients with Type 1 diabetes were more likely to have an 
hypoglycaemic event (HRadjl.5 in the all-patient analysis) compared to those with Type 
2 diabetes. While their likelihood of an event was also raised in the complete case 
analysis (H R adjl-3), this was not statistically significant. While the frequency of 
hypoglycaemic events reported in the literature varies, reflecting different definitions and 
data collection methods, rates are generally higher in Type 1 diabetes than in Type 
2, so this result was expected.
The analysis found no statistically significant differences in the risk of serious 
hypoglycaemic events between the different pre- or post-switch insulin exposures in 
either the all-patient or complete case analyses. However all of the patients who had a 
hypoglycaemic event in the 6 months before their switch date subsequently also had an 
event post-switch. This is in-line with the finding of the DCCT trial, that the risk of 
severe hypoglycaemia (defined as needing 3’’^  party assistance) was 33%  higher in (Type 
1) patients on intensive insulin therapy, and 70% higher in patients on the (then) 
conventional insulin therapy if they had a history of hypoglycaemia. It is also consistent 
with study by Donnelly et a l , who found that a history of hypoglycaemia was a 
significant predictor of hypoglycaemia in Type 1 diabetes, while in patients with Type 2 
diabetes a hypoglycaemic episode in the previous month was a significant predictor.
The likelihood of a serious hypoglycaemic event (adjusted for the type of diabetes) was
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nearly halved in patients with concomitant metformin prescribing compared to patients 
who were not prescribed metformin, and this was seen in both the all-patient and 
complete-case analyses (HRadjO.42 in both). This contradicted a finding by Donelly,^^^ 
that co-prescribing of oral hypoglycaemic drugs increased the likelhood of a 
hypoglycaemic episode. However, Donelly’s analysis was based on the total number of 
hypoglycaemic events, not just the more serious or server ones, so the outcomes are not 
directly comparable. Metformin reduces hepatic glucose production, increases cellular 
glucose uptake, and slows the absorption of glucose from the gut: actions more likely to 
increase the risk of hypoglycaemia (as Donelly found) than reduce it. An RCT by 
WulfFele et a l found that patients using metformin in combination with insulin 
achieved tighter glycaemic control than those on insulin alone, with a mean daily blood 
glucose lower by 0.7 mmol/1, and achieved this with a 10% decrease in their daily insulin 
dose. Again, tighter glycaemic control would suggest an increased risk of hypoglycaemia 
rather than a reduction. It is difficult to explain this result, which must therefore, be 
treated with caution. Further analyses, specifically comparing patients with and without 
co-prescribed metformin, may determine whether it was genuine.
There was also an association between the risk of a hypoglycaemic event and the 
patient’s pre-switch clinical contact rate, with patients with a lower pre-switch contact 
rate more likely to have an event (Figure 9.3), although not all levels of the covariate were 
statistically significant. It might be conjectured that patients with more clinical contacts 
in the period leading up to their change in regime were managing their diabetes better.
Overall, the evidence produced by this analysis for differences in the risk of 
hypoglycaemia under different insulin exposures following a change in insulin must be 
considered ambiguous.
The statistically significant lower likelihood of a hypoglycaemic event seen in uses of 
long-acting analogue insulins compared to the reference group of pre-mixed human 
insulin users was in line with the findings of the RCTs that reported significant 
differences. However, the lower likelihood was close to that seen between pre-mixed 
human and only intermediate or long-acting human insulin. Unfortunately, time 
constraints meant that the data could not be re-analysed with the different reference
225
9. Discussion Other patient characteristics affecting the risk of hypoglycaemia
-J
U  ^ I
to
% E
| îO  in 
L_ bo
11
4.5 1
3.5
2.5
2 .
1.5
l |
a  Ï
V(Ü
£  1
0.5 -
H All-patient analysis  
N  C om plete-case analysis
Pre-switch health care contact rate (contacts/year)
Figure 9.3: A d j u s t e d  h a z a r d  r a t i o s  f o r  t h e  r i s k  o f  a  s e r i o u s
HYPOGLYCAEMIC EVENT BY PRE-SWITCH CLINICAL CONTACT 
RATE
group. This would be worthwhile in any further work.
9.6 Other patient characteristics affecting the risk of hypoglycaemia
In addition to the insulin exposure, other patient characteristics were also found to 
influence a patient’s risk of risk of hypoglycaemic events.
Ethnicity
Ethnically Black patients were less likely to be prescribed analogue insulin when they 
started on insulin therapy, and those with Type 2 diabetes were also more likely to have 
hypoglycaemic events (HRadj2.3 Clgsfl.l, 5.1]) than were Caucasians. Unfortunately 
their risk of hypoglycaemia could not be identified in patients with Type 1 diabetes as 
too few patients had an ethnic classification.
There are known to be metabolic differences between ethnic groups that are relevant to 
diabetic treatment. Davidson et al. compared African, Asian and Hispanic patients
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with Caucasians in a post hoc analysis of data from the DURABLE trial.^ In patients 
with Type 2 diabetes newly-starting insulin therapy (equivalent to the lype 2 patients in 
this analysis), they found that postprandial glucose was lower in African patients than in 
Caucasians, and they required lower dosages of insulins. A systematic review and 
meta-analysis by Kodama et a l compared insulin sensitivity and acute insulin 
response in Caucasians, East Asians, and Africans. They found that insulin sensitivity 
was lower in Africans compared with Caucasians, while insulin response was higher.
Such differences might have affected a patient’s response to insulin. For example, it was 
possible that the increased risk of hypoglycaemia was related to Davidson’s finding that 
Black patients required lower insulin dosages. It is however, difficult to see how such 
differences would affect the initial choice between analogue and human insulin. A study 
comparing health treatments in ethnic groups in Wandsworth, London, by Millet et 
a l found no statistically significant differences between the proportions of White 
British and Black Caribbean patients who were prescribed insulin. While the ethnic 
classifications used by Millet were not identical to those in the GPRD, they suggest that 
Black ethnicity did not affect whether or not the patient was treated with insulin.
There are differences in health and health outcomes between ethnic groups in the UK.
The Office for National Statistics has published data '^^  ^showing that Black Caribbean 
men are 4.2 times more likely, and Black Caribbean women 2.5 times more likely, to 
have diabetes than were the general UK population. Black Caribbean patients also had 
poorer (self-reported) health than the general population (although Asians have the 
poorest self-reported health), and Black Caribbean men were more likely to smoke. The 
ethnic differences observed in this study may be related not only to metabolic 
differences, but to differences in overall heath or socio-economic status.
Age and duration of diabetes
A review by Akram et a l looked at the risk factors for "severe" hypoglycaemia in 
patients with Type 2 diabetes. Factors associated with an increased risk of severe
 ^ A 30 month multinational RCT examining the durability of glycaemic control in new insulin users with 
lype  2 diabetes
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hypoglycaemia included increasing age, longer duration of diabetes, and impaired 
hypoglycaemic awareness. Loss of glycaemic awareness cannot be determined from 
GPRD data: the GPRD2009 clinical dictionary did not have specific clinical codes for 
hypoglycaemic awareness, and such subjective conditions cannot be accurately identified 
from the other data available in the GPRD.
Both the recurrent event survival analyses and the survival analysis in insulin switchers 
found a small, but statistically significant, greater likelihood of "serious" hypoglycaemia 
with increasing age, consistent with Akram’s findings.
While the analysis in insulin switchers did not find any association between the patient’s 
duration of diabetes at their switch date and their risk of a hypoglycaemic event, a 
statistically significant association was seen in the recurrent event analysis in Type 2 
patients. Patients who had had diabetes for less than a year at their first insulin 
prescription were 47% more likely to have a hypoglycaemic event. However, no 
statistically significant differences were found in the risk of an event between patients 
with a diabetes duration of 1-5 years at their first insulin prescriptions, and those with 
longer durations.
The recurrent event survival analysis patients all had at least one year of UTS time before 
their first insulin prescription, so to have "less than one year of UTS time" there must 
have been less than a year between their index date and their first insulin prescription.
They were therefore, either recently diagnosed with diabetes, and hence learning how to 
manage their condition, or they had recently changed GP, with, perhaps, an associated 
change in their management.
Alcohol usage
The all-patient (but not the complete-case) analysis of Type 2 patients newly starting 
insulin therapy found that those who either did not drink alcohol or who were heavy 
drinkers were more likely to have serious hypoglycaemia than were "drinkers", the 
category that included alcohol consumption within the UK national guidelines.
Alcohol is known to induce hypoglycaemia due to its inhibitory effect on 
gluconeogensis, so an increased risk in heavy drinkers was not unexpected. However,
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non-drinkers of alcohol were also a 16% more likely to have an event. The effect 
remained when the multivariate analysis was repeated using different categories of 
alcohol usage as the reference group. The "non-drinkers" category included patients with 
a history of alcohol abuse who were currently not drinking. It was possible that some of 
the patients in this group were actually relapsed problem drinkers. Alternatively, they 
may be patients with health problems that both leads them to avoid alcohol and makes 
them more liable to hypoglycaemic events. A more detailed analysis of the patients 
overall medical histories may clarify this, however the patient’s GPRD alcohol usage 
status cannot be considered definitive. Apart from problems of differential recording 
noted elsewhere, patients are not always honest with their GPs about their alcohol usage.
Glycaemic control
HbAic, indicative of a patient’s medium-term glycaemic control, was found to be a 
significant factor in both the initial choice between human and analogue insulin for a 
patient, and their risk of hypoglycaemic events following the start of insulin therapy.
Patients with good glycaemic control at their first insulin prescription were less likely to 
start on analogue insulin, in both Type 1 and Type 2 diabetes (ORadjO-77 and 0 .17  
respectively), compared to patients with an HbAic of between 7 .5  and 10.0% . Patients 
with an HbAic of over 10 were also less likely to start on analogue insulin. This suggests 
that GPs were directing analogue insulins towards patients with borderline glycaemic 
control. The reasons must be speculative, but it is possible that GPs felt that greater 
flexibility of injection times would be helpful to these patients.
Patients with Type 2 diabetes with poor glycaemic control at their first insulin 
prescription were more likely (in the all-case analysis) to have a serious hypoglycaemic 
event after starting insulin therapy than were patients with moderate glycaemic control 
(H R adjl.2 ). This might suggest that patients with poor control, in trying to get their 
HbAic closer to target, were more likely to over-medicate. However, the effect was not 
seen in the complete case analysis, which did, however, find that patients with good 
glycaemic control at their first insulin prescription were 73% more likely to have a 
hypoglycaemic event. This inconsistency may have been due differences between the 
all-patient and complete-case subjects, although further analysis would be required to
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confirm this.
9.7 M ethodological is s u e s
All observational studies are at risk of bias, leading to an over- or under-estimate of the 
associations in the analyses. Accurate identification of the subjects, events and outcomes 
is important to reduce bias.
IDENTIFICATION OF STUDY SUBJECTS AND CLASSIFICATION OF TYPE OF DIABETES
This base study population was diabetics who used insulin. Insulin is used specifically to 
treat diabetes, so there can be little doubt that the study subjects were accurately 
identified, however, the censored nature of GPRD data meant there were uncertainties in 
the classification of the type of diabetes, particularly for patients who started on insulin 
before their left-censor date and who were aged 35 or older at that date.
IDENTIFICATION OF HYPOGLYCAEMIC EVENTS
The rates of serious hypoglycaemia found in the base study population were 6.6 per 100 
patient-years in Type 1 diabetes and 4.5 per 100 patient-years in Type 2 diabetes, around 
half the rates of severe hypoglycaemia found in the observational study by Leese et al. 
However, the Leese study had direct access to hospital inpatient and accident and 
emergency admission data, ambulance records, and regional laboratory results as well as 
primary care records, and were able to carry out more extensive searches for 
hypoglycaemic events.
The study rates were also substantially lower than those reported by Donelly et al.
Using patient diaries they estimated a frequency of 115 severe events per 100 
patient-years in Type 1 diabetes, and 35 events per 100 patient-years in Type 2 diabetes.
The identification of hypoglycaemic events in the GPRD presented challenges, and it is 
likely that extent of hypoglycaemia in the study subjects was underestimated.
The GPRD does not contain information on a patient’s day-to-day glycaemic control. 
Diabetic patients are advised to regularly check their blood glucose levels, but the results
230
9. Discussion Methodological issues
of these self-monitoring tests were not recorded in the GPRD. Laboratory blood glucose 
test results were available, and could provide an objective record of hypoglycaemia, but 
recording of test results was not mandatory.
Hypoglycaemic episodes can vary from mild, self-treated events (Cryer et al. 
estimated that patients with Type 1 diabetes averaged 2 such episodes a week) to comas 
that require emergency treatment and hospitalisation. Van Staa et al. found 90.7% of 
hospitalisations for hypoglycaemia were recorded, however most hypoglycaemic events 
do not result in hospitalisation. It seems unlikely that patients would report minor events 
to their GP, so, overall, hypoglycaemic events recorded in the GPRD were likely to be 
either the more serious episodes (for example, those that involved health care providers 
other than the GP), or were recorded retrospectively at the patient’s next visit to the GP.
While Henderson et al. noted that "retrospective recall of severe hypoglycaemia is 
reasonably robust", such retrospective recording of events introduces recall bias, in 
particular probably tending to omit minor events. In addition historical events reported at 
a GP consultation would be recorded against the consultation date rather than the date 
they occurred. Similarly, a GP will be informed of a patient’s hospitalisation, but the 
GPRD record may be recorded against a discharge date rather than an admission date 
(which was presumably when the episode occurred).
There must, therefore, be some level of uncertainty in the timing of the hypoglycaemic 
events recorded in the GPRD. While a review of laboratory test results found that the 
majority of results were recorded against the date the sample was taken, in around 7% of 
records they seemed to have been recorded up to a week later. This may have resulted in 
incorrect assignments of events to insulin exposures, introducing misclassification bias 
into the study.
I n s u l i n  e x p o s u r e s
The mapping process used to identify insulin exposures made assumptions about the 
patient’s insulin use. It was assumed that patients used all the insulin prescribed to them, 
and that usage started on the day of prescription: neither assumption is likely to be true.
Patients will refill prescriptions early, to ensure they do not run out of insulin, and
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unused stored insulin may be discarded. Prescriptions may not be collected, they may be 
lost, or incorrect prescriptions may be issued (and not filled by the patient). Although the 
prescription processing attempted to identify and remove incorrect or replaced 
prescriptions, the extent to which that was successful is unknown.
In addition, the GPRD only included prescriptions issued through the GP practice.
Although GPs are central to the care and management of patients with diabetes, for some 
patients, particularly in newly-diagnosed young children, a significant component of care 
is provided thorough hospitals or specialist services. This means that insulin prescribing 
records may have been incomplete, and the first GPRD insulin prescriptions may not 
actually be the patient’s first insulins. While the risk of this in most Type 2 patients was 
probably low, GPRD prescribing for younger Type 1 patients may not accurately reflect 
their insulin exposures. An additional complication in mapping prescribing in these 
patients was the practice of some GPs to record "dummy" prescriptions 
(indistinguishable from genuine ones) against the patient’s year of birth or the date they 
joined the practice. Although, for this reason, prescriptions in the patient’s year of birth 
were ignored, this still made it harder to accurately assign a diabetes index date in 
children. There was, therefore, a risk of misclassiflcation of study subjects, particularly 
young children, as "new" insulin users when they had already been exposed to insulin, 
introducing misclassification bias.
Further, the assumptions used in the prescription mapping process may have produced 
artefacts; either generating spurious changes in exposure, or incorrectly extending 
exposures.
It was therefore possible that insulin exposures were misclassified. To reduce the impact 
of this on the analyses, strict criteria were set for the selection of sub-groups of patients 
for the analyses. To be defined as a "new insulin user" a patient must have had at least a 
year of UTS time before their first insulin prescription. Since insulin prescriptions are 
unlikely to last for a year, it was hoped that this would exclude patients who had received 
insulin from sources other than their GP, although (as noted above) this possibility could 
not be eliminated. Similarly, to try and ensure that the change in exposure was genuine, 
insulin switchers had to have been on their pre-switch exposure for at least 6 months
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before their switch date, their post-switch exposure had to contain at least one insulin not 
present in their pre-switch exposure, and their post-switch exposure had to be at least 3 
days long.
A v a i l a b i l i t y  o f  c o v a r ia t e s
Recording levels for the covariates of interest in this study were often poor, and 
recording was often differential. For example, 82% of the base study population did not 
have an ethnicity record, while patients newly-starting on analogue insulin were more 
likely to have records for BMI, HbAic and socio-economic status than were patients 
starting on human insulin. This is a source of information bias in the analyses. Also, GPs 
chose to record data on some patients but not on others, presumably those where the 
information was felt to be more clinically significant, suggesting some patients were 
more closely monitored than others. Outcomes, such as hypoglycaemia, are more likely 
to be detected in closely monitored patients, introducing surveillance bias into the study.
T h e  GPRD a s  a  s o u r c e  o f  e p i d e m i o l o g i c a l  d a t a
Like all data sources, the GPRD is imperfect. Participating GPs use the system primarily 
to manage their patients; the production of information for research is a by-product.
Practices differed in the extent of recording of non-mandatory data, and some 
information of potential importance to researchers was not routinely collected.
Recording of ancillary data (such as ethnicity or alcohol use) was not (unlike the clinical 
information) subject to quality control or any standardisation on how often records 
should be updated. Overall, recording of some important data, including ethnic group, 
was found to be poor, and, as noted above, recording levels were often dependent on the 
patient’s previous records.
The GPRD contains only information collected from patients registered with 
participating practices, so, from an epidemiological standpoint, some population groups 
were missing or under-represented. These included prisoners, members of the armed 
forces, the homeless (as registration with a GP requires an address), and those who had 
chosen not to register with a doctor. Since these groups were not randomly drawn from 
the general population (it seems likely, for example, that they contain a higher proportion
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of younger men) there was a risk of selection bias. However, since it is highly unlikely 
that a diabetic under insulin therapy would not be under the care of a GP, this was not felt 
to be a significant source of bias in this study.
Patients were lost to the GPRD if they transferred out of the GP’s practice and although 
they may subsequently re-register with another contributing GP they would be allocated 
a different reference number and it is not possible to identify them as the same patient.
Although the GPRD prescription data are (generally) of good quality, it contains only 
those drugs prescribed through the GP surgery, so those from other sources, including 
hospitals, were missing. While the GPRD records the prescriptions issued, it cannot 
indicate patient compliance. A study by Cramer and Pugh of patients with Type 2 
diabetes estimated insulin usage at 77.4% of prescribed amounts while Morris et 
a l  studying patients aged ~16  years, found 28% obtained less insulin than they were 
prescribed. Overall it seems likely that the assumption (described in the Methods 
section) that patients fill all the insulin prescriptions issued to them will tend to 
overestimate insulin usage.
The GPRD is a collection of data harvested from participating GPs, and, despite the 
quality control procedures, this collection process occasionally fails. Jick et a l  noted 
gaps in nominally UTS VAMP data where practice records were missing for periods, and 
the author found similar gaps in some practices in the MHRA database. How these 
practices were handled is discussed in the Methods section. In addition, since UTS status 
is never revoked, data that does not meet the quality standard may be accepted into the 
database, and this is impossible to detect.
The process of computerisation also affected the completeness of the information in the 
GPRD. When GP practices initially computerised most historical data was not 
transferred to the computer (although major clinical events were generally recorded, 
often under a "dummy" date), and the same happened when practices migrated from the 
original VM software to the windows-based VISION system. Similarly, in most cases 
patients who died or transferred out of the practice before the change in computer 
systems were not migrated. This would affect calculated incidence, prevalence and death
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rates where practices achieved UTS during a study period. While this was not relevant to 
this study, the recording of "dummy" events (which may have been on the patient’s 
left-censor date or at their "new-patient" screening), when a patient transferred into a 
practice means that their diabetes index date may be inaccurate.
Despite these limitations, which are common to all primary care database, the GPRD has 
considerable strengths as a source of epidemiological data. In the UK the GP is the 
patient’s primary point of contact, so most morbidities should appear in the GPRD. The 
inclusive nature of the NHS reduces the risk of selection bias compared with, for 
example, insurance-based databases. As a prospective system where data are collected at 
the point of care, the risk of information bias is reduced, although to some extent 
recording levels reflect individual GPs’ views on what information is relevant for the 
management of their patients.
9.8 C on clu sion s
In terms of the research hypotheses, the conclusions of this study are:
(A) The GPRD is a good source of prescribing information in the UK population, 
and can be used to track changes in insulin prescribing over the study period. 
However, at an individual level insulin exposures were harder to determine. 
The assumptions made about insulin usage (particularly that insulin use starts 
on the day of prescription), the lack of prescriptions from non-GP sources, 
and the lack of compliance information means that there was some 
uncertainty in the assignment of insulin exposures.
(B) The initial choice of human or analogue insulin was correctly predicted for 
78% of patients with Type 1 diabetes and 82% of those with Type 1 diabetes 
using GPRD data, so, to some extent hypothesis (B) was confirmed. However, 
the most important predictor of the choice was not the patient’s characteristics 
or their medical or prescribing history, but the calendar year in which they 
started insulin therapy. This correctly predicted, on its own, 77% of the
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assignments. While the choice of insulin may have been influenced by factors 
not available in the GPRD, the rapid uptake of analogue insulins over the study 
seemed to have been largely driven by clinician (or patient) choice. However, 
some patient characteristics, including their ethnicity, were influential in the 
initial choice of insulin. By the end of the study period analogues were the 
most commonly prescribed insulins, so it seems likely that the effect of the 
calendar year would diminish in GPRD data after 2009. An analysis of more 
recent GPRD data might provide better information that patient characteristics 
that influence the choice of analogue or human insulin for new insulin users.
(C) GPRD data could be used to identify factors influencing a change in insulin 
exposure in established insulin users. The factors seen reflected patient 
management: patients newly-starting on insulin therapy were more likely to 
switch (as their treatment was adjusted to their needs), while those who were 
stable on their existing insulin exposure were less likely to change. The 
patient’s clinical contact rate also influenced their risk of a change in 
exposure: switching was more likely in patients with more health care 
contacts. Again, an analysis of more recent GPRD data, now that analogue 
insulins are established, may give an insight into whether or not that 
association resulted from GPs taking the opportunity to "modernise" a 
patient’s treatment to analogue insulins.
(D) The analyses of the relative risk of hypoglycaemic events under different 
insulin exposures did find statistically significant differences between some 
insulin exposures. Specifically they found a reduction in the likelihood of 
hypoglycaemic events in users of long-acting analogue insulins and 
intermediate or long human insulins compared with a reference group of 
pre-mixed human insulin users. To that extent, the hypothesis that GPRD 
records could be used to determine differences in the "real-life" risk of 
hypoglycaemic events between patients using analogue and human insulins 
was confirmed. However the results must not be over-interpreted. The effect 
sizes in long-acting analogues and intermediate or long human insulin were
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similar, so the analysis did not demonstrate that long-acting analogue insulin 
offered a "real-life" benefit over intermediate human insulin.
The GPRD has been widely used for epidemiological studies, and is generally 
considered to be a good quality and reasonably complete data source. It also has the 
advantage of size. One of the strengths of this study was the size of the available 
population: a base study population of 55,914 insulin users, 21,314 "new" insulin users, 
and 17,777 insulin "switchers". The GPRD is also representative of the UK population, 
including sections of the population, such as children, not normally included in clinical 
trials. Hence the study results are generalisable to the UK population and to other 
populations of similar composition.
However, the study also had limitations.
Unlike clinical trials, where the researchers are able to define relevant covariates and 
ensure their collection at appropriate times, database studies are limited to the available 
data. Potentially valuable covariates were not available in the GPRD, and thee recording 
levels of other data were poor.
It was not possible to categorise hypoglycaemic events in the terms used in most of the 
published studies. Mild hypoglycaemia was unlikely to be reported to the GP, and 
nocturnal hypoglycaemia could not be identified from the data available in the GPRD. 
The relatively strict criteria used to identify hypoglycaemic events meant the overall 
rates of hypoglycaemia were almost certainly underestimated, however, they did give 
reasonable confidence that the events were genuine. However, the timing of 
hypoglycaemic events may not have been accurate, with the concomitant risk of 
incorrect assignment of hypoglycaemic events to insulin exposures.
All observational studies are at risk of bias. Misclassification of "new" insulin users 
(particularly in young children), incorrect assignment of hypoglycaemic events to insulin 
exposures, and differential monitoring of patients were all potential sources of bias in 
this study. Further, the high proportion of patients with missing covariates introduced
237
9. Discussion Conclusions
information bias into the analyses. In many cases the "unknown" levels had statistically 
significant associations with the analysis outcome, suggesting some residual 
confounding. The complete-case analyses used to mitigate this introduced selection bias 
as they were not representative of their underlying analysis subjects: they included only 
English patients, and probably patients under more intensive GP management.
Accordingly the complete-case results must be treated with caution.
Although these analyses confirmed the reductions in hypoglycaemia with longer-acting 
analogue insulins seen in clinical trials, the results were not definitive. Given that similar 
risk reductions were seen in uses of intermediate-acting (or long-acting) human insulins, 
the comparison group generally used in clinical trials, they did not provide evidence for 
the superiority of long-acting analogue insulin to intermediate-acting human insulin.
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APPENDIX A l
Literature review
A.1 Modified CASP q u e stio n s  u sed  to appraise articies
All publications
Systematic reviews 
or meta-analyses
Clinical trials
Cohort studies
All publications
Did the publication report on differences in the risk of hypoglycaemia 
between users of human and analogue insulins?
Did the authors look for the right type of papers?
Do you think the important, relevant studies were included?
Did the review’s authors do enough to assess the quality of 
the included studies?
If the results of the review have been combined, was it reasonable to do so? 
What are the overall results of the review?
Was the assignment of patients to treatments randomised?
Were all of the patients who entered the trial properly accounted for 
at its conclusion?
Were patients, health workers and study personnel "blind" to treatment? 
Were the groups similar at the start of the trial?
Aside from the experimental intervention, were the groups treated equally? 
How large was the treatment effect?
Was the cohort recruited in an acceptable way?
Was the exposure accurately measured to minimise bias?
Was the outcome accurately measured to minimise bias?
Have the authors identified all important confounding factors and 
taken them into account in the design and/or analysis?
Was the follow up of subjects long enough and complete enough?
What are the results of this study?
Do you believe the results?
Do the results of this study fit with other available evidence?
How precise are the result or the estimate of the treatment effect?
Can the results be applied to the UK population?
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APPENDIX B l
GPRD codes
B.1 Human and analogue insulin product codes and ciassification
Table: B.1 : GPRD2009 human and analogue insulin codes and classification
Code Product name Source Action
1588 ACTRAPID injection 100 iu/ml [NOVO] Human Short
1594 ACTRAPID NOVOLET 100 iu/ml [NOVO] Human Short
1592 ACTRAPID PENFILL 100 iu/ml [NOVO] Human Short
7349 ACTRAPID VIAL injection solution 100 units/ml [NOVO] Human Short
14345 APIDRA CARTRIDGE injection solution 100 units/ml [SANOFI/AVE] Analogue Fast
29953 APIDRA OPTICLIK injection solution 100 units/ml [SANOFI/AVE] Analogue Fast
21583 APIDRA OPTISET injection solution 100 units/ml [SANOFI/AVE] Analogue Fast
36920 APIDRA SOLOSTAR injection solution 100 units/ml [SANOFI/AVE] Analogue Fast
19491 APIDRA VIAL injection solution 100 units/ml [SANOFI/AVE] Analogue Fast
31465 EXUBERA powder for inhalation Img [PFIZER] Human Short
31467 EXUBERA powder for inhalation 3mg [PFIZER] Human Short
8118 HUMAJECT 1 pen 100 iu/ml [LILLY] Human Intermediate
10915 HÜMAJECT Ml pen 100 iu/ml [LILLY] Human Pre-mix
10910 HUMAJECT M2 pen 100 iu/ml [LILLY] Human Pre-mix
7793 HUMAJECT M3 pen 100 iu/ml [LILLY] Human Pre-mix
17809 HUMAJECT M4 pen 100 iu/ml [LILLY] Human Pre-mix
22155 HUMAJECT M5 pen 100 iu/ml [LILLY] Human Pre-mix
9565 HUMAJECT S DISPOSABLE PEN injection solution 100 units/ml [LILLY] Human Short
7318 HUMALOG CARTRIDGE injection solution 100 units/ml [LILLY] Analogue Fast
10264 HUMALOG DISPOSABLE PEN injection solution 100 units/ml [LILLY] Analogue Fast
322 HUMALOG injection 100 iu/ml [LILLY] Analogue Fast
10243 HUMALOG MIX 25 CARTRIDGE injection suspension 100 units/ml 
[LILLY]
Analogue Pre-mix
14270 HUMALOG MIX 25 DISPOSABLE PEN injection suspension 100 
units/ml [LILLY]
Analogue Pre-mix
4715 HUMALOG MIX 25 injection 25:75; 100 units/ml [LILLY] Analogue Pre-mix
18593 HUMALOG MIX 50 CARTRIDGE injection suspension 100 units/ml 
[LILLY]
Analogue Pre-mix
10001 HUMALOG MIX 50 DISPOSABLE PEN injection suspension 100 
units/ml [LILLY]
Analogue Pre-mix
18224 HUMALOG VIAL injection solution 100 units/ml [LILLY] Analogue Fast
1649 HUMAN ACTRAPHANE injection 100 iu/ml [NOVO] Human Pre-mix
34097 HUMAN INITARD 50/50 injection 100 units/ml [NOVO] Human Pre-mix
7772 HUMAN PROTAPHANE injection 100 units/ml [NOVO] Human Intermediate
7771 HUMAN PROTAPHANE PENFILL 100 units/ml [NOVO] Human Intermediate
14357 HUMULIN 1 CARTRIDGE injection suspension 100 units/ml [LILLY] Human Intermediate
10229 HUMULIN 1 DISPOSABLE PEN injection suspension 100 units/ml 
[LILLY]
Human Intermediate
4760 HUMULIN 1 injection 100 units/ml [LILLY] Human Intermediate
14918 HUMULIN 1 VIAL injection suspension 100 units/ml [LILLY] Human Intermediate
10547 HUMULIN LENTE injection 100 units/ml [LILLY] Human Intermediate
4199 HUMULIN Ml injection 100 units/ml [LILLY] Human Pre-mix
4093 HUMULIN M2 injection 100 units/ml [LILLY] Human Pre-mix
10277 HUMULIN M3 CARTRIDGE injection suspension 100 units/ml [LILLY] Human Pre-mix
16160 HUMULIN M3 DISPOSABLE PEN injection suspension 100 units/ml 
[LILLY]
Human Pre-mix
4198 HUMULIN M3 injection 100 units/ml [LILLY] Human Pre-mix
Continued.
260
B. Appendices Human and analogue insulin product codes and classification
Table: B.1 (continued): GPRD2009 human and analogue insulin codes and classification
Code Product name Source Action
19513 HUMULIN M3 VIAL injection suspension 100 units/ml [LILLY] Human Pre-mix
11107 HUMULIN M4 injection 100 units/ml [LILLY] Human Pre-mix
8841 HUMULIN M5 injection 100 units/ml [LILLY] Human Pre-mix
14944 HUMULIN S CARTRIDGE injection solution 100 units/ml [LILLY] Human Short
1840 HUMULIN S injection 100 units/ml [LILLY] Human Short
21235 HUMULIN S VIAL injection solution 100 units/ml [LILLY] Human Short
7537 HUMULIN ZN injection 100 units/ml [LILLY] Human Intermediate
5891 INSULATARD FLEXPEN injection 100 iu/ml [NOVO] Human Intermediate
1886 INSULATARD ge injection 100 iu/ml [NOVO] Human Intermediate
33966 INSULATARD injection 100 units/ml [NOVO] Human Intermediate
9737 INSULATARD INNOLET injection 100 iu/ml [NOVO] Human Intermediate
10208 INSULATARD INNOLET injection suspension 100 units/ml [NOVO] Human Intermediate
1595 INSULATARD NOVOLET 100 iu/ml [NOVO] Human Intermediate
1593 INSULATARD PENFILL 100 iu/ml [NOVO] Human Intermediate
14290 INSULATARD PENFILL injection suspension 100 units/ml [NOVO] Human Intermediate
14928 INSULATARD VIAL injection suspension 100 units/ml [NOVO] Human Intermediate
16142 insulin aspart cartridge injection solution 100 units/ml Analogue Fast
19877 insulin aspart disposable pen injection solution 100 units/ml Analogue Fast
6447 insulin aspart human pyr injection 100 iu/ml Analogue Fast
29567 insulin aspart vial injection solution 100 units/ml Analogue Fast
24795 insulin diphasic aspart cartridge injection suspension 30:70; 100 units/ml Analogue Pre-mix
23099 insulin diphasic aspart disposable pen injection suspension 30:70; 100 
units/ml
Analogue Pre-mix
10067 insulin diphasic aspart human pyr injection 30:70; 100 units/ml Analogue Pre-mix
25736 insulin diphasic isophane human cartridge injection suspension 10:90; 
100 units/ml
Human Pre-mix
25735 insulin diphasic isophane human cartridge injection suspension 20:80; 
100 units/ml
Human Pre-mix
36194 insulin diphasic isophane human cartridge injection suspension 25:75; 
100 units/ml
Human Pre-mix
16152 insulin diphasic isophane human cartridge injection suspension 30:70; 
100 units/ml
Human Pre-mix
21422 insulin diphasic isophane human cartridge injection suspension 40:60; 
100 units/ml
Human Pre-mix
28096 insulin diphasic isophane human cartridge injection suspension 50:50; 
100 units/ml
Human Pre-mix
33167 insulin diphasic isophane human crd injection 25:75; 100 units/ml Human Pre-mix
33232 insulin diphasic isophane human crd injection 50:50; 100 units/ml Human Pre-mix
19878 insulin diphasic isophane human disposable pen injection suspension 
30:70; 100 units/ml
Human Pre-mix
13837 insulin diphasic isophane human prd injection 10:90; 100 units/ml Human Pre-mix
14644 insulin diphasic isophane human prd injection 20:80; 100 units/ml Human Pre-mix
29837 insulin diphasic isophane human prd injection 25:75; 100 units/ml Human Pre-mix
9341 insulin diphasic isophane human prd injection 30:70; 100 units/ml Human Pre-mix
21374 insulin diphasic isophane human prd injection 40:60; 100 units/ml Human Pre-mix
21110 insulin diphasic isophane human prd injection 50:50; 100 units/ml Human Pre-mix
14649 insulin diphasic isophane human pyr injection 10:90; 100 units/ml Human Pre-mix
11055 insulin diphasic isophane human pyr injection 20:80; 100 units/ml Human Pre-mix
11056 insulin diphasic isophane human pyr injection 30:70; 100 units/ml Human Pre-mix
21395 insulin diphasic isophane human pyr injection 40:60; 100 units/ml Human Pre-mix
22697 insulin diphasic isophane human pyr injection 50:50; 100 units/ml Human Pre-mix
21232 insulin diphasic isophane human vial injection suspension 30:70; 100 
units/ml
Human Pre-mix
28185 insulin diphasic lispro cartridge injection suspension 25:75; 100 units/ml Analogue Pre-mix
36146 insulin diphasic lispro cartridge injection suspension 50:50; 100 units/ml Analogue Pre-mix
31258 insulin diphasic lispro disposable pen injection suspension 25:75; 100 
units/ml
Analogue Pre-mix
35701 insulin diphasic lispro disposable pen injection suspension 50:50; 100 
units/ml
Analogue Pre-mix
5250 insulin diphasic lispro human prd injection 25:75; 100 units/ml Analogue Pre-mix
27177 insulin diphasic lispro human prd injection 50:50; 100 units/ml Analogue Pre-mix
14301 insulin detemir cartridge injection solution 100 units/ml Analogue Long
14330 insulin detemir disposable pen injection solution 100 units/ml Analogue Long
10184 insulin detemir injection solution 100 iu/ml Analogue Long
7393 insulin glargine cartridge injection solution 100 units/ml Analogue Long
7400 insulin glargine disposable pen injection solution 100 units/ml Analogue Long
5953 insulin glargine injection 100 iu/ml Analogue Long
10259 insulin glargine vial injection solution 100 units/ml Analogue Long
14299 insulin glulisine cartridge injection solution 100 units/ml Analogue Fast
Continued.
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Table: B.1 (continued): GPRD2009 human and analogue insulin codes and classification
Code Product name Source Action
21590 insulin glulisine disposable pen injection solution 100 units/ml Analogue Fast
28442 insulin glulisine injection solution 100 units/ml Analogue Fast
28101 insulin glulisine vial injection solution 100 units/ml Analogue Fast
20672 INSULIN HUM/ACTRAPID Human Short
32053 INSULIN HUMALOG MIX 25 Analogue Fast
25006 INSULIN HUMAN ACTRAPID (NEUTRAL) Human Short
321 INSULIN HUMAN ACTRAPID (NEUTRAL) 40 l/U INJ Human Short
27911 INSULIN HUMAN ACTRAPID PENFILL Human Short
36355 insulin human powder for inhalation Img Human Short
36356 insulin human powder for inhalation 3mg Human Short
2373 INSULIN HUMAN VELOSULIN 100 l/U INJ Human Short
1839 INSULIN HUMULIN 1 (ISOPHANE) 100 l/U INJ Human Intermediate
10566 INSULIN HUMULIN M CARTRIDGE 100 l/U Human Pre-mix
22161 INSULIN HUMULIN Ml VIAL Human Pre-mix
22094 INSULIN HUMULIN M2 VIAL Human Pre-mix
10546 INSULIN HUMULIN M4 100 l/U INJ Human Pre-mix
10545 INSULIN HUMULIN M4 CARTRIDGE 100 l/U Human Pre-mix
19707 INSULIN HUMULIN S (NEUTRAL SOLUBLE) Human Short
7861 INSULIN HUMULIN S (NEUTRAL) CARTRIDGE 100 l/U Human Short
7783 INSULIN ISOPHANE (HUMAN) 100 l/U INJ Human Intermediate
10691 INSULIN ISOPHANE (NPH) 100 l/U INJ Human Intermediate
23003 INSULIN ISOPHANE (NPH) 40 l/U Human Intermediate
22823 INSULIN ISOPHANE (PURIFIED) 100 l/U INJ Human Intermediate
8376 INSULIN ISOPHANE 100 l/U Human Intermediate
24722 INSULIN ISOPHANE 50%/NEUTRAL 50% 100 l/U INJ Human Pre-mix
8354 INSULIN ISOPHANE 70%/NEUTRAL 30% 100 l/U INJ Human Pre-mix
10207 insulin isophane human cartridge injection suspension 100 units/ml Human Intermediate
15961 insulin isophane human orb injection 100 iu/ml Human Intermediate
25812 insulin isophane human disposable pen injection suspension 100 
units/ml
Human Intermediate
13729 insulin isophane human emp injection 100 units/ml Human Intermediate
11080 insulin isophane human prb injection 100 iu/ml Human Intermediate
10175 insulin isophane human pyr injection 100 iu/ml Human Intermediate
14925 insulin isophane human vial injection suspension 100 units/ml Human Intermediate
14313 insulin lispro cartridge injection solution 100 units/ml Analogue Fast
14362 insulin lispro disposable pen injection solution 100 units/ml Analogue Fast
5214 insulin lispro human prb injection 100 iu/ml Analogue Fast
26060 insulin lispro vial injection solution 100 units/ml Analogue Fast
7959 INSULIN MIXTARD 30/70 40 l/U INJ Human Pre-mix
15040 INSULIN MONOPHANE (ISOPHANE) 100 l/U INJ Human Intermediate
7765 INSULIN NEUTRAL (HUMAN) 100 l/U INJ Human Short
1645 INSULIN NOVO ACTRAPID MC 100 l/U INJ Human Short
19829 INSULIN NOVO MONOTARD MC Human Intermediate
1643 INSULIN NOVO MONOTARD MC 100 l/U INJ Human Intermediate
4248 INSULIN NOVO ULTRATARD MC 100 l/U INJ Human Long
12060 INSULIN OUlCKSOL (SOLUBLE NEUTRAL) 100 l/U INJ Human Short
9079 INSULIN SOLUBLE 100 l/U INJ Human Short
20196 INSULIN SOLUBLE 40 l/U INJ Human Short
16129 insulin soluble human cartridge injection solution 100 units/ml Human Short
26621 insulin soluble human orb injection 100 iu/ml Human Short
36430 insulin soluble human disposable pen injection solution 100 units/ml Human Short
15710 insulin soluble human emp injection 100 units/ml Human Short
12654 insulin soluble human prb injection 100 units/ml Human Short
12638 insulin soluble human pyr injection 100 units/ml Human Short
27402 insulin soluble human vial injection solution 100 units/ml Human Short
18301 INSULIN SOLUBLE INJ l/U-2 Human Short
8646 INSULIN ZINC CRYSTALLINE susp 100 l/U INJ Human Intermediate
30861 INSULIN ZINC HUMAN SUSPENSION Human Long
26784 INSULIN ZINC SEMILENTE SUSP BP 100 l/U INJ Human Intermediate
18931 insulin zinc suspension crystalline human prb - intermediate acting 
injection 100 units/ml
Human Intermediate
9376 insulin zinc suspension crystalline human pyr - long acting injection 100 
units/ml
Human Long
18461 insulin zinc suspension mixed human prb injection 100 units/ml Human Long
8322 insulin zinc suspension mixed human pyr injection 100 units/ml Human Long
27461 INSUMAN BASAL CARTRIDGE injection suspension 100 units/ml 
[AVENTIS]
Human Intermediate
5501 INSUMAN BASAL injection 100 iu/ml [AVENTIS] Human Intermediate
Continued.
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Table: B.1 (continued): GPRD2009 human and analogue Insulin codes and classification
Code Product name Source Action
23992 INSUMAN BASAL OPTISET injection suspension 100 units/ml 
[AVENTIS]
Human Intermediate
35468 INSUMAN BASAL VIAL injection suspension 100 units/ml [AVENTIS] Human Intermediate
20422 INSUMAN COMB 15 injection 100 iu/ml [AVENTIS] Human Pre-mix
30819 INSUMAN COMB 15 OPTISET injection suspension 100 units/ml 
[AVENTIS]
Human Pre-mix
24993 INSUMAN COMB 25 CARTRIDGE injection suspension 100 units/ml 
[AVENTIS]
Human Pre-mix
15199 INSUMAN COMB 25 injection 100 iu/ml [AVENTIS] Human Pre-mix
25133 INSUMAN COMB 25 OPTISET injection suspension 100 units/ml 
[AVENTIS]
Human Pre-mix
24002 INSUMAN COMB 25 VIAL injection suspension 100 units/ml [AVENTIS] Human Pre-mix
35253 INSUMAN COMB 50 CARTRIDGE injection suspension 100 units/ml 
[AVENTIS]
Human Pre-mix
21554 INSUMAN COMB 50 injection 100 iu/ml [AVENTIS] Human Pre-mix
31205 INSUMAN COMB 50 OPTISET injection suspension 100 units/ml 
[AVENTIS]
Human Pre-mix
22983 INSUMAN RAPID CARTRIDGE injection solution 100 units/ml 
[AVENTIS]
Human Short
22945 INSUMAN RAPID injection 100 iu/ml [AVENTIS] Human Short
23993 INSUMAN RAPID OPTISET injection solution 100 units/ml [AVENTIS] Human Short
7266 LANTUS CARTRIDGE injection solution 100 units/ml [AVENTIS] Analogue Long
6057 LANTUS injection 100 iu/ml [AVENTIS] Analogue Long
10225 LANTUS OPTICLIK injection solution 100 units/ml [AVENTIS] Analogue Long
7237 LANTUS OPTISET injection solution 100 units/ml [AVENTIS] Analogue Long
36853 LANTUS SOLOSTAR injection solution 100 units/ml [SANOFI/AVE] Analogue Long
7402 LANTUS VIAL injection solution 100 units/ml [AVENTIS] Analogue Long
6958 LEVEMIR FLEXPEN injection solution 100 iu/ml [NOVO] Analogue Long
35260 LEVEMIR INNOLET injection solution 100 units/ml [NOVO] Analogue Long
6965 LEVEMIR PENFILL injection solution 100 units/ml [NOVO] Analogue Long
2456 MIXTARD 10 NOVOLET 100 iu/ml [NOVO] Human Pre-mix
5255 MIXTARD 10 PENFILL 100 iu/ml [NOVO] Human Pre-mix
10245 MIXTARD 10 PENFILL injection suspension 100 units/ml [NOVO] Human Pre-mix
2455 MIXTARD 20 NOVOLET 100 iu/ml [NOVO] Human Pre-mix
3551 MIXTARD 20 PENFILL 100 iu/ml [NOVO] Human Pre-mix
7319 MIXTARD 20 PENFILL injection suspension 100 units/ml [NOVO] Human Pre-mix
2929 MIXTARD 30 ge injection 100 iu/ml [NOVO] Human Pre-mix
5845 MIXTARD 30 INNOLET injection suspension 30:70; 100 units/ml [NOVO] Human Pre-mix
2221 MIXTARD 30 NOVOLET 100 iu/ml [NOVO] Human Pre-mix
2454 MIXTARD 30 PENFILL 100 iu/ml [NOVO] Human Pre-mix
7231 MIXTARD 30 PENFILL injection suspension 100 units/ml [NOVO] Human Pre-mix
7300 MIXTARD 30 VIAL injection suspension 100 units/ml [NOVO] Human Pre-mix
1805 MIXTARD 30/70 injection 100 units/ml [NOVO] Human Pre-mix
2812 MIXTARD 40 NOVOLET 100 iu/ml [NOVO] Human Pre-mix
3550 MIXTARD 40 PENFILL 100 iu/ml [NOVO] Human Pre-mix
10244 MIXTARD 40 PENFILL injection suspension 100 units/ml [NOVO] Human Pre-mix
12818 MIXTARD 50 injection 50:50; 100 units/ml [NOVO] Human Pre-mix
5933 MIXTARD 50 NOVOLET 100 iu/ml [NOVO] Human Pre-mix
4790 MIXTARD 50 PENFILL 100 iu/ml [NOVO] Human Pre-mix
13277 MIXTARD 50 PENFILL injection suspension 100 units/ml [NOVO] Human Pre-mix
1587 MONOTARD injection 100 units/ml [NOVO] Human Intermediate
7228 NOVOMIX 30 FLEXPEN injection suspension 100 units/ml [NOVO] Analogue Pre-mix
6061 NOVOMIX 30 injection 30:70; 100 units/ml [NOVO] Analogue Pre-mix
7267 NOVOMIX 30 PENFILL injection suspension 100 units/ml [NOVO] Analogue Pre-mix
17336 NOVOPEN injection device 100 units/ml [NOVO] Human Short
5892 NOVORAPID FLEXPEN injection solution 100 units/ml [NOVO] Analogue Fast
11337 NOVORAPID NOVOLET injection 100 iu/ml [NOVO] Analogue Fast
5021 NOVORAPID PENFILL injection solution 100 units/ml [NOVO] Analogue Fast
6209 NOVORAPID VIAL injection solution 100 units/ml [NOVO] Analogue Fast
3439 PENMIX 10/90 pen [NOVO] Human Pre-mix
3396 PENMIX 10/90 PENFILL PENFILL [NOVO] Human Pre-mix
2220 PENMIX 20/80 pen [NOVO] Human Pre-mix
10484 PENMIX 20/80 PENFILL PENFILL [NOVO] Human Pre-mix
27614 PENMIX 30/70 injection 100 iu/ml [NOVO] Human Pre-mix
1806 PENMIX 30/70 PENFILL injection 100 iu/ml [NOVO] Human Pre-mix
21347 PENMIX 40/60 injection 100 iu/ml [NOVO] Human Pre-mix
10887 PENMIX 40/60 PENFILL injection 100 iu/ml [NOVO] Human Pre-mix
17731 PENMIX 50/50 injection 100 iu/ml [NOVO] Human Pre-mix
8203 PENMIX 50/50 PENFILL injection 100 iu/ml [NOVO] Human Pre-mix
Continued.
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Table: B.1 (continued): GPRD2009 human and analogue Insulin codes and classification
Code Product name Source Action
22058 PUR-IN MIX 15/85 injection [CP PHARM] Human Pre-mix
26403 PUR-IN MIX 25/75 injection [CP PHARM] Human Pre-mix
24846 PUR-IN NEUTRAL injection 100 units/ml [CP PHARM] Human Short
1844 ULTRATARD injection 100 units/ml [NOVO] Human Long
4706 VELOSULIN VIAL injection solution 100 units/ml [NOVO] Human Short
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B.2 GPRD diabetes clinical "entity" codes
The GPRD has 460 "entity" codes which the GP can (optionally) use to structure clinical 
data. They are grouped into 25 categories, shown in the table below, one of which is 
"Diabetes", The individual codes within the Diabetes category are also shown.
Table B.2: C l i n i c a l  r e c o r d  e n t i t y  c a t e g o r i e s  a n d  d i a b e t e s  c o d e s
Entity category
Number
codes
Entity categories Allergy and Intolerance 2
Asthma 17
Biochemistry (Hormone) 25
Biochemistry (Other) 41
Biochemistry (Routine) 54
CV / Hypertension 3
Child Health Surveillance 33
Death Administartion 2
Diabetes 10
Diagnostic Imaging 44
Diagnostic Tests 25
Disease Registers 7
Elderly 18
Epilepsy 4
Examination Findings 13
HP Interventions 7
Haematology 39
Immunisations 1
Lifestyle 12
Maternity 27
Medical History 3
Microbiology 29
Miscellaneous 7
Other Pathology Tests 5
Serology and Immunology 31
Description Code
Entity codes within "Diabetes" category Diabetes annual check 22
Current Diabetes status 26
Ankle neuropathy 59
Diabetic consultation 65
Diabetes concerns 91
Insulin dosage 97
Foot pulse right leg 117
Foot pulse left leg 118
Visual acuity right eye 134
Visual acuity left eye 135
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B.3 Clinical codes for hypoglycaemia
Table B.3: C linical c o d e s  f o r  hy po gly caem ia
Code Read code Description
1410 Cl 12.00 Hypoglycaemia unspecified
2472 Cl 10.00 Hypoglycaemic coma
4563 Cl 12000 Reactive hypoglycaemia NOS
18583 66Ad.OO Hypoglycaemic attack requiring 3rd party assistance
20368 C112Z00 Hypoglycaemia unspecified NOS
21420 66AJ200 Loss of hypoglycaemic warning
24405 C112100 Spontaneous hypoglycaemia NOS
31529 U602300 [X]lnsul/oral hypoglyc drugs caus adverse eff therapeut use
31949 ZV65318 [V]Dietary counselling in hypoglycaemia
32885 CIlylOO Drug-induced hypoglycaemia without coma
39070 C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma
42729 C108E11 Type 1 diabetes mellitus with hypoglycaemic coma
43785 C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma
44440 C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma
46917 C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma
51371 CIIOzOO Hypoglycaemic coma NOS
52409 Cyu3000 [X]Other hypoglycaemia
53630 C110.11 Insulin coma
56268 C109D11 Type II diabetes mellitus with hypoglycaemic coma
61071 C109D12 Type 2 diabetes mellitus with hypoglycaemic coma
68960 F374500 Polyneuropathy in hypoglycaemia
70766 C108E12 Type 1 diabetes mellitus with hypoglycaemic coma
95920 Cl 16.00 Other hypoglycaemia
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